0001171843-23-001846.txt : 20230323 0001171843-23-001846.hdr.sgml : 20230323 20230323094144 ACCESSION NUMBER: 0001171843-23-001846 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230323 DATE AS OF CHANGE: 20230323 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNITED GUARDIAN INC CENTRAL INDEX KEY: 0000101295 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] IRS NUMBER: 111719724 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10526 FILM NUMBER: 23754737 BUSINESS ADDRESS: STREET 1: 230 MARCUS BLVD CITY: HAUPPAUGE STATE: NY ZIP: 11788 BUSINESS PHONE: 631-273-0900 MAIL ADDRESS: STREET 1: P.O. BOX 18050 STREET 2: 230 MARCUS BLVD. CITY: HAUPPAUGE STATE: NY ZIP: 11788 FORMER COMPANY: FORMER CONFORMED NAME: UNITED INTERNATIONAL RESEARCH INC DATE OF NAME CHANGE: 19820422 10-K 1 ug20221231_10k.htm FORM 10-K ug20221231_10k.htm
0000101295 UNITED GUARDIAN INC false --12-31 FY 2022 20,063 20,252 0.10 0.10 10,000,000 10,000,000 4,594,319 4,594,319 4,594,319 4,594,319 1.13 1.13 0.68 0.68 5 7 40 0 4 6 0 0 0 0 109,000 2 6 Although a significant percentage of ASI’s purchases from the Company are sold to foreign customers, all sales to ASI are considered U.S. sales for financial reporting purposes, since all shipments to ASI are shipped to ASI’s warehouses in the U.S. A certain percentage of those products are subsequently shipped by ASI to its foreign customers. Based on sales information provided to the Company by ASI, 66% of ASI’s sales in 2022 were to customers in foreign countries, compared with 74% in 2021. ASI’s largest foreign market in both 2022 and 2021 was China, which accounted for approximately 38% of ASI’s sales in 2022 and 42% of sales in 2021. 00001012952022-01-012022-12-31 iso4217:USD 00001012952022-06-30 xbrli:shares 00001012952023-03-01 thunderdome:item 00001012952021-01-012021-12-31 iso4217:USDxbrli:shares 00001012952022-12-31 00001012952021-12-31 0000101295us-gaap:CommonStockMember2020-12-31 0000101295us-gaap:RetainedEarningsMember2020-12-31 00001012952020-12-31 0000101295us-gaap:RetainedEarningsMember2021-01-012021-12-31 0000101295us-gaap:DividendDeclaredMember2021-01-012021-12-31 0000101295us-gaap:DividendDeclaredMemberus-gaap:RetainedEarningsMember2021-01-012021-12-31 0000101295us-gaap:DividendPaidMember2021-01-012021-12-31 0000101295us-gaap:DividendPaidMemberus-gaap:RetainedEarningsMember2021-01-012021-12-31 0000101295us-gaap:CommonStockMember2021-12-31 0000101295us-gaap:RetainedEarningsMember2021-12-31 0000101295us-gaap:RetainedEarningsMember2022-01-012022-12-31 0000101295us-gaap:DividendDeclaredMember2022-01-012022-12-31 0000101295us-gaap:DividendDeclaredMemberus-gaap:RetainedEarningsMember2022-01-012022-12-31 0000101295us-gaap:DividendPaidMember2022-01-012022-12-31 0000101295us-gaap:DividendPaidMemberus-gaap:RetainedEarningsMember2022-01-012022-12-31 0000101295us-gaap:CommonStockMember2022-12-31 0000101295us-gaap:RetainedEarningsMember2022-12-31 xbrli:pure 0000101295us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberug:LUBRAJELAndRENACIDINIRRIGATIONMember2022-01-012022-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberug:LUBRAJELAndRENACIDINIRRIGATIONMember2021-01-012021-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberug:LubrajelMember2022-01-012022-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberug:LubrajelMember2021-01-012021-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberug:RenacidinMember2022-01-012022-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberug:RenacidinMember2021-01-012021-12-31 0000101295ug:AccruedExpensesMember2022-12-31 0000101295ug:AccruedExpensesMember2021-12-31 0000101295ug:CosmeticIngredientsMember2022-01-012022-12-31 0000101295ug:CosmeticIngredientsMember2021-01-012021-12-31 0000101295ug:PharmaceuticalsMember2022-01-012022-12-31 0000101295ug:PharmaceuticalsMember2021-01-012021-12-31 0000101295ug:MedicalLubricantsMember2022-01-012022-12-31 0000101295ug:MedicalLubricantsMember2021-01-012021-12-31 0000101295ug:IndustrialAndOtherMember2022-01-012022-12-31 0000101295ug:IndustrialAndOtherMember2021-01-012021-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:PersonalCareMemberus-gaap:NonUsMember2022-01-012022-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:PersonalCareMemberus-gaap:NonUsMember2021-01-012021-12-31 0000101295country:US2022-01-012022-12-31 0000101295country:US2021-01-012021-12-31 0000101295us-gaap:NonUsMember2022-01-012022-12-31 0000101295us-gaap:NonUsMember2021-01-012021-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:ASIMemberus-gaap:NonUsMember2022-01-012022-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:ASIMemberus-gaap:NonUsMember2021-01-012021-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:ASIMembercountry:CN2022-01-012022-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberug:ASIMembercountry:CN2021-01-012021-12-31 00001012952022-05-102022-05-10 00001012952022-11-152022-11-15 00001012952021-05-182021-05-18 00001012952021-11-162021-11-16 utr:Y 0000101295ug:FactoryEquipmentAndFixturesMembersrt:MinimumMember2022-01-012022-12-31 0000101295ug:FactoryEquipmentAndFixturesMember2022-01-012022-12-31 0000101295us-gaap:BuildingMember2022-01-012022-12-31 0000101295us-gaap:BuildingImprovementsMember2022-01-012022-12-31 0000101295ug:DistributorsAndMarketingPartnersMember2022-01-012022-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberug:DistributorsAndMarketingPartnersMember2022-01-012022-12-31 0000101295us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberug:DistributorsAndMarketingPartnersMember2022-01-012022-12-31 0000101295ug:DistributorsAndMarketingPartnersMember2021-01-012021-12-31 0000101295us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberug:DistributorsAndMarketingPartnersMember2021-01-012021-12-31 0000101295us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberug:DistributorsAndMarketingPartnersMember2021-01-012021-12-31 0000101295us-gaap:CostOfGoodsProductLineMemberus-gaap:SupplierConcentrationRiskMemberug:SixRawMaterialVendorsMember2022-01-012022-12-31 0000101295us-gaap:CostOfGoodsProductLineMemberus-gaap:SupplierConcentrationRiskMemberug:SixRawMaterialVendorsMember2021-01-012021-12-31 0000101295us-gaap:ShippingAndHandlingMember2022-01-012022-12-31 0000101295us-gaap:ShippingAndHandlingMember2021-01-012021-12-31 0000101295us-gaap:DemandDepositsMember2022-12-31 0000101295us-gaap:DemandDepositsMember2021-12-31 0000101295us-gaap:USTreasurySecuritiesMember2022-12-31 0000101295us-gaap:FixedIncomeSecuritiesMember2022-12-31 0000101295ug:EquityAndOtherMutualFundsMember2022-12-31 0000101295us-gaap:FixedIncomeSecuritiesMember2021-12-31 0000101295ug:EquityAndOtherMutualFundsMember2021-12-31 0000101295ug:DCPlanMember2022-01-012022-12-31 0000101295ug:DCPlanMemberug:DiscretionaryContributionsVestingAtTwoYearsMember2022-01-012022-12-31 0000101295ug:DCPlanMemberug:DiscretionaryContributionsVestingEachAdditionalYearMember2022-01-012022-12-31 0000101295us-gaap:SalesRevenueProductLineMemberus-gaap:GeographicConcentrationRiskMemberug:MedicalLubricantsMemberug:USWithSubsequentShipmentToForeignLocationsMember2022-01-012022-12-31 0000101295ug:CustomerAMember2022-01-012022-12-31 0000101295ug:CustomerAMember2021-01-012021-12-31 0000101295ug:CustomerBMember2022-01-012022-12-31 0000101295ug:CustomerBMember2021-01-012021-12-31 0000101295ug:CustomerCMember2022-01-012022-12-31 0000101295ug:CustomerCMember2021-01-012021-12-31 0000101295ug:CustomerDMember2022-01-012022-12-31 0000101295ug:CustomerDMember2021-01-012021-12-31 0000101295ug:AllOtherCustomersMember2022-01-012022-12-31 0000101295ug:AllOtherCustomersMember2021-01-012021-12-31 0000101295ug:AccountingAndTaxServicesMembersrt:DirectorMember2022-01-012022-12-31 0000101295ug:AccountingAndTaxServicesMembersrt:DirectorMember2021-01-012021-12-31 0000101295ug:ConsultingServicesMemberug:PreviousPresidentAndCeoMember2022-01-012022-12-31 0000101295ug:PurchaseOfUsedVehicleMemberug:PreviousPresidentAndCeoMember2022-11-012022-11-30
 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

FORM 10-K

 

(Mark One)

 

☒

ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

  
 For the fiscal year ended December 31, 2022
  
 OR
  
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
  
 For the transition period from __________ to ____________

 

Commission file number 1-10526

 

 

UNITED-GUARDIAN, INC.

(Exact name of Registrant as specified in its charter)

 

Delaware 11-1719724
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

 

230 Marcus Blvd., Hauppauge, NY 11788

(Address of principal executive offices, including zip code)

 

(631) 273-0900 .
Registrant's telephone number, including area code

 

Securities registered pursuant to Section l2(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $.10 par value

UG

The NASDAQ Global Market

 

Securities registered pursuant to Section 12(g) of the Act:

None

 

 

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

 
 

 

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer 

☐

 

Smaller reporting company  

☒

Accelerated filer  

☐

 

Emerging growth company

☐

Non-accelerated filer  

☒

   

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes ☐ No ☒

 

As of June 30, 2022, the last business day of the Registrant’s most recently completed second fiscal quarter, the aggregate market value of the voting and non-voting common equity held by non-affiliates, computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, was approximately $68,868,800 (based on a closing price of $14.99 per share). (For the purpose of this report it has been assumed that all officers and directors of the Registrant, as well as all stockholders holding 10% or more of Registrant's stock, are affiliates of the Registrant).

 

As of March 1, 2023, the Registrant had issued and outstanding 4,594,319 shares of Common Stock, $.10 par value per share ("Common Stock").

 

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Certain information required by Items 10, 11, 12, and 13 of Part III of this Annual Report on Form 10-K is incorporated by reference to our definitive Proxy Statement for the 2023 Annual Meeting of Shareholders to be filed with the Securities and Exchange Commission within 120 days after the fiscal year ended December 31, 2022.

 

 
 

 

 

UNITED-GUARDIAN, INC.

 

This Annual Report on Form 10-K (“Annual Report”) contains both historical and forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a safe harbor for forward-looking statements by the Registrant about its expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters. The Registrant desires to take advantage of such "safe harbor" provisions and is including this statement for that express purpose. Words such as "anticipates", "believes", "expects", "intends", "future", and similar expressions identify forward-looking statements. Any such forward-looking statements in this report reflect the Registrant's views as of the date of filing of this report with the United States Securities and Exchange Commission (the “SEC”) with respect to future events and financial performance, and are subject to a variety of factors that could cause the Registrant's actual results or performance to differ materially from historical results or from the anticipated results or performance expressed or implied by such forward-looking statements. Because of such factors, there can be no assurance that the actual results or developments anticipated by the Registrant will be realized or, even if substantially realized, that they will have the anticipated results. The risks and uncertainties that may affect the Registrant's business include, but are not limited to: economic conditions, governmental regulations, technological advances, pricing and competition, acceptance by the marketplace of new products, retention of key personnel, the sufficiency of financial resources to sustain and expand the Registrant's operations, and other factors described in this report and in prior filings with the SEC. Readers should not place undue reliance on such forward-looking statements, which speak only as of the date hereof, and should be aware that except as may be otherwise legally required of the Registrant, the Registrant undertakes no obligation to publicly revise any such forward-looking statements to reflect events or circumstances that may arise after the date hereof. Past results are no guaranty of future performance.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1
 

 

UNITED-GUARDIAN, INC.

 

INDEX TO ANNUAL REPORT ON FORM 10-K

 

Part I 

   3

Item 1.

 Business 3

Item 1A.

 Risk Factors 14

Item 1B.

 Unresolved Staff Comments 14

Item 2.

 Properties 14

Item 3.

 Legal Proceedings 14

Item 4.

 Mine Safety Disclosures 14
     

Part II

   14

Item 5.

 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 14

Item 6.

 [Reserved] 15

Item 7.

 Management’s Discussion and Analysis of Financial Condition and Results of Operations 15

Item 7A.

 Quantitative and Qualitative Disclosures About Market Risk 20

Item 8.

 Financial Statements and Supplementary Data 20

Item 9.

 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 20

Item 9A.

 Controls and Procedures 20

Item 9B.

 Other Information 21

Item 9C.

 Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 21
     

Part III

   21

Item 10.

 Directors, Executive Officers and Corporate Governance 21

Item 11.

 Executive Compensation 22

Item 12.

 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 22

Item 13.

 Certain Relationships and Related Transactions and Director Independence 22

Item 14.

 Principal Accountant Fees and Services 22
     

Part IV

   23

Item 15.

 Exhibits and Financial Statement Schedules 23
     

Signatures

   23

 

 

 

2
 

 

UNITED-GUARDIAN, INC.

 

PART I

 

Item 1. Business.

 

(a) Introduction   

 

United-Guardian, Inc. (“Registrant” or “Company”) is a Delaware corporation that, through its Guardian Laboratories division, manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. We also conduct research and product development, primarily related to the development of new and unique cosmetic ingredients. Our research and development department also modifies, refines, and expands the uses for existing products, with the goal of further developing the market for our products. The Company also develops new products using natural and environmentally friendly raw materials, which is a priority to many of the Company’s cosmetic customers.

 

Our predecessor entity, United International Research, Inc. ("UIR"), was founded and incorporated in New York in 1942 by Dr. Alfred R. Globus, the Company's Chairman and Director of Research until his death on April 9, 2009. On February 10, 1982, a merger took place between UIR and Guardian Chemical Corporation ("Guardian"), an affiliate of UIR, whereby Guardian was merged into UIR and the name was changed to United-Guardian, Inc., a New York corporation. On September 14, 1987, United-Guardian, Inc. (New York) was merged with and into a newly formed Delaware corporation by the same name, United-Guardian, Inc., for the purpose of changing the domicile to the State of Delaware.

 

The cornerstone of our business is our product innovation. We use our product development and formulation expertise to maintain our market position and to propel future growth. We also focus on the development of new products that fill unmet market needs and have unique properties.

 

Our products are sold into stable and growing markets such as personal care, medical lubricants and pharmaceutical products. Our current product offerings include cosmetic ingredients, medical lubricants, pharmaceuticals and specialty industrial products. In the second quarter of 2023, we plan to discontinue the manufacturing and sale of our specialty industrial products. The decision to discontinue this product line was made based on the fact that these products represented less than 2% of our gross sales over the past several years, and the small production scale

 

Our product offerings are segregated into the following categories:

 

 

●

Cosmetic Ingredients: Cosmetic ingredients is an extensive line of multifactional water-based gel formulations designed to mainly offer sensory enhancement, lubrication, texture and moisturization to personal care products.

 

 

●

Medical Lubricants:  Medical lubricants include a line of water-based gel formulations designed to mainly offer sensory enhancement and lubrication to medical products.

 

 

●

Pharmaceutical Products: Pharmaceutical products include an FDA approved prescription drug that is used primarily to prevent and to dissolve calcifications in urethral catheters, as well as a chlorine-based topical antimicrobial.

 

 

●

Industrial Products: Industrial products include cleaning solutions used in various industrial applications. As discussed above, we plan to discontinue the manufacturing and sale of these products beginning in the second quarter of 2023.

 

Our internet address is http://www.u-g.com. On this website, we make available, free of charge, our annual reports on Form 10-K, quarterly reports on Form 10-Q, and any amendments to those reports. All such reports are available as soon as reasonably practicable after they are electronically filed with, or electronically furnished to, the U. S. Securities and Exchange Commission (“SEC”). These documents are also available in print to any stockholder who requests them. Information contained on our website is not part of this annual report on Form 10-K and is not incorporated by reference in this document. The SEC maintains an internet site (http://www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC.

 

 

3
 

 

UNITED-GUARDIAN, INC.

 

(b) Description of Business

 

We manufacture and market cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. We also conduct research and development, primarily related to the development of new and unique cosmetic ingredients. We focus on the development of products that fill unmet market needs, have unique properties, and use proprietary technology that we typically protect as trade secrets rather than with patents. Many of our products are marketed through collaborative agreements with larger companies.

 

The cosmetic ingredients manufactured by us are marketed to end users through our worldwide network of distributors and are currently used by many of the major manufacturers of cosmetic products. We ship our cosmetic ingredients to our distributors Ex Works (“EXW”) from our facility in Hauppauge, New York. Those distributors in turn resell those products to their customers, who are typically the manufacturers and marketers of cosmetic and personal care products. The cosmetic ingredients are not sold on a consignment basis, so unless a product is determined to be defective, it is not returnable, except at the discretion of the Company.

 

Our pharmaceutical products are sold primarily to several full-line drug wholesalers which in turn supply those products to pharmacies, physicians, and hospitals. We arrange for, and cover the cost of, shipping our pharmaceutical products, and sales of those products are final when shipped. They are returnable only under specific circumstances in accordance with pharmaceutical industry standards, such as if the products are (a) damaged when received; (b) defective; (c) too close to their expiration dates to sell; or (d) within a year after their expiration dates.

 

We operate in one business segment. Our products are separated into four distinct product categories: cosmetic ingredients, pharmaceuticals, medical lubricants, and industrial products. Each product category is marketed differently.  

 

Our cosmetic ingredients are currently marketed globally by five distributors, of which Ashland Specialty Ingredients (“ASI”), a business segment of Ashland, Inc., is the largest. ASI manufactures and markets globally an extensive line of personal care and pharmaceutical additives and various other specialty products. We sell our cosmetic ingredients directly to those distributors, which in turn resell those products to their customers for use in the formulation of one or more of the customers’ personal care and cosmetic products. Our non-pharmaceutical medical lubricants (referred to hereinafter as the Company’s “medical lubricants”) and our specialty industrial products are sold directly to marketers of finished products or to the contract manufacturers utilized by those marketers. We market our pharmaceutical products primarily through our dedicated Renacidin® website. The pharmaceutical products are sold to hospitals and pharmacies primarily through full-line drug wholesalers, which purchase our products outright for resale to their customers. We also sell a small quantity of pharmaceutical products directly to hospitals and pharmacies. Our products are sold under trademarks or trade names owned by the Company, some of which are registered with the United States Patent and Trademark Office as well as with comparable regulatory agencies in some foreign countries. We maintain a corporate website at www.u-g.com, and a specific website for Renacidin at www.renacidin.com.

 

All references in this Annual Report to “sales” or “Sales” shall mean “net sales” unless specifically identified as “gross sales.”

 

PRODUCTS

 

As stated above, we operate in one business segment, and our product lines are separated into four distinct categories:

 

4
 

 

UNITED-GUARDIAN, INC.

 

COSMETIC INGREDIENTS

 

The cosmetic ingredients we manufacture are marketed and sold to the end users through our worldwide network of distributors. Our cosmetic ingredients are currently sold globally by five distributors, of which Ashland Specialty Ingredients (“ASI”), a business segment of Ashland, Inc., is the largest. ASI is the exclusive distributor of our products in the United States, Canada, Asia, South & Central America, Mexico, Europe (all regions other than France, the United Kingdom, Italy & Switzerland), Scandinavia, Africa, Australia, the Middle East and Korea.

 

Our other distributors are: Azelis UK Ltd in the United Kingdom, Sederma SAS, a subsidiary of Croda International Plc. in France, Safic-Alcan S.p.A. in Italy, and Azelis Cosmetics GmbH in Switzerland.

 

We ship our cosmetic ingredients to our distributors EXW from our facility in Hauppauge, New York. The distributors resell the products to their customers, who are typically major manufacturers and marketers of cosmetic and personal care products. They utilize our products in their finished products. The cosmetic ingredients are not sold on a consignment basis, so unless a product is determined to be defective, it is not returnable, except at our discretion.

 

We believe that in the event ASI were to cease marketing and selling our products, alternative distribution agreements could be signed with other global distributors of cosmetic ingredients. These new appointed distributors would continue supplying products to customers currently using our products, without any significant interruption of sales. We also believe that if we choose to replace one or more of our current distributors, we would be able to put in place new distribution agreements to service our customers in all the geographic areas affected. If necessary, we would also be able to sell directly to the end users of our products until a new distribution arrangement was put in place.

 

PRODUCTS - COSMETIC INGREDIENTS:

 

LUBRAJEL® is an extensive line of multifunctional water-based gel formulations designed to mainly provide sensory enhancement, lubrication, and texture to personal care products. Some of the Lubrajel products also offer skin moisturization benefits. Many of the Lubrajel products are biodegradable. The Lubrajel products are primarily used in skin care products such as moisturizers, anti-aging creams, body lotions, face serums, spa products and sunscreens. The Lubrajel products are also used in makeup products such as primers and foundations. Each Lubrajel product offers unique benefits for the formulation of skin care and color cosmetic products. The basic product line includes Lubrajel CG, Lubrajel DV, Lubrajel IIXD, Lubrajel MS, Lubrajel NP and Lubrajel Oil.

 

To address customer demand for preservative-free products, we developed and launched Lubrajel DV PF, Lubrajel IIXD PF, Lubrajel MS PF, Lubrajel Oil PF and Lubrajel PF. To address customer demand for phenoxyethanol-free products, we developed and launched Lubrajel DV free, Lubrajel IIXD free, Lubrajel MS free, Lubrajel NP Free and Lubrajel Oil free.

 

In the last few years, to meet the growing consumer demand for “green” and sustainable products, we have focused on developing and launching new products which only contain ingredients that are considered “natural”. The Lubrajel products in the new natural line have been certified by the Cosmetic Organic and Natural Standard (“COSMOS”). This standard is recognized globally by the cosmetic industry.

 

LUBRAJEL NATURAL was the first product that was launched using only ingredients that are considered natural. This is a unique formulation of natural polymers and glycerin. Lubrajel Natural imparts a light and velvety skin feel, improving the sensory characteristics of personal care formulations, while providing a powerful skin moisturizing effect.

 

LUBRAJEL MARINE™ was the second product that we developed for our new line of natural products. It was formulated using naturally derived polymers, with some of the ingredients sourced from marine vegetation. This product was developed jointly with ASI, and for that reason is being sold globally on an exclusive basis by ASI.

 

5
 

 

UNITED-GUARDIAN, INC.

 

Other products in the Lubrajel Natural line of Lubrajel products are:

 

LUBRAJEL OlL NATURAL was developed as a ”green”, low viscosity alternative. Lubrajel Oil Natural is a unique formulation of the natural film former pullulan, cellulose gum, xanthan gum and glycerin. It imparts a silky, silicone-like skin feel and a long playtime as well as moisturization. Lubrajel Oil Natural makes possible the creation of smooth, luxuriant textures without adding viscosity. Since it also has good clarity, it is an excellent choice for clear formulations.

 

LUBRAJEL TERRA is a multifunctional, moisturizing hydrogel with unique aesthetic qualities for natural formulations. Lubrajel Terra’s synthetic-like texture can be attributed to the novel complex of polysaccharides, Konjac Mannan, derived from the Asian plant, Amorphophallus Konjac, also known as Devil’s Tongue, and Galactoarabinan, derived from the Larch tree, which are acclaimed for their outstanding moisture retaining and film forming properties, as well as cellulose gum.

 

In addition to the Lubrajel line of products, we also manufacture other cosmetic ingredients noted below: which accounted fortless than 10% of total sales in 2022:

 

B-122™ is a powdered lubricant used in the manufacture of certain cosmetics, such as pressed powders, eyeliners, and rouges, as well as some industrial products. The product acts as a binder, increases water-repellency and drop strength, and lowers the coefficient of friction in the products in which it is used.

 

ORCHID COMPLEX™ is an oil-based extract of fresh orchids. It is characterized by its excellent lubricity, spreadability, light feel, and emolliency. Because of its alcohol solubility it may also be used in fragrance products, such as perfumes and toiletries. Its emolliency makes it an excellent additive to shampoos, bath products and facial cleansers.

 

LUBRASIL™ II SB is a special formulation of Lubrajel in which silicone oil is incorporated into a Lubrajel base using proprietary technology that enables the product to maintain much of the clarity of regular Lubrajel. The product has a silky feel and is water resistant while at the same time providing moisturization.

 

Sales of our cosmetic ingredients represented approximately 41% of total our total sales for the year ended December 31, 2022.

 

We believe that there is potential to continue growing the sales of our cosmetic ingredients through new product development, development of new product applications, development of additional claim substantiations, and geographic expansion. Although we have experienced significant pricing pressure from low-cost competitors, we believe that we can compete with these low-cost competitors because our customers value our innovation capabilities, the quality of our products, the reliability of supply and the outstanding technical support.

 

MEDICAL LUBRICANTS

 

Our medical lubricants are sold directly to manufacturers and marketers of finished products or to the contract manufacturers utilized by those companies. Sales of our medical lubricants are shipped EXW from our facility in Hauppauge, New York. Sales are deemed final upon shipment, and we have no obligation to repurchase or allow the return of these goods unless they are defective.

 

PRODUCTS – MEDICAL LUBRICANTS

 

Our medical lubricants are also sold under the Lubrajel brand since they are water-based gel formulations designed to mainly provide sensory enhancement and lubrication to medical products. The Lubrajel medical lubricant products are primarily used in catheters, condoms, personal lubricants and in oral care applications such as mouth washes.

 

6
 

 

UNITED-GUARDIAN, INC.

 

Currently, we offer six medical lubricant products for catheter lubrication, one product for the lubrication of condoms and one product for oral care. In addition, we develop and sell customized exclusive products for all these applications.

 

Our medical lubricants include the following:

 

LUBRAJEL MG was the first medical lubricant product developed by the Company. It has been used by many medical device manufacturers for lubricating urinary catheters, pre-lubricated enema tips, and other medical devices.

 

LUBRAJEL MGL is a medical lubricant with a lower viscosity than our standard medical lubricant, Lubrajel MG. It can be used as a general and instrument lubricant for use during physical exams. It can be applied to catheters, thermometers and other instruments to ensure ease of use and patient comfort.

 

LUBRAJEL RR and RC are both water-based gels used primarily as lubricants for urinary catheters. Lubrajel RR and Lubrajel RC can withstand sterilization by gamma radiation, which is one of the methods of terminally sterilizing medical and hospital products. Lubrajel RR was the first radiation resistant Lubrajel product. Lubrajel RC was developed as a lower-cost alternative to Lubrajel RR for those customers who are in more cost-sensitive markets.

 

LUBRAJEL FLUID is a water-based condom lubricant designed as an alternative to traditional silicone-based lubricants. The water-based formula cleans up easily with soap and water and does not stain clothing. The lubrication system employed in Lubrajel Fluid is specifically designed to be compatible with traditional condom release powders, which are used during the manufacture of latex condoms.

 

LUBRAJEL LC, LUBRAJEL BA and LUBRAJEL FA are Lubrajel formulations that were developed for use in oral care applications.

 

Sales of medical lubricants represented approximately 19% of our total sales for the year ended December 31, 2022.

 

We believe that there is potential to continue growing the sales of our medical lubricants through new product development, development of new product applications, and geographic expansion.

 

PHARMACEUTICALS

 

We sell our pharmaceutical products primarily to full-line drug wholesalers, which in turn supply those products to pharmacies, physicians, hospitals, long-term care facilities, the U.S. Department of Veterans Affairs, and other government agencies. We also sell a small quantity of pharmaceutical products directly to hospitals and pharmacies. We arrange for, and cover the cost of, shipping our pharmaceutical products, and sales of those products are final when shipped. The pharmaceutical products are returnable only under specific circumstances in accordance with pharmaceutical industry standards, such as if the products are (a) damaged when received; (b) defective; (c) too close to their expiration dates to sell; or (d) within a year after their expiration dates. These return policies are in conformance with standard pharmaceutical industry practice.

 

PRODUCTS - PHARMACEUTICALS

 

RENACIDIN is a prescription drug approved by the FDA that is used primarily to prevent and to dissolve calcifications in urethral catheters. We maintain a specific website dedicated to this product at www.renacidin.com.

 

7
 

 

UNITED-GUARDIAN, INC.

 

CLORPACTIN® WCS-90 is a chlorine-based drug that is marketed as a topical antimicrobial and is also used in urology. It is also a powerful disinfectant, fungicide, and deodorizer.

 

Our pharmaceutical products represented 39% of our total sales for the year ended December 31, 2022.

 

We believe that there is potential to grow the sales of our pharmaceutical products through geographic expansion.

 

INDUSTRIAL PRODUCTS

 

DESELEX™ is a sequestering and chelating agent that is used primarily as a replacement for phosphates in the manufacture of detergents. It also has some use in personal care products as a chelating agent in shampoos and body washes. In March 2022, we discontinued this product due to minimal sales and a significant increase in raw material costs.

 

THOROCLENS is a chlorine-based industrial cleanser which we manufacture and package for a small company in New England. Beginning in the second quarter of 2023, we will discontinue the manufacturing and sale of this product.

 

FOREIGN SALES

 

For the years ended December 31, 2022 and 2021, approximately 25% and 20%, respectively, of our sales revenue was from foreign sources, and was derived from (a) sales of our cosmetic ingredients to foreign distributors, which accounted for approximately 9% of sales in both 2022 and 2021, and (b) sales of medical lubricants directly to certain customers in foreign countries, which accounted for approximately 16% and 11% of our sales revenue for the years ended December 31, 2022 and 2021, respectively.

 

Because all shipments to our largest distributor, ASI, are delivered to ASI’s warehouses in the U.S., all sales to ASI are considered domestic sales, even though a significant percentage of ASI’s sales of our products are to customers in foreign countries. Based on sales information provided by ASI, 66% of ASI’s sales of our products in 2022 were to customers in foreign countries, compared with 74% in 2021. ASI’s largest foreign market in both 2022 and 2021 was China, which accounted for approximately 38% of ASI’s sales of our products in 2022 and 42% in 2021.

 

Since sales of our products are denominated in U.S. Dollars, our selling prices are generally not affected by fluctuations in foreign currency exchange rates, except to the extent that a stronger dollar compared with foreign currencies can make our products less competitive in foreign markets, sometimes requiring adjustments to our prices in order to be more competitive. The strengthening of the U.S. dollar in 2022, which reached its highest level in 20 years, made our products less competitive and they became pricier in other countries. We continue to work closely with our network of distributors to price our products as competitively as possible and, when appropriate, to offer additional volume discounts and more aggressive pricing to maintain and increase sales and expand our customer base.

 

DOMESTIC SALES

 

For the years ended December 31, 2022 and 2021, approximately 75% and 80%, respectively, of our sales were from domestic sources.

 

COSMETIC INGREDIENTS:

 

In the United States, our cosmetic ingredient products are marketed and distributed exclusively by ASI in accordance with a marketing agreement entered into in 1996 with its predecessor company, International Specialty Products (“ISP”). That agreement was for the marketing of the Company’s cosmetic ingredients in North, Central, and South America. Since that time, this initial agreement has been modified and expanded multiple times (see “Marketing Agreements” below), most recently in 2019 when Korea was added to ASI’s marketing territory. ASI also has the exclusive right to market four of the Company’s products globally: Lubrajel Marine, which was the second product in our Lubrajel Natural line of products; Lubrajel BA, an oral care product which was specifically developed for ASI in 2012; and two of our preservative-free products, Lubrajel Oil PF and Lubrajel II XD PF. The current agreement with ASI automatically renewed on January 1, 2022 and will automatically renew again on January 1, 2024 unless either party chooses to terminate, which can be done by giving 60 days’ notice prior to the then expiration date.

 

8
 

 

UNITED-GUARDIAN, INC.

 

Domestic sales of cosmetic ingredients accounted for approximately 32% of total sales in 2022, compared with 41% in 2021. Sales to our largest distributor, ASI, accounted for approximately 32% of total sales in 2022 and 42% of sales in 2021.

 

PHARMACEUTICALS:

 

Our pharmaceutical products are marketed only in the United States and are sold primarily through full-line drug wholesalers. Sales of those products accounted for approximately 39% of sales in 2022, compared with approximately 34% in 2021.

 

During 2022 and 2021, we participated in various government drug rebate programs related to the sale of Renacidin®, our most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (“FSS”), and the Medicare Part D Coverage Gap Discount Program (“CGDP”). These programs require us to sell our product at a discounted price, typically given in the form of a rebate. Our sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized.

 

MEDICAL LUBRICANTS:

 

We sell our medical lubricants directly to end users or to contract manufacturers utilized by the end users. Domestic sales of medical lubricants accounted for approximately 3% of our total sales in 2022, compared with 4% in 2021. Although all shipments of medical lubricants to U.S. locations are considered domestic sales, a percentage of those shipments are subsequently shipped by some customers to foreign manufacturing facilities, which then produce finished products that could be marketed globally.

 

INDUSTRIAL PRODUCTS:

 

Domestic sales of our specialty industrial products accounted for less than 2% of our sales in both 2022 and 2021. These products are sold directly to end-user customers or their contract manufacturers, who incorporate these products into their finished products. We will discontinue manufacturing and distribution of these products in the second quarter of 2023. because sales of these products represent less than 2% of total sales, and the small production scale.

 

ISO 9001:2015 CERTIFICATION

 

On July 23, 2018, we were certified by DQS Inc. to be in compliance with the latest ISO standard, ISO 9001:2015, indicating that our documented procedures and overall operations had attained the high level of quality needed to comply with this current ISO certification level.

 

Our current ISO 9001:2015 certification is valid through July 22, 2024. We have been in continuous compliance with ISO standards since November 1998. Between November 1998 and December 2003, we were registered under the ISO 9002 standard. From December 2003 to December 2009, we were registered under the ISO 9001:2000 standard. From December 2009 to July 2018, we were registered under the ISO 9001:2008 standard.

 

9
 

 

UNITED-GUARDIAN, INC.

 

COMPETITION

 

We primarily compete in the specialty ingredients/products space. The participants in this space offer a broad range of product lines designed to meet specific customer needs. Competition is largely based on product performance, price, quality, service, product availability, security of supply, and responsiveness of product development in cooperation with customers. Many key competitors are significantly larger than us and have greater financial resources, leading to greater operating and financial flexibility.

 

To improve our competitive position, we are strengthening our core capabilities and investing in product development, especially in naturally derived products. We will also continue providing high-quality products, excellent technical service and continue to be a reliable supplier.

 

INTELLECTUAL PROPERTY

 

In recent years. we have elected to rely on trade secret protection to protect our intellectual property for proprietary product formulations and manufacturing methods. We will file for patent protection in situations where we believe that relying on trade secret protection alone would not provide sufficient protection.

 

We own the Lubrajel®, Renacidin®, and Clorpactin® trademarks.

 

RAW MATERIALS

 

We purchase raw materials from multiple sources in the United States and believe that raw material supplies will be available in quantities sufficient to meet demand in 2023. Although some of those raw materials may be manufactured overseas, all of our suppliers are located within the United States. All of our products were impacted, to varying degrees, by the volatility of raw material costs during 2022, and these conditions are likely to continue in 2023.

 

The principal raw materials we use consist of common industrial organic and inorganic chemicals. We have six major raw material vendors that together accounted for approximately 90% of our raw material purchases in 2022 and 94% in 2021.

 

INVENTORIES, RETURNS, and ALLOWANCES

 

We believe it is important to maintain moderate inventory levels of certain of our finished goods in order to fulfill purchase orders in a timely manner. Historically, sufficient inventory levels, returns, and allowances have not been a significant factor in our business.

 

BACKLOG

 

We do not currently have any significant backlog of orders.

 

SEASONALITY

 

Due to the nature of our business and the types of products that we market, we are not subject to any significant seasonal fluctuations in sales.

 

CUSTOMERS

 

Our cosmetic ingredients are currently marketed and sold globally by five distributors. Those distributors, in turn, market and distribute those products to their customers. Although we depend on these distributors for the marketing and distribution of our cosmetic ingredients, we believe that if any of our distributors were to decide not to sell our products, or if we chose to replace one or more of those distributors, we would be able to put new marketing agreements in place to service our customers in all the geographic areas affected. If necessary, we would also be able to sell directly to the end users of our products until such time as a new distributor is put in place.

 

10
 

 

UNITED-GUARDIAN, INC.

 

Our pharmaceutical products are sold to, and distributed by, full-line drug wholesalers throughout the United States. Our medical and specialty industrial products are sold directly by us to the end users of those products or, in some cases, to contract manufacturers used by some of those end users.

 

RESEARCH AND DEVELOPMENT

 

Our research and development (“R&D”) team’s main focus is to develop new products and product-line extensions. The product development activities are focused on developing products for identified customers and market needs. We frequently collaborate with customers to develop the desired product to meet their specific needs. The R&D team also provides technical support services to assist our customers with application development and co-development. In addition, the R&D team provides ongoing technical assistance and know-how to quality assurance and manufacturing personnel to ensure consistent standards for our products and to deliver environmentally responsible products that exceed customer expectations.

 

Our research and development expenses in 2022 were $490,770 compared with $478,642 in 2021. We expect our research and development expenses in 2023 to be higher than those of 2022 in order to support innovation and growth. Any additional increase in R&D expenses will also depend on whether capital investments are required in order to continue development work on, or to manufacture, any of the new products under development.

 

We require all employees and consultants who may receive confidential and proprietary information to agree in writing to keep such information confidential.

 

GOVERNMENT REGULATION

 

Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacturing and marketing of many of our products. Some of the products we develop and sell in the United States may require approval from federal regulatory agencies, such as the U.S. Food & Drug Administration (“FDA”), as well as state regulatory agencies. Some products sold outside the United States may require approval from foreign regulatory agencies.

 

Our operations and many of our products are subject to chemical control laws. These laws include regulation of chemical substances and inventories under and the Registration, Evaluation and Authorization of Chemicals (“REACH”) regulation in Europe, Right to Know laws under the Global Harmonized System (“GHS”) for hazard communication, and the regulation of chemicals used in the manufacture of pharmaceuticals and personal care products and contact food under the Food, Drug and Cosmetics Act in the United States. We are an FDA Drug Establishment registered site.

 

We are required to comply with all pertinent current Good Manufacturing Practices of the FDA for medical devices and drugs our products may be subject to. Accordingly, the regulations to which we and certain of our products may be subject, and any changes with respect thereto, may materially affect our ability to produce and market new products..

 

Our present and future activities are, and will likely continue to be, subject to varying degrees of additional regulation under the Occupational Safety and Health Act, Environmental Protection Act, import, export and customs regulations, and other present and possible future foreign, federal, state and local regulations.

 

Portions of our operating expenses are directly attributable to complying with federal, state, and local environmental statutes and regulations. In 2022 and 2021, we incurred approximately $39,000 and $32,000, respectively, in federal, state, and local environmental law compliance expenses. There was no material financial or other impact on our results of operations as a result of compliance with environmental laws.

 

11
 

 

UNITED-GUARDIAN, INC.

 

EMPLOYEES HEALTH AND SAFETY

 

We value all of our employees, suppliers, customers and distributors as well as the broader environment in which we all live and work. We are committed to protecting the safety, health and security of our employees and that of the environment in which we operate. We are further committed and have implemented strict policies against anti-discrimination, anti-harassment and anti-bulling, and will not compromise employee health and safety or the environment for profit.

 

ENVIRONMENTAL AND CORPORATE SOCIAL RESPONSIBILITY

 

We have a proactive mindset for sustainability. We are committed to sustainable growth and minimizing our impact on the local community and the environment. We are committed to measuring and monitoring our impact on the environment and, where appropriate, making improvements. We comply in all material respects with all federal, state and local environmental regulations.

 

We have recently established a carbon footprint monitoring program. In 2023, we will be setting goals in order to minimize our impact on the environment. We have also joined initiatives for core raw materials, such as the Roundtable on Sustainable Palm Oil (“RSPO”), to ensure that we support suppliers in protecting the environment and the people in it. We are committed to using green chemistry principles to produce biodegradable, natural, and safe products with renewable feedstocks.

 

SOLID WASTE

 

We do not produce hazardous waste. We comply with U.S. Environmental Protection Agency (“EPA”) and Department of Transportation’s (“DOT”) regulations for the disposal of the solid waste.

 

WATER

 

We comply in all material respects with all laws and regulations on water discharge.

 

ECOVADIS

 

We joined EcoVadis as part of our commitment to Corporate Social Responsibility (“CSR”). EcoVadis is a global leader in guiding, measuring, and improving corporate environmental and social responsibility and sustainability performance. The EcoVadis assessment measured 21 key issues centered around the environment, labor & human rights, ethics, and sustainable procurement. In its latest evaluation we scored in the top 15% of companies evaluated.

 

As part of the assessment, it was determined that we were strong in the following four areas:

 

 

1)

Environmental
 

a)

Company-specific emergency preparedness and response procedure regarding customer health and safety
 

b)

Measures to detect and/or eliminate accidental water contamination
 

c)

Formalized procedure related to materials/chemicals management
 

d)

Provision of Safety Data Sheets
 

e)

Employee awareness/training program on transportation of hazardous materials
 

f)

Measures to avoid emissions of dust or particles

 

12
 

 

UNITED-GUARDIAN, INC.

 

 

2)

Labor & Human Rights
 

a)

Labor and human rights policy
 

b)

Formalized procedure related to employee health and safety
 

c)

Compensation for extra or atypical working hours
 

d)

Additional leave beyond standard vacation days
 

e)

Bonus scheme related to Company performance
 

f)

Heath care coverage of employees in place
 

g)

Whistleblower procedure on discrimination and harassment
 

h)

Awareness training regarding diversity, discrimination and/or harassment
 

i)

Regular assessment (yearly) of individual performance
 

j)

Active preventative measures for stress and noise
 

k)

Training of relevant employees on health and safety risks and best working practices

 

 

3)

Ethics
  a) Disciplinary sanctions to deal with policy violations
  b) Policy on information security
  c) Polices on corruption
  d) Whistleblower procedure to report ethics issues

 

  4) Sustainable Procurement

 

  a) RSPO Supply Chain Certification
  b) Formal assessment of supplier’s progress with regards to REACH requirements
  c) No use of tin, tantalum, tungsten, gold, and/or their derivatives

 

Areas that required continual improvements were reviewed, and programs and policies were implemented as follows:

 

 

1)

Environmental impact from product end of life: we joined a prescription take-back program for our pharmaceutical products in the state of California.

 

 

2)

Measures on energy consumption and GHG’s: we created a carbon footprint procedure that will roll out later in 2023 to assess our current energy consumption, with the goal of reducing that consumption in subsequent years.

 

 

3)

Established formal CSR Policy: we created a CSR policy to establish a framework for our commitment to sustainable performance.

 

HUMAN CAPITAL MANAGEMENT

 

We currently have 24 employees, 4 of whom serve in an executive capacity, 15 in research, quality control and manufacturing, 3 in maintenance and construction, and 2 in office and administrative support services. Of the total number of employees, 23 are full time.

 

COMPETITIVE PAY AND BENEFITS

 

We are committed to paying our employees in a fair and equitable manner, regardless of race, gender or country of origin. We believe employees should be compensated equitably based on performance, skills, and experience. We offers a competitive benefits program to support employees through all life stages.

 

INCLUSION AND DIVERSITY

 

We focus significant resources on developing and retaining diverse talent and are committed to actively creating a collaborative environment of innovation that leverages the talents of a diverse workforce to drive sustainable growth and create value for our shareholders, customers, employees, and the community in which we operate.

 

13
 

 

UNITED-GUARDIAN, INC.

 

TALENT MANAGEMENT

 

The talent management process includes a well-established performance management process that seeks to provide employees ongoing feedback to enhance their performance in support of business objectives.

 

Item 1A. Risk Factors.

 

The information to be reported under this item is not required of smaller reporting companies.

 

Item 1B. Unresolved Staff Comments.

 

None.

 

Item 2. Properties

 

We own our principal office, manufacturing, and research and development facility consisting of a 50,000 square foot facility on a 2.7-acre parcel located at 230 Marcus Boulevard, Hauppauge, New York 11788. Of the 50,000 square feet, approximately 30,000 square feet is manufacturing space, 15,000 square feet is warehouse space, and 5,000 square feet is office and laboratory space. We have fully developed the 2.7 acres, and fully utilize the building occupying the land. We believe that the property is adequate for our immediately foreseeable needs. The property is presently unencumbered and adequately insured.

 

Item 3. Legal Proceedings

 

From time to time, we are subject to ordinary routine litigation and claims incidental to our business. We are not currently involved in any legal proceedings that we believe are material.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 

Market Information

 

Our Common Stock is currently traded on the NASDAQ Global Market, under the symbol “UG”

 

Holders of Record

 

As of March 1, 2023, there were 371 holders of record of Common Stock.

 

Cash Dividends

 

On May 10, 2022, our Board of Directors declared a semi-annual cash dividend of $0.37 per share, which was paid on June 1, 2022 to all stockholders of record as of May 23, 2022. On November 15, 2022, our Board of Directors declared a semi-annual cash dividend of $0.31 per share, which was paid on December 7, 2022 to all stockholders of record as of November 28, 2022.

 

On May 18, 2021, our Board of Directors declared a semi-annual cash dividend of $0.48 per share, which was paid on June 7, 2021 to all stockholders of record as of May 31, 2021. On November 16, 2021, our Board of Directors declared a semi-annual cash dividend of $0.65 per share, which was paid on December 7, 2021 to all stockholders of record as of November 29, 2021.

 

14
 

 

UNITED-GUARDIAN, INC.

 

Item 6. [RESERVED]

 

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

 

Impact of the Coronavirus Pandemic, Global Supply Chain Instability and Inflation

 

While the coronavirus pandemic continues to impact certain areas of our operations, the current impact on our financial performance is coming primarily from 1) higher raw material costs and increased shipping costs, which had an impact on our gross profit margins during 2022, and 2) a decrease in cosmetic ingredient sales in China due to China’s zero-COVID mandate that was in effect for a substantial part of 2022.

 

The pandemic did not significantly affect our ability to obtain raw materials, but due to supply chain instability, we have experienced longer lead times and higher prices for many of our raw materials. The increased raw material prices had an impact on our gross profit margins in 2022 and may continue to have an impact on gross profit margins in upcoming quarters. In response to rising raw material prices, we have instituted price increases on many of our products, which will help to reduce the impact on our gross margins in the future.

 

As a result of the lingering effects of the coronavirus pandemic as described above, combined with global supply chain instability, there continues to be uncertainty regarding the potential impact on our operations or financial results. We believe that we are still unable to provide an accurate estimate or projection as to what the future impact of the pandemic will be on our future operations or financial results.

 

While it is unknown whether inflation will continue to increase or will begin to mitigate during 2023, continued inflation is likely to result in further increases in raw material costs, shipping costs, and internal labor costs, which could impact our future results of operations.

 

Critical Accounting Policies

 

Our financial statements have been prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“US GAAP”). Preparation of financial statements requires us to make estimates and assumptions affecting the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities. We use our historical experience and other relevant factors when developing our estimates and assumptions, which are continually evaluated. Note A, Nature of Business and Summary of Significant Accounting Policies, of the Notes to Financial Statements, included in Item 8, Financial Statements and Supplementary Data, of this Annual Report includes a discussion of our significant accounting policies. The following accounting policies are those that we consider critical to an understanding of the financial statements because their application places the most significant demands on management’s judgment. Our financial results might have been different if other assumptions had been used or other conditions had prevailed.

 

Marketable Securities

 

Our marketable securities include investments in equity and fixed income mutual funds. Our marketable equity securities are reported at fair value with the related unrealized and realized gains and losses included in net income. Realized gains or losses on mutual funds are determined on a specific identification basis. We evaluate our investments periodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extent to which fair value had been below cost basis, the financial condition of the issuer and our ability and intent to hold the investment for a period of time which may be sufficient for anticipated recovery of market value. We record an impairment charge to the extent that the cost of the available-for-sale securities exceeds the estimated fair value of the securities and the decline in value is determined to be other-than-temporary. During 2022 and 2021, we did not record an impairment charge regarding our investment in marketable securities because our management believes, based on an evaluation of the circumstances, that the decline in fair value below the cost of certain of our marketable securities is temporary.

 

15
 

 

UNITED-GUARDIAN, INC.

 

Revenue Recognition

 

We record revenue in accordance with ASC Topic 606 “Revenue from Contracts with Customers.” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. Our principal source of revenue is product sales.

 

Our sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period in which the revenue is recognized. Such deductions, primarily related to the sale of our pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with our current participation in Medicare programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period.

 

During 2022 and 2021, we participated in various government drug rebate programs related to the sale of Renacidin®, our most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (“FSS”), and the Medicare Part D Coverage Gap Discount Program (“CGDP”). These programs require us to sell our products at a discounted price, typically in the form of a rebate. Our sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized.

 

As long as a valid purchase order has been received and future collection of the sale amount is reasonably assured, we recognize revenue from sales of our products when those products are shipped, which is when our performance obligation is satisfied. Our cosmetic products are shipped “Ex-Works” from our facility in Hauppauge, NY, and the risk of loss and responsibility for the shipment passes to the customer upon shipment. Sales of our medical lubricant products are deemed final upon shipment, and we have no obligation to repurchase or allow the return of these goods unless they are defective. Sales of our pharmaceutical products are final upon shipment unless (a) they are found to be defective; (b) the product is damaged in shipping; (c) the product is too close to its expiration date for the customer to sell; or (d) the product is expired but is not more than one year after its expiration date. These return policies are in conformance with standard pharmaceutical industry practice. We estimate an allowance for outdated material returns based on previous years’ historical returns of our pharmaceutical products.

 

We do not make sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is not contingent upon the customer being able to sell the goods to a third party.

 

Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606-10-32-8. We have not experienced significant fluctuations between estimated allowances and actual activity.

 

The timing between recognition of revenue for product sales and the receipt of payment is not significant. Our standard credit terms, which vary depending on the customer, range between 30 and 60 days. We use our judgment on a case-by-case basis to determine our ability to collect outstanding receivables and provide allowances for any receivables for which collection has become doubtful. As of December 31, 2022 and December 31, 2021, the allowance for doubtful accounts receivable was $20,063 and $20,252, respectively. Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken.

 

We have distribution agreements with certain distributors of our pharmaceutical products that entitle those distributors to distribution and services-related fees. We record distribution fees, and estimates of distribution fees, as offsets to revenue.

 

16
 

 

UNITED-GUARDIAN, INC.

 

Accounts Receivable Allowance

 

We perform ongoing credit evaluations of our customers and adjust credit limits, as determined by a review of current credit information. We continuously monitor collection and payments from customers and maintain an allowance for doubtful accounts based upon historical experience, anticipation of uncollectible accounts receivable and any specific customer collection issues that have been identified. While our credit losses have historically been low and within expectations, we may not continue to experience the same credit loss rates that have historically been attained. The receivables are highly concentrated in a relatively small number of customers. Therefore, a significant change in the liquidity, financial position, or willingness to pay timely, or at all, of any one of our significant customers would have a significant impact on our results of operations and cash flows.

 

Inventory Valuation Allowance

 

In conjunction with our ongoing analysis of inventory valuation, management constantly monitors projected demand on a product-by-product basis. Based on these projections, management evaluates the levels of write-downs required for inventory on hand and inventory on order from contract manufacturers. Although we believe that we have been reasonably successful in identifying write-downs in a timely manner, sudden changes in buying patterns from customers, either due to a shift in product interest and/or a complete pull back from their expected order levels, may result in the recognition of larger-than-anticipated write-downs. We have performed an evaluation of our inventory on hand as of December 31, 2022, and believe the reserve is adequate to cover any slow-moving or obsolete inventory. We do not believe the value of our finished products, work in process or raw material inventories have been adversely affected by the current inflationary environment.

 

RESULTS OF OPERATIONS

 

Sales

 

Sales decreased by approximately 9%, from $13,929,629 in 2021 to $12,698,503 in 2022. The decrease in sales was primarily due to a decrease in sales of our cosmetic ingredient products, specifically a decrease of 28% in sales to our largest distributor, ASI, in 2022 compared with 2021.

 

 

(a)

Cosmetic Ingredients

 

Sales of our cosmetic ingredients decreased by approximately 25%, from $6,872,714 in 2021, to $5,167,909 in 2022. The decrease in sales of cosmetic ingredients was caused by the following factors: 1) supply chain issues faced by certain contract manufactures caused them to overstock products in 2021 in order to avoid not being able to obtain products in 2022, which resulted in a reduction of purchases of these products by certain contract manufacturers in 2022, and 2) lower demand in Asia, especially in China, due to China’s zero-COVID mandate that was in place for much of 2022. Sales to our other four distributors decreased by a net of approximately 11%, and sales to four of our small direct cosmetic ingredient customers decreased by approximately 54%.

 

We continue to experience global competition from Asian and European companies that manufacture and sell products that are competitive with our products. These competitive products are usually sold at a lower price than our products; however they may not compare favorably to the level of performance and quality of our products.

 

The strengthening of the U.S. dollar in 2022, which reached its highest level in 20 years, made our products less competitive, as they became more expensive in other countries. We continue to work closely with our network of distributors to price our products as competitively as possible and, when appropriate, to offer additional volume discounts and more aggressive pricing to maintain and increase sales and expand our customer base.

 

17
 

 

UNITED-GUARDIAN, INC.

 

We expect that this competitive environment will continue in 2023 and we plan to enhance our competitive position by strengthening our core capabilities and investing in new products, especially in the area of naturally-derived products. We will also continue providing high-quality products, excellent technical support, and the reliability our customers have come to expect from us.

.

 

(b)

Pharmaceuticals

 

Because there are fees, rebates, and allowances associated with sales of our two pharmaceutical products, Renacidin and Clorpactin, discussion of our pharmaceutical sales includes references to both gross sales (before fees, rebates and allowances) and net sales (after fees, rebates and allowances). Gross sales of our two pharmaceutical products, Renacidin and Clorpactin, together increased by 3%, from $5,748,244 in 2021 to $5,929,216 in 2022. Gross sales of Renacidin increased by 3%, from $5,041,460 in 2021 to $5,181,190 in 2022, and gross sales of Clorpactin increased by 6% from $706,784 in 2021 to $748,026 in 2022.

 

Net sales of our pharmaceutical products increased by approximately 4% in 2022 compared with the same period in 2021. The increase in net sales was due to the combination of 1) an increase in gross sales of both of our pharmaceutical products, and 2) a decrease in certain pharmaceutical-related rebates and allowances. The decrease in pharmaceutical-related rebates and allowances in 2022 was primarily due to a decrease in rebates on sales of our products to the VA and a reduction in sales returns.

 

 

(c)

Medical Lubricants

 

Sales of our medical lubricants increased by approximately 14% in 2022, from $2,171,204 in 2021 to $2,470,163 in 2022. The increase in sales was driven by higher demand from one of our larger contract manufacturer customers located in China, whose sales doubled in 2022 compared to 2021.

 

  (d) Industrial Products

      

Sales of our industrial products decreased by 22% in 2022 compared with 2021. We plan on discontinuing the manufacturing and sales of specialty industrial products in the second quarter of 2023. These products sales represent less than 2% of total sales.

 

Gross Profit on Sales

 

Gross profit on sales was 53% in 2022 compared with 59% in 2021. The decrease in gross profit was due to 1) a decrease in sales of our cosmetic ingredients in 2022 compared to 2021. These products carry a higher profit margin than our pharmaceutical products. In 2022, our pharmaceutical sales as a percentage of gross sales was 43% compared to 38% in 2021; 2) increased raw material and shipping costs in 2022 compared with 2021; 3) the recording of $206,621 in rebates payable to one of our marketing partners during 2022; and 4) the recording of a one-time Employee Retention Credit (“ERC”) in the amount of approximately $105,000 in 2021, which reduced cost of sales during that period.

 

Operating Expenses

 

Operating expenses increased by approximately 7%, from $2,035,970 in 2021 to $2,174,127 in 2022. The increase was mainly attributable to the following factors: 1) increases in fees paid to the independent members of our Board of Directors during 2022 for special projects; 2) an increase in payroll and payroll related expenses, insurance expense and utilities; and 3) the recording of a one-time ERC in the amount of approximately $31,000 in 2021, which reduced operating expenses for that period. We anticipate that operating expenses will remain relatively consistent for 2023.

 

 

18
 

 

UNITED-GUARDIAN, INC.

 

Research and Development Expenses

 

Research and development expenses increased by approximately 3%, from $478,642 in 2021 to $490,770 in 2022. The increase was primarily related to an increase in payroll and payroll related expenses combined with the recording of an ERC during 2021 in the amount of $28,000 which reduced R&D expenses for that period.

 

Investment Income

 

Investment income increased by approximately 1%, from $233,857 in 2021 to $236,695 in 2022. The increase was due to an increase in dividend income from both stock and bond mutual funds.

 

Net loss on Marketable Securities

 

The net loss on marketable securities increased from a net loss of $23,018 in 2021 to a net loss of $1,046,245 in 2022. The increased loss was primarily due to 1) the recognition of increased unrealized losses during 2022 due primarily to rising interest rates combined with the downward trajectory of the financial markets during 2022. Our portfolio of marketable securities is predominantly invested in fixed income mutual funds. When interest rates began to rise during the year, the value of these funds declined; and 2) increased realized losses on those same fixed income mutual funds that were sold during the year. During 2021, we recognized realized gains of $111,917 from the sale of marketable securities, while in 2022, we recorded $364,074 in realized losses from the sale of marketable securities.

 

Provision for Income Taxes

 

The provision for income taxes decreased from $1,219,383 in 2021 to $658,168 in 2022. This decrease was due to a decrease in income before taxes. Our effective income tax rate was 20.4% in 2022 and 20.7% in 2021.

 

Liquidity and Capital Resources

 

Working capital decreased from $9,245,629 at December 31, 2021 to $8,596,939 at December 31, 2022. The current ratio increased from 5.0 to 1 at December 31, 2021 to 7.3 to 1 at December 31, 2022. The decrease in working capital was mainly due to a decrease in marketable securities and accounts receivable.

 

Accounts receivable (net of allowance for doubtful accounts) as of December 31, 2022 decreased from $1,813,346 in 2021 to $1,427,576 in 2022. The decrease in accounts receivable was due to a decrease in sales during the third and fourth quarter of 2022. The receivables turnover, or “Days Sales Outstanding”, for 2022, was 47 days, compared with 42 days in 2021. The increase in Days Sales Outstanding was primarily due to an increase in the sales of our medical lubricant products in 2022. These products are primarily sold to customers located overseas and the payment terms for these customers is typically 60 days, as compared with 30-45 days for our domestic customers. The allowance for doubtful accounts receivable decreased from $20,252 in 2021 to $20,063 in 2022, and we believe that the net balance of our accounts receivable as of December 31, 2022 was, and continues to be, fully collectible.

 

We generated cash from operations of $2,525,169 in 2022 compared with $5,313,277 in 2021. The decrease in 2022 was primarily due to a decrease in net income in 2022 compared with 2021, combined with decreases in accounts payable, accrued expenses and deferred revenue.

 

Net cash provided by investing activities was $897,562 for the year ended December 31, 2022. Net cash used in investing activities was $183,475 for the year ended December 31, 2021. The increase in net cash provided by investing activities was mainly due an increase in net proceeds from the sale of marketable securities combined with a decrease in acquisitions of property, plant and equipment in 2022 compared with 2021.

 

19
 

 

UNITED-GUARDIAN, INC.

 

Net cash used in financing activities was $3,123,492 and $5,190,033 for the years ended December 31, 2022 and 2021, respectively. The decrease was due to the payment of lower dividends in 2022 compared with 2021. During 2022, we paid dividends of $0.68 per share compared with $1.13 per share in 2021.

 

We believe that our working capital is sufficient to support our operating requirements for the next fiscal year. Our long-term liquidity position will be dependent upon our ability to generate sufficient cash flow from profitable , and we expect to continue to use our cash to make dividend payments, purchase marketable securities, and to take advantage of other opportunities that may arise that are in the best interest of our Company and our shareholders.

 

We expect to incur costs of approximately $100,000 in the first six months of 2023 in connection with an upgrade to our building sprinkler system.

 

We have no off-balance-sheet transactions that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

New Accounting Pronouncements

 

See Note “A” to the financial statements regarding new accounting pronouncements, which note is incorporated herein by reference.

 

Item 7A. Quantitative and Qualitative Disclosures about Market Risk.

 

The information to be reported under this item is not required of smaller reporting companies.

 

Item 8. Financial Statements and Supplementary Data.

 

Annexed hereto starting on page F-1.

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 

None.

 

Item 9A. Controls and Procedures.

 

  (a) Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, has evaluated the design, operation, and effectiveness of the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act as of December 31, 2022. On the basis of that evaluation, management concluded that our disclosure controls and procedures are designed to be, and are, effective at providing reasonable assurance that the information required to be disclosed in reports filed or submitted pursuant to the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to management, including our Principal Executive Officer and Principal Financial Officer as appropriate, to allow timely decisions regarding required disclosure.

 

  (b) Management’s Report on Internal Control over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Our internal control system is designed to provide reasonable assurance to management and to our Board of Directors regarding the preparation and fair presentation of published financial statements. Under the supervision and with the participation of management, including our Principal Executive Officer and Principal Financial Officer, management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO 2013”). Based on management’s evaluation under the framework in Internal Control—Integrated Framework, management concluded that our internal control over financial reporting was effective as of December 31, 2022.

 

This Annual Report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Since we are a non-accelerated filer, management’s report is not subject to attestation by our registered public accounting firm pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002. As a result, this Annual Report contains only management’s report on internal controls.

 

20
 

 

UNITED-GUARDIAN, INC.

 

  (c) Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting in the fourth quarter of 2022 that materially affected, or would be reasonably likely to materially affect, our internal control over financial reporting.

 

  (d) Limitations of the Effectiveness of Internal Controls

 

 

The effectiveness of our system of disclosure controls and procedures and internal control over financial reporting is subject to certain limitations, including the exercise of judgment in designing, implementing and evaluating the control system, the assumptions used in identifying the likelihood of future events, and the inability to eliminate fraud and misconduct completely. As a result, there can be no assurance that our disclosure controls and procedures and internal control over financial reporting will detect all errors or fraud. However, our control systems have been designed to provide reasonable assurance of achieving their objectives, and our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures and internal control over financial reporting are effective at the reasonable assurance level.

 

Item 9B. Other Information.

 

None.

 

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 

Not applicable.

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance.

 

The information required by this item is incorporated by reference to the section entitled “Directors and Executive Officers” to be contained in the Company’s 2023 Proxy Statement.

 

CODE OF ETHICS

 

We have adopted a Code of Business Conduct and Ethics that applies to all of our officers, directors, and employees serving in any capacity, including the Chief Executive Officer and/or President, Chief Financial Officer, and Principal Accounting Officer. A copy of our Code of Business Conduct and Ethics is available on our website at http://www.u-g.com/corporate. If applicable, we intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K relating to amendments to or waivers from any provision of our Code of Business Conduct and Ethics applicable to the Chief Executive Officer, Chief Financial Officer, and Principal Accounting Officer by posting this information on our website.

 

21
 

 

UNITED-GUARDIAN, INC.

 

AUDIT COMMITTEE

 

We have an Audit Committee (“Committee”) that is currently composed of three independent members of our Board of Directors, as well as an additional outside director that has expertise in both accounting and financial reporting, who acts as an advisor to the Committee. The members of the Committee are elected annually by the Board of Directors. The Committee was established for the purpose of assisting the Board of Directors in fulfilling its oversight responsibilities, including (a) overseeing our accounting and financial reporting processes, including preparation of financial statements and audits; (b) assuring compliance with all applicable legal, regulatory, and ethical responsibilities; (c) evaluating the qualifications and independence of our independent registered public accounting firm; and (d) assessing the effectiveness of our internal controls and risk management procedures. The Committee currently meets five times a year and is governed by a charter that was adopted in 2006 and updated in 2020.

 

Item 11. Executive Compensation.

 

The information required by this item is incorporated by reference to the section entitled “Directors and Executive Officers” to be contained in the Company’s 2023 Proxy Statement.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 

The information required by this item is incorporated by reference to the section entitled “Directors and Executive Officers” to be contained in the Company’s 2023 Proxy Statement.

 

Item 13. Certain Relationships and Related Transactions, and Director Independence.

 

The information required by this item is incorporated by reference to the section entitled “Directors and Executive Officers” to be contained in the Company’s 2023 Proxy Statement.

 

Item 14. Principal Accounting Fees and Services.

 

Audit Fees

 

The aggregate fees that have been billed by Baker Tilly US, LLP (“Baker Tilly”), our principal accountants, for the quarterly reviews of our financial statements for the first, second and third quarters of 2021 and the audit of our financial statements for the 2021 fiscal year were $90,500.

 

The aggregate fees that have been, or are expected to be, billed by Baker Tilly for the quarterly reviews of our financial statements for the first, second and third quarters of 2022 and the audit of our financial statements for the 2022 fiscal year are $97,000.

 

Audit-Related Fees

 

During 2022, there were no fees paid to Baker Tilly in connection with our compliance with Section 404 of the Sarbanes-Oxley Act of 2002.

 

No other fees were billed by Baker Tilly for the last two fiscal years that were reasonably related to the performance of the audit or review of our financial statements and not reported under "Audit Fees" above.

 

22
 

 

UNITED-GUARDIAN, INC.

 

Tax Fees

 

There were no fees billed by Baker Tilly during the last two fiscal years for professional services rendered for tax compliance, tax advice, or tax planning. Accordingly, none of such services were approved pursuant to pre-approval procedures or permitted waivers thereof.

 

All Other Fees

 

There were no other non-audit-related fees billed by Baker Tilly in 2022 or 2021.

 

PART IV

 

Item 15. Exhibits, Financial Statement Schedules.

 

(a)

Documents filed as part of this report.

 

 

 

 

(i)

Financial Statements - see Item 8. Financial Statements and Supplementary Data.

 

 

 

 

(ii)

Financial Statement Schedules – None. (Financial statement schedules have been omitted either because they are not applicable, not required, or the information required to be set forth therein is included in the financial statements or notes thereto.)

 

 

 

(iii)

Report of Independent Registered Public Accounting Firm.
   

 

(iv)

Notes to Financial Statements.
   

(b)

Exhibits
   

 

The exhibits listed on the accompanying Exhibit Index are filed as part of this Annual Report.

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  UNITED-GUARDIAN, INC.  
       
Date: March 16, 2023     By: /s/ Beatriz Blanco  
    Beatriz Blanco     
    President and Director  

 


                   

 

23
 

 

UNITED-GUARDIAN, INC.

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
           
By: /s/ Beatriz Blanco   President (Principal Executive Officer); Director   March 16, 2023
  Beatriz Blanco        
           
By: /s/ Andrea J. Young   Chief Financial Officer (Controller, Principal Financial Officer,   March 16, 2023
  Andrea J. Young   and Principal Accounting Officer); Treasurer; Secretary    
           
By: /s/ Lawrence F. Maietta   Director; Advisor to the Audit Committee   March 16, 2023
  Lawrence F. Maietta        
           
By: /s/ Arthur M. Dresner   Director; Chairman of the Audit Committee   March 16, 2023
  Arthur M. Dresner        
           
By: /s/ Andrew A. Boccone   Director; Audit Committee member   March 16, 2023
  Andrew A. Boccone        
           
By: /s/ S. Ari Papoulias   Director; Audit Committee member   March 16, 2023
  S. Ari Papoulias        
           
By: /s/ Ken Globus   Chairman of the Board of Directors   March 16, 2023
  Ken Globus        

 

 

 

24
 

 

UNITED-GUARDIAN, INC.

 

EXHIBIT INDEX

 

Exhibit #

Description

2.1

Certificate of Merger of United-Guardian, Inc. (New York) with and into United-Guardian, Inc. (Delaware) as filed with the Secretary of State of the State of Delaware on September 10, 1987. (Incorporated by reference to Exhibit 3(b) of the Registrant's Annual Report on Form 10-K for the fiscal year ended February 29, 1988)

3.1

Certificate of Incorporation of the Company as filed April 22, 1987 (Incorporated by reference to Exhibit 4.1 of the Registrant's Current Report on Form 8-K, dated September 21, 1987)

3.2

By-laws of the Company (Incorporated by reference to Exhibit 4.2 of the Registrant's Current Report on Form 8-K, dated September 21, 1987)

4.1

Specimen Certificate for shares of Common Stock of the Company (Incorporated by reference to Exhibit 4(a) of the Registrant's Annual Report on Form 10-K for the fiscal year ended February 29, 1988)

10.1

Qualified Retirement Income Plan for Employees of the Company, as restated April 1, 1976 (Incorporated by reference to Exhibit 11(c) of the Registrant's Registration Statement on Form S-1 (Registration No. 2-63114) declared effective February 9, 1979)

10.2

Exclusive Distributor Agreement between the Company and ISP Technologies Inc. dated July 5, 2000 (Incorporated by reference to Exhibit 10(d) of the Registrant's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2000)

10.3

Letter Amendment between the Company and ISP Technologies Inc. dated December 16, 2002 amending the Exclusive Distributor Agreement between the Registrant and ISP Technologies Inc. dated July 5, 2000 (Incorporated by reference to Exhibit 10(d) to the Registrant's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2002)

10.4

Letter Amendment between the Company and ISP Technologies Inc. dated December 20, 2005 amending the Exclusive Distributor Agreement between the Registrant and ISP Technologies Inc. dated July 5, 2000 and amended on December 31, 2002 (Incorporated by reference to Exhibit 10(d) of the Registrant's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2005)

10.5

Letter Amendment between the Company and ISP Technologies Inc. dated May 5, 2010 amending the Exclusive Distributor Agreement between the Company and ISP Technologies Inc. dated July 5, 2000 and amended on December 16, 2002 and December 20, 2005 (Incorporated by reference to Exhibit 10.1 of the Registrant's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2010)

10.6

Manufacturing and Supply Agreement between the Company and Smiths Medical ASD, Inc. signed November 12, 2013 and effective as of November 1, 2013 (Incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K dated and filed November 18, 2013)

10.7**

Employment agreement between Beatriz Blanco and the Company dated October 10, 2022 (Incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 10-Q for the fiscal quarter ended September 30, 2022)

 

 

25
 

 

UNITED-GUARDIAN, INC.

 

10.8**

Memorandum of Understanding (separation agreement) between Ken Globus and the Company effective November 1, 2022 (Incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 10-Q for the fiscal quarter ended September 30, 2022)

14.1

Code of Ethics and amendments thereto (Incorporated by reference to Exhibit 14 of the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2019)

31.1*

Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002

31.2*

Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002

32*

 Joint certification pursuant to Section 906 of Sarbanes-Oxley Act of 2002

101.INS***

 Inline XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document.

101.SCH***

Inline XBRL Taxonomy Extension Schema Document

101.CAL***

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF***

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB***

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE***

Inline XBRL Taxonomy Extension Label Presentation Document
104*** Cover Page Interactive Data File (Embedded within the inline XBRL document and included in Exhibit 101.1).

 

* Filed herewith.

 

** Management contract or compensatory arrangement.

 

*** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and otherwise is not subject to liability under these sections.

 

 

 

26
 

 

 

UNITED-GUARDIAN, INC.

 

INDEX TO FINANCIAL STATEMENTS

(For the years ended December 31, 2022 and 2021)

 

Report of Baker Tilly U.S. LLP, Independent Registered Public Accounting Firm (PCAOB ID 23)

F-2

  

Financial Statements  

 

  

       Statements of Income

F-3

  

       Balance Sheets

F-4 & F-5

                         

 

       Statements of Stockholders' Equity

F-6

  

       Statements of Cash Flows

F-7

  

       Notes to Financial Statements  

F-8 - F-20

 

 

 

 

 

 

 

F-1
 

 

UNITED-GUARDIAN, INC.

 

REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM

 

To the shareholders and the board of directors of United-Guardian, Inc.:

 

Opinion on the Financial Statements

 

We have audited the accompanying balance sheets of United-Guardian, Inc. (the "Company") as of December 31, 2022 and 2021, the related statements of income, stockholders' equity, and cash flows, for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

 

/s/ Baker Tilly US, LLP

 

We have served as the Company's auditor since 2019.

 

Uniondale, NY

March 16, 2023

 

 

F-2
 

 

 

UNITED-GUARDIAN, INC.

 

STATEMENTS OF INCOME

 

   

Years ended December 31,

  
   

2022

    

2021

  
                 

Net sales

   $ 12,698,503     $ 13,929,629  
                 

Costs and expenses:

                

Cost of sales

     5,996,376       5,747,931  

Operating expenses

     2,174,127       2,035,970  

Research and development

     490,770       478,642  

Total costs and expenses

     8,661,273       8,262,543  

Income from operations

    4,037,230       5,667,086  

Other (loss) income:

                

Investment income

     236,695       233,857  

Net loss on marketable securities

     (1,046,245

)

     (23,018

)

Total other (loss) income

    (809,550

)

     210,839  
                 

Income before provision for income taxes

     3,227,680       5,877,925  
                 

Provision for income taxes

     658,168       1,219,383  

Net income

   $ 2,569,512     $ 4,658,542  
                 

Earnings per common share (basic and diluted)

   $ 0.56     $ 1.01  
                 

Weighted average shares (basic and diluted)

     4,594,319       4,594,319  

 

See Notes to Financial Statements

 

 

 

 

 

 

F-3
 

 

 

UNITED-GUARDIAN, INC.

 

BALANCE SHEETS

ASSETS

 

  

December 31,

 
  

2022

  

2021

 
         

Current assets:

        

Cash and cash equivalents

 $830,452  $531,213 

Marketable securities

  5,653,516   7,635,463 

Accounts receivable, net of allowance for doubtful accounts of $20,063 in 2022 and $20,252 in 2021

  1,427,576   1,813,346 

Inventories (net)

  1,672,012   1,410,789 

Prepaid expenses and other current assets

  201,846   192,579 

Prepaid income taxes

  185,228   --- 
         

Total current assets

  9,970,630   11,583,390 
         

Deferred income taxes, net

  110,544   --- 
         

Property, plant, and equipment:

        

Land

  69,000   69,000 

Factory equipment and fixtures

  4,585,055   4,605,742 

Building and improvements

  2,895,742   2,853,718 

Total property, plant and equipment

  7,549,797   7,528,460 
         

Less accumulated depreciation

  6,990,636   6,869,598 

Total property, plant, and equipment, net

  559,161   658,862 
         

TOTAL ASSETS

 $10,640,335  $12,242,252 

 

See Notes to Financial Statements

 

 

 

 

 

 

 

F-4
 

 

UNITED-GUARDIAN, INC.

 

BALANCE SHEETS

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

  

December 31,

 
  

2022

  

2021

 
         

Current liabilities:

        

Accounts payable

 $30,415  $410,894 

Accrued expenses

  1,322,056   1,627,390 

Deferred revenue

  ---   190,164 

Income taxes payable

  ---   88,738 

Dividends payable

  21,220   20,575 

Total current liabilities

  1,373,691   2,337,761 
         

Deferred income taxes (net)

  ---   83,222 
         

Commitments and contingencies

          
         
Stockholders’ equity:        

Common stock, $.10 par value; 10,000,000 shares authorized; 4,594,319 shares issued and outstanding at December 31, 2022 and 2021, respectively

  459,432   459,432 

Retained earnings

  8,807,212   9,361,837 

Total stockholders’ equity

  9,266,644   9,821,269 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 $10,640,335  $12,242,252 

 

See Notes to Financial Statements

 

 

 

 

 

 

 

 

F-5
 

 

 

UNITED-GUARDIAN, INC.

 

STATEMENTS OF STOCKHOLDERS' EQUITY

 

Years ended December 31, 2022 and 2021

 

 

  Common stock       
  

 

Shares

Amount  

 

Retained earnings

  

Total

 
                 

Balance, January 1, 2021

  4,594,319  $459,432  $9,894,875  $10,354,307 
                 
                 

Net income

  ---   ---   4,658,542   4,658,542 
                 

Dividends declared, not paid ($1.13 per share)

  ---   ---   (1,547

)

  (1,547

)

                 

Dividends declared and paid ($1.13 per share)

  ---   ---   (5,190,033

)

  (5,190,033

)

                 

Balance, December 31, 2021

  4,594,319  $459,432  $9,361,837  $9,821,269 
                 
                 

Net income

  ---   ---   2,569,512   2,569,512 
                 

Dividends declared, not paid ($0.68 per share)

  ---   ---   (645

)

  (645

)

                 

Dividends declared and paid ($0.68 per share)

  ---   ---   (3,123,492

)

  (3,123,492

)

                 

Balance, December 31, 2022

  4,594,319  $459,432  $8,807,212  $9,266,644 

 

See Notes to Financial Statements

 

 

 

 

 

F-6
 

 

 

UNITED-GUARDIAN, INC.

 

STATEMENTS OF CASH FLOWS

 

   

Years ended December 31,

  
   

2022

    

2021

  
                 

Cash flows from operating activities:

                

Net income

   $ 2,569,512     $ 4,658,542  

Adjustments to reconcile net income to net cash provided by operating activities:

                

Depreciation and amortization

     135,396       145,977  

Loss (gain) on sale of asset

     2,445       (14,799

)

Net loss on marketable securities

     1,046,245       23,018  

Allowance for doubtful accounts

     (189

)

     6,235  

Reserve for inventory obsolescence

     29,000       ---  

Deferred income taxes

     (193,766

)

     (68,462

)

Decrease (increase) in operating assets:

                

Accounts receivable

     385,959       (431,883

)

Inventories

     (290,223

)

     4,984  

Prepaid expenses and other current assets

     (9,267

)

     (31,371

)

Prepaid income taxes

     (185,228

)

     99,107  

(Decrease) increase in operating liabilities:

                

Accounts payable

     (380,479

)

     379,094  

Accrued expenses

     (305,334

)

     263,933  

Deferred revenue

     (190,164

)

     190,164  

Income taxes payable

     (88,738

)

     88,738  

Net cash provided by operating activities

    2,525,169       5,313,277  
                 

Cash flows from investing activities:

                

Acquisitions of property, plant and equipment

     (75,179

)

     (116,375

)

Proceeds from sale of asset

     37,039       ---  

Purchases of marketable securities

     (1,931,969

)

     (4,219,760

)

Proceeds from sales of marketable securities

     2,867,671       4,152,660  

Net cash provided by (used in) investing activities

    897,562       (183,475

)
                 

Cash flows from financing activities:

                

Dividends paid

     (3,123,492

)

     (5,190,033

)

Net cash used in financing activities

    (3,123,492

)

     (5,190,033

)
                 

Net increase (decrease) in cash and cash equivalents

     299,239       (60,231

)

Cash and cash equivalents, beginning of year

     531,213       591,444  

Cash and cash equivalents, end of year

   $ 830,452     $ 531,213  
                 

Supplemental disclosure of cash flow information

                

Taxes paid

   $ 1,125,000     $ 1,100,000  
                 

Supplemental disclosure of non-cash items:

               

Dividends payable

   $ 645     $ 1,547  

Trade-in received from sale of asset

   $ ---     $ 29,000  

 

See Notes to Financial Statements

 

F-7
 

 

UNITED-GUARDIAN, INC.

 

NOTES TO FINANCIAL STATEMENTS

 

 

NOTE A - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Business

 

United-Guardian, Inc. (the "Company") is a Delaware corporation that, through its Guardian Laboratories division, manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. It also conducts research and product development, primarily related to the development of new and unique cosmetic ingredients. The Company’s research and development department also modifies, refines, and expands the uses for existing products, with the goal of further developing the market for the Company's products. Two major product lines, Lubrajel® and Renacidin® Irrigation Solution (“Renacidin”) together accounted for approximately 92% and 93% of the Company’s sales for the years ended December 31, 2022 and December 31, 2021, respectively. Lubrajel accounted for approximately 59% and 64% of the Company’s sales for the years ended December 31, 2022 and December 31, 2021, respectively, and Renacidin accounted for approximately 33% and 29% of the Company’s sales for the years ended December 31, 2022 and December 31, 2021, respectively.

 

Impact of the Coronavirus Pandemic, Global Supply Chain Instability and Inflation

 

While the coronavirus pandemic continues to impact certain areas of the Company’s operations, the current impact on the Company’s financial performance is coming primarily from 1) higher raw material costs and increased shipping costs, which had an impact on the Company’s gross profit margins during 2022 and 2) a decrease in cosmetic ingredient sales in China due to China’s zero-COVID mandate that was in effect for a substantial part of 2022.

 

The pandemic did not affect the Company’s ability to obtain raw materials but due to supply chain instability, the Company experienced longer lead times and higher prices for many of its raw materials. The increased raw material prices had an impact on the Company’s gross profit margins in 2022 and may continue to have an impact on gross profit margins in upcoming quarters. In response to the rising raw material prices the Company has instituted price increases on many of its products, which will help to reduce the impact on the Company’s gross margins in the future.

 

As a result of the lingering effects of the coronavirus pandemic as described above, combined with global supply chain instability, there continues to be uncertainty in regard to its future potential impact on the Company’s operations or financial results. The Company believes that it is still unable to provide an accurate estimate or projection as to what the future impact of the pandemic will be on its future operations or financial results.

 

While it is unknown whether inflation will continue to increase or will begin to decrease during 2023, continued inflation is likely to result in further increases in raw material costs, shipping costs, and internal labor costs, which could impact the Company’s results of operations.

 

Use of Estimates

 

In preparing financial statements in conformity with a Generally Accepted Accounting Principles in the United States of America (“US GAAP”), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for bad debts, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities and the allocation of overhead.

 

F- 8
 
 

UNITED-GUARDIAN, INC.

 

Accounts Receivable and Reserves

 

The carrying amount of accounts receivable is reduced by a valuation allowance that reflects the Company’s best estimate of the amounts that will not be collected. The reserve for accounts receivable comprises the allowance for doubtful accounts. In addition to reviewing delinquent accounts receivable, the Company considers many factors in estimating this reserve, including historical data, experience, customer types and credit worthiness, and economic trends. At December 31, 2022 and 2021, the allowance for doubtful accounts receivable amounted to $20,063 and $20,252, respectively. From time to time, the Company adjusts its assumptions for anticipated changes in any of these or other factors expected to affect collectability.

 

Revenue Recognition

 

The Company records revenue in accordance with ASC Topic 606 “Revenue from Contracts with Customers.” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company’s principal source of revenue is product sales.

 

The Company’s sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period in which the revenue is recognized. Such deductions, primarily related to the sale of the Company’s pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with the Company’s current participation in Medicare programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period.

 

During 2022 and 2021, the Company participated in various government drug rebate programs related to the sale of Renacidin®, its most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (“FSS”), and the Medicare Part D Coverage Gap Discount Program (“CGDP”). These programs require the Company to sell its product at a discounted price. The Company’s sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized.

 

As long as a valid purchase order has been received and future collection of the sale amount is reasonably assured, the Company recognizes revenue from sales of its products when those products are shipped, which is when the Company’s performance obligation is satisfied. The Company’s cosmetic products are shipped “Ex-Works” from the Company’s facility in Hauppauge, NY, and the risk of loss and responsibility for the shipment passes to the customer upon shipment. Sales of the Company’s non-pharmaceutical medical products are deemed final upon shipment, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective. Sales of the Company’s pharmaceutical products are final upon shipment unless (a) they are found to be defective; (b) the product is damaged in shipping; (c) the product cannot be sold because it is too close to its expiration date; or (d) the product has expired (but it is not more than one year after the expiration date). This return policy conforms to standard pharmaceutical industry practice. The Company estimates an allowance for outdated material returns based on previous years’ historical returns of its pharmaceutical products.

 

The Company does not make sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is not contingent upon the customer being able to sell the goods to a third party.

 

F- 9
 
 

UNITED-GUARDIAN, INC.

 

Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606-10-32-8. At December 31, 2022 and 2021, the Company had an allowance of $369,154 and $313,904, respectively, for possible outdated material returns, which is included in accrued expenses.

 

The timing between recognition of revenue for product sales and the receipt of payment is not significant. The Company’s standard credit terms, which vary depending on the customer, range between 30 and 60 days. The Company uses its judgment on a case-by-case basis to determine its ability to collect outstanding receivables and provides allowances for any receivables for which collection has become doubtful. Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken.

 

At December 31, 2021, the Company recorded an advance payment from one of its customers in the amount of $190,164, which was recorded as deferred revenue on the balance sheet. The related performance obligation associated with this payment was satisfied in the first quarter of 2022. No such advanced payment exists at December 31, 2022.

 

The Company has distribution agreements with certain distributors of its pharmaceutical products that entitles those distributors to distribution and services-related fees. The Company records distribution fees, and estimates of distribution fees, as offsets to revenue.

 

Disaggregated net sales by product class are as follows:

 

  

Years ended December 31,

 
  2022  2021 
         

Cosmetic ingredients

 $5,167,909  $6,872,714 

Pharmaceuticals

  4,943,605   4,735,324 

Medical lubricants

  2,470,163   2,171,204 

Industrial and other

  116,826   150,387 

Total Net Sales

 $12,698,503  $13,929,629 

 

The Company’s cosmetic ingredients are currently marketed worldwide by five distributors, of which the United States (“U.S.”)-based ASI purchases the largest volume. For the years ended December 31, 2022 and 2021, approximately 25% and 20%, respectively, of the Company’s sales were to (a) its foreign-based distributors (which does not include ASI), which marketed and distributed the Company’s cosmetic ingredients to customers outside the U.S, and (b) a few foreign customers for the Company’s medical lubricants sold directly by the Company.

 

Disaggregated sales by geographic region are as follows:

 

  Years ended December 31, 
  

2022

  

2021

 
         

United States*

 $9,537,124  $11,159,341 

Other countries

  3,161,379   2,770,288 

Net Sales

 $12,698,503  $13,929,629 

 

* Although a significant percentage of ASI’s purchases from the Company are sold to foreign customers, all sales to ASI are considered U.S. sales for financial reporting purposes, since all shipments to ASI are shipped to ASI’s warehouses in the U.S. A certain percentage of those products are subsequently shipped by ASI to its foreign customers. Based on sales information provided to the Company by ASI, 66% of ASI’s sales in 2022 were to customers in foreign countries, compared with 74% in 2021. ASI’s largest foreign market in both 2022 and 2021 was China, which accounted for approximately 38% of ASI’s sales in 2022 and 42% of sales in 2021.

 

 

F- 10
 
 

UNITED-GUARDIAN, INC.

 

Cash and Cash Equivalents

 

For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at the time of purchase. The Company deposits cash and cash equivalents with high credit quality financial institutions and believes that any amounts in excess of insurance limitations to be at minimal risk. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of $250,000. At December 31, 2022, approximately $105,000 exceeded the FDIC limit.

 

Dividends

 

On May 10, 2022, the Company’s Board of Directors declared a semi-annual cash dividend of $0.37 per share, which was paid on June 1, 2022 to all stockholders of record as of May 23, 2022. On November 15, 2022, the Company’s Board of Directors declared a semi-annual cash dividend of $0.31 per share, which was paid on December 7, 2022, to all stockholders of record as of November 28, 2022. In 2022, the Company declared a total of $3,124,137 in dividends, of which $3,123,492 was paid. The balance of $645 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment.

 

On May 18, 2021, the Company’s Board of Directors declared a semi-annual cash dividend of $0.48 per share, which was paid on June 7, 2021 to all stockholders of record as of May 31, 2021. On November 16, 2021, the Company’s Board of Directors declared a semi-annual cash dividend of $0.65 per share which was paid on December 7, 2021 to all stockholders of record as of November 29, 2021. In 2021, the Company declared a total of $5,191,580 in dividends, of which $5,190,033 was paid. The balance of $1,547 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment.

 

Marketable Securities

 

The Company’s marketable securities include investments in equity and fixed income mutual funds. The Company’s marketable equity securities are reported at fair value with the related unrealized and realized gains and losses included in net income. Realized gains or losses on mutual funds are determined on a specific identification basis. The Company evaluates its investments periodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extent to which fair value had been below cost basis, the financial condition of the issuer and the Company’s ability and intent to hold the investment for a period of time which may be sufficient for anticipated recovery of market value. The Company would record an impairment charge to the extent that the cost of the available-for-sale securities exceeds the estimated fair value of the securities and the decline in value is determined to be other-than-temporary. During 2022 and 2021, the Company did not record an impairment charge regarding its investment in marketable securities because management believes, based on its evaluation of the circumstances, that the decline in fair value below the cost of certain of the Company’s marketable securities is temporary.

 

Inventories

 

Inventories are valued at the lower of cost and net realizable value. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Inventory costs include material, labor and factory overhead.

 

F- 11
 
 

UNITED-GUARDIAN, INC.

 

Property, Plant and Equipment

 

Property, plant and equipment are carried at cost, less accumulated depreciation. Major replacements and betterments are capitalized, while routine maintenance and repairs are expensed as incurred. Assets are depreciated under both accelerated and straight-line methods. Depreciation charged as a result of using accelerated methods was not materially different than that which would result from using the straight-line method for all periods presented. Certain factory equipment and fixtures are constructed by the Company using purchased materials and in-house labor. Such assets are capitalized and depreciated on a basis consistent with the Company's purchased fixed assets.

 

Estimated useful lives are as follows: 

 

Factory equipment and fixtures  

5 - 7 years  

           Building

40 years  

Building improvements  

Lesser of useful life or 20 years

 

Impairment of Long-Lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairments were necessary at December 31, 2022 and 2021.

 

Fair Value of Financial Instruments

 

Management of the Company believes that the fair value of financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, approximates their carrying value due to their short payment terms and liquid nature.

 

Concentration of Credit Risk

 

Accounts receivable potentially exposes the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether any credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its accounts receivable credit risk has been reduced.

 

For the year ended December 31, 2022, four of the Company’s pharmaceutical wholesalers and cosmetic ingredient distributors accounted for approximately 72% of the Company’s gross sales during the year and approximately 81% of its outstanding accounts receivable at December 31, 2022. For the year ended December 31, 2021, the same four pharmaceutical wholesalers and cosmetic ingredient distributors accounted for a total of approximately 75% of the Company’s gross sales during the year and 80% of its outstanding accounts receivable at December 31, 2021.

 

F- 12
 
 

UNITED-GUARDIAN, INC.

 

Vendor Concentration

 

Most of the principal raw materials used by the Company consist of common industrial organic and inorganic chemicals and are available in ample supply from numerous sources. However, there are some raw materials used by the Company that are not readily available or require long lead times. During 2022, the Company periodically experienced longer lead times due to shipping delays and supply chain issues related to the pandemic. The Company has six major raw material vendors that collectively accounted for approximately 90% and 94% of the raw material purchases by the Company in 2022 and 2021, respectively.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to the temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized.

 

Uncertain tax positions are accounted for utilizing a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As of December 31, 2022 and 2021, the Company did not have any unrecognized income tax benefits. It is the Company’s policy to recognize interest and penalties related to taxes as interest expense as incurred. During the years ended December 31, 2022 and 2021, the Company did not record any tax-related interest or penalties. The Company’s tax returns for 2019 and all subsequent years are subject to examination by the United States Internal Revenue Service and by the State of New York.

 

Research and Development

 

Research and development expenses are expenditures incurred in connection with in-house research on new and existing products. It includes payroll and payroll related expenses, outside laboratory expenditures, lab supplies, and equipment depreciation.

 

Shipping and Handling Expenses

 

Shipping and handling costs are classified in operating expenses in the accompanying statements of income. Shipping and handling costs were approximately $97,000 and $82,000 for the years ended December 31, 2022 and 2021, respectively.

 

Advertising Expenses

 

Advertising costs are expensed as incurred. For the years ended December 31, 2022 and 2021, the Company incurred approximately $19,000 and $31,000, respectively, in advertising expense, which primarily relates to the internet marketing of Renacidin, one of the Company’s pharmaceutical products.

 

F- 13
 
 

UNITED-GUARDIAN, INC.

 

Earnings Per Share Information

 

Basic earnings per share are computed by dividing net income by the weighted average number of common shares outstanding during the year. Diluted earnings per share would include the dilutive effect of outstanding stock options, if any.

 

New Accounting Standards

 

In June 2016, the FASB issued ASU-2016-13 “Financial Instruments – Credit Losses”. This guidance affects organizations that hold financial assets and net investments in leases that are not accounted for at fair value with changes in fair value reported in net income. The guidance requires organizations to measure all expected credit losses for financial instruments at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. It is effective for fiscal years beginning after December 15, 2022. The Company does not expect that the implementation of this standard will have a material effect on its’ financial statements.

 

 

NOTE B – CASH AND CASH EQUIVALENTS

 

Cash and cash equivalents include currency on hand, demand deposits with banks or financial institutions, and short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. The following table summarizes the Company’s cash and cash equivalents:

 

  Years ended December 31, 
  2022  2021 
         

Demand Deposits

 $333,275  $531,213 

U.S. Treasury Bills (original 2-month maturity)

  497,177   --- 

Total cash and cash equivalents

 $830,452  $531,213 

 
 

NOTE C - MARKETABLE SECURITIES

 

Marketable securities include investments in fixed income and equity mutual funds with maturities greater than 3 months, which are reported at their fair values.

 

The disaggregated net gains and losses on the marketable securities recognized in the income statement for the years ended December 31, 2022 and 2021 are as follows:

 

  Years ended December 31,    
  2022  2021 
       

Net losses recognized during the year on marketable securities

 $(1,046,245

)

 $(23,018

)

Less: Net losses (gains) realized during the year on marketable securities sold during the period

  364,074   (111,917

)

 

Net unrealized loss recognized during the reporting year on marketable securities still held at the reporting date

 $(682,171

)

 $(134,935

)

 

 

F- 14
 
 

UNITED-GUARDIAN, INC.

 

The fair values of the Company’s marketable securities are determined in accordance with US GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by US GAAP, which prioritizes the inputs used in measuring fair value as follows:

 

•    Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

•    Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

•    Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

The Company’s marketable equity securities, which are considered available-for-sale securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs using quoted prices (unadjusted) for identical assets in active markets. The following tables summarize the Company’s investments:

 

December 31, 2022

 

          Unrealized 
  Cost  Fair Value  (Loss)Gain 
             

Equity Securities

            

Fixed income mutual funds

 $5,449,227  $4,924,497  $(524,730

)

Equity and other mutual funds

  717,165   729,019   11,854 

Total equity securities

  6,166,392   5,653,516   (512,876

)

Total marketable securities

 $6,166,392  $5,653,516  $(512,876

)

 

December 31, 2021

 

          Unrealized 
    Cost  Fair Value  Gain 
             

Equity Securities

            

Fixed income mutual funds

 $6,814,420  $6,873,333  $58,913 

Equity and other mutual funds

  651,748   762,130   110,382 

Total equity securities

  7,466,168   7,635,463   169,295 

Total marketable securities

 $7,466,168  $7,635,463  $169,295 

 

Investment income is recognized when earned and consists principally of dividend income from equity and fixed income mutual funds and interest income on United States Treasury Bills. Realized gains and losses on sales of investments are determined on a specific identification basis.

 

Proceeds from the sale and redemption of marketable securities amounted to $2,867,671 for the year ended December 31, 2022, which included realized losses of $364,074. Proceeds from the sale and redemption of marketable securities for the year ended December 31, 2021 amounted to $4,152,660, which included realized gains of $111,917.

 

 

F- 15
 
 

UNITED-GUARDIAN, INC.

 

 

NOTE D – INVENTORIES 

 

Inventories consist of the following:

 

  

December 31,

 
  

2022

  

2021

 
         

Raw materials

 $601,125  $494,348 

Work in process

  16,520   119,069 

Finished products

  1,054,367   797,372 

Total Inventories

 $1,672,012  $1,410,789 

 

Inventories are valued at the lower of cost and net realizable value. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out method. Finished product inventories at December 31, 2022 and December 31, 2021 are net of a reserve of $64,000 and $35,000, respectively.

 

 

NOTE E – INCOME TAXES

 

The provision for income taxes consists of the following:

 

  

Years ended December 31,

 

Current

 

2022

  

2021

 

Federal

 $850,344  $1,287,749 

State

  1,590   96 

Total current provision for income taxes

  851,934   1,287,845 

 

Deferred

        

Federal

  (193,766

)

  (68,462

)

State

  ---   --- 

Total deferred benefit from income taxes

  (193,766

)

  (68,462

)

         

Total provision for income taxes

 $658,168  $1,219,383 

 

The following is a reconciliation of the Company’s effective income tax rate to the Federal statutory rate:         

 

  

Years ended December 31,

 
  2022  2021 
   ($)  

Tax rate

   ($)  

Tax rate

 
                 

Income taxes at statutory federal income tax rate

 $677,813   21.0

%

 $1,234,364   21.0

%

State taxes, net of federal benefit

  1,256   ---   76   --- 

Research & development credits

  (10,000

)

  (0.3)  (10,000

)

  (0.2

)

Non-taxable dividends

  (6,300

)

  (0.2)  (2,923

)

  (0.1

)

Other, net

  (4,601

)

  (0.1)  (2,134

)

  --- 

Provision for income taxes

 $658,168   20.4

%

 $1,219,383   20.7

%

 

F- 16
 
 

UNITED-GUARDIAN, INC.

 

The tax effects of temporary differences which comprise the deferred tax assets and liabilities are as follows:

 

  

December 31, .

 
  

2022

  

2021

 
         

Deferred tax assets

        

Allowance for doubtful accounts

 $4,213  $4,253 

Inventories

  13,440   7,350 

Accounts payable

  6,367   86,288 

R&D expenses

  92,756   --- 

Unrealized loss on marketable securities

  107,704   --- 

Accrued expenses

  277,326   339,884 

Total deferred tax assets

 $501,806  $437,775 

Deferred tax liabilities

        

Accounts receivable

  (304,004

)

  (385,056

)

Prepaid expenses

  (42,446

)

  (38,918

)

Depreciation on property, plant and equipment

  (44,812

)

  (61,471

)

Unrealized gain on marketable securities

  ---   (35,552

)

Total deferred tax liabilities

  (391,262

)

  (520,997

)

Net deferred tax asset (liability)

 $110,544  $(83,222

)

 
 

NOTE F - BENEFIT PLANS

 

Defined Contribution Plan

 

The Company sponsors a 401(k) defined contribution plan ("DC Plan") that provides for a dollar-for-dollar employer matching contribution of the first 4% of each employee's pay. Employees become fully vested in employer matching contributions immediately. Company 401(k) matching contributions were approximately $81,000 and $80,000 for the years ended December 31, 2022 and 2021, respectively.

 

The Company also makes discretionary contributions to each employee's account based on a "pay-to-pay" safe-harbor formula that qualifies the 401(k) Plan under current IRS regulations. For the years ended December 31, 2022 and 2021, respectively, the Company’s Board of Directors authorized discretionary contributions in the amount of $109,000 to be allocated among all eligible employees. Employees become vested in the discretionary contributions as follows: 20% after two years of employment, and 20% for each year of employment thereafter until the employee becomes fully vested after six years of employment. The discretionary contribution for 2022 will be paid in February 2023. The amount paid in February 2023 has been reduced by an amount paid to Ken Globus upon his retirement from the Company during 2022. The remaining contribution payable is included in accrued expenses at December 31, 2022.

 

 

NOTE G - GEOGRAPHIC and OTHER INFORMATION

 

Through its Guardian Laboratories division, the Company conducts research, product development, manufacturing, and marketing of cosmetic ingredients, personal and health care products, pharmaceuticals, non-pharmaceutical medical products, and proprietary specialty industrial products. All the products that the Company markets, exception for Renacidin, are produced at its facility in Hauppauge, New York. Renacidin, a urological product, is manufactured for the Company by an outside contract manufacturer. The Company’s R&D department not only develops new products but also modifies and refines existing products, with the goal of expanding the potential markets for the Company’s products. Many of the cosmetic ingredients manufactured by the Company, particularly its Lubrajel line of water-based moisturizing and lubricating gels, are currently used by many of the major multinational personal care products companies.

 

F- 17
 
 

UNITED-GUARDIAN, INC.

 

The Company operates in one business segment. The Company’s products are separated into four distinct product categories: cosmetic ingredients, pharmaceuticals, medical lubricants, and industrial products. Each product category is marketed differently. The cosmetic ingredients are marketed through a global network of distributors. These distributors purchase product outright from the Company and provide the marketing functions for these products on behalf of the Company. They in turn receive their compensation for those efforts by re-selling those products at a markup to their customers. This enables the Company to aggressively have its products marketed without the high cost of maintaining its own in-house marketing staff. The Company has written marketing arrangements with only one of its global distributors, ASI, and that contract renews every two years unless cancelled for any reason by either party at least 60 days prior to the expiration of the two-year marketing period in effect at that time. The current marketing period with ASI ends on December 31, 2023. The Company’s other distributors are not under any contractual obligation to market the Company’s cosmetic ingredients, and the Company has the ability to cancel those marketing arrangements at any time upon reasonable notice. All sales of the Company’s cosmetic ingredients are final other than product later determined to be defective, and the Company does not make any sales on consignment.

 

No prior regulatory approval is needed by the Company to sell any products other than its pharmaceutical products. The end users of its products may or may not need regulatory approvals, depending on the intended claims and uses of those products.

 

The pharmaceutical products include a urological product and a topical bioticide that are sold to end users primarily through distribution agreements with the major drug wholesalers. For these products, the Company does the marketing, and the drug wholesalers supply the product to the end users, such as hospitals and pharmacies. The Company’s marketing effort for Renacidin, its most important drug product, centers around a separate Renacidin website. There is currently no active marketing effort for Clorpactin. Both of these products were originally developed in the 1950s. Clorpactin pre-dated the need for a formal New Drug Application (“NDA”), and the current sterile liquid form of Renacidin is marketed under an NDA that was approved by the FDA in 1990.

 

The medical lubricants are not pharmaceutical products. They consist primarily of water-based lubricating gels, which are marketed by the Company directly to manufacturers that incorporate them into urologic catheters and other medical devices and products that they sell. These products are distinguished from the pharmaceutical products in that, unlike the pharmaceutical products, the Company is not required to obtain regulatory approval prior to marketing them. Approvals are the responsibility of the companies that market the products in which the Company’s products are used, which are typically classified as medical devices. However, the Company is responsible for manufacturing these products in accordance with current Good Manufacturing Practices for medical devices, and its manufacturing facility is subject to regular FDA oversight.

 

The industrial products are also marketed by the Company directly to manufacturers, and generally do not require that the Company obtain regulatory approval. However, the manufacturers of the finished products may have to obtain such regulatory approvals before marketing these products. The Company plans on discontinuing the sales of its industrial products in the second quarter of 2023.

 

The following tables present the significant concentrations of the Company’s sales. Although a significant percentage of Customer A’s purchases from the Company are sold to foreign customers, in table “b” below all sales to Customer A are included in “The United States” sales revenue because all shipments to Customer A are delivered to Customer A's warehouses in the U.S.

 

F- 18
 
 

UNITED-GUARDIAN, INC.

 

In addition, there are four customers for the Company’s medical lubricants that take delivery of their shipments in the U.S. but potentially ship some of that product to manufacturing facilities outside the U.S. Since the Company makes those shipments to U.S. locations, sales to those customers are also included in the “The United States” revenue number in the table below.

 

 

(a)

Net Sales

 

   Years ended December 31, 
   2022   2021  
         

Cosmetic Ingredients

 $5,388,365  $6,872,714 

Pharmaceuticals

  5,929,216   5,748,244 

Medical Lubricants

  2,471,555   2,175,822 

Industrial and other

  116,826   150,387 

Gross Sales

  13,905,962   14,947,167 

Less: Discounts and allowances

  (1,207,459

)

  (1,017,538

)

Net Sales

 $12,698,503  $13,929,629 

 

 

(b)

Geographic Information

 

  

Years ended December 31,

 
  

2022

  

2021

 
         

United States

 $9,537,124  $11,159,341 

Other countries

  3,161,379   2,770,288 

Net Sales

 $12,698,503  $13,929,629 

 

 

(c)

Gross Sales to Major Customers

 

 

  Years ended December 31, 
  

2022

  

2021

 
         

Customer A

 $4,284,799  $5,641,279 

Customer B

  2,527,743   2,526,869 

Customer C

  1,613,597   1,522,882 

Customer D

  1,553,885   1,488,301 

All other customers

  3,925,938   3,767,836 

Total Gross Sales

 $13,905,962  $14,947,167 

 
 

NOTE H - ACCRUED EXPENSES

 

Accrued expenses at December 31, 2022 and 2021 consist of:

 

  

2022

  

2021

 
         

Bonuses

 $175,496  $348,000 

Distribution fees

  395,536   359,550 

Payroll and related expenses

  53,475   292,560 

Company 401(k) contribution

  94,326   109,000 

Annual report expenses

  68,349   64,038 

Audit fee

  66,500   61,500 

Reserve for outdated material returns

  369,154   313,904 

Sales rebates

  80,926   56,857 

Other

  18,294   21,981 

Total accrued expenses

 $1,322,056  $1,627,390 

 

 

F- 19
 
 

UNITED-GUARDIAN, INC.

 

 

NOTE I - SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES

 

As of December 31, 2022, the Company had a number of unconverted Guardian Chemical shares that would convert to approximately 447 shares of United-Guardian, Inc. common stock if all of the remaining holders of those Guardian shares converted their Guardian stock to United-Guardian stock. The Company’s transfer agent continues to try to locate the holders of those shares in anticipation of escheating them to the appropriate state jurisdictions. The Company is currently accruing dividends on the 447 shares that have not yet been exchanged or designated for escheatment as of December 31, 2022, and the Company will continue to do so as dividends are declared.

 

 

NOTE J - RELATED PARTY TRANSACTIONS

 

During the years ended December 31, 2022 and 2021, the Company paid PKF O’Connor Davies $14,500 and $19,500, respectively, for accounting and tax services. Lawrence Maietta, a partner at PKF O’Connor Davies, is a director of the Company.

 

For the year ended December 31, 2022, the Company paid Ken Globus, the Company’s previous President and CEO, $20,000 for consulting services subsequent to his departure from the Company. The Company’s consulting agreement with Ken Globus expires on May 31, 2023. Ken Globus is a director of the Company and currently serves as Chairman of the Board of Directors. In addition, in November 2022, Ken Globus purchased a used vehicle from the Company for $37,039.

 

 

 

 

 

 

 

 

 

 

 

 

 

F-20
EX-31.1 2 ex_488287.htm EXHIBIT 31.1 ex_488287.htm

EXHIBIT 31.1

 

SECTION 302 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

 

I, Beatriz Blanco, certify that:

 

1. I have reviewed this Annual Report of United-Guardian, Inc. on Form 10-K for the year ended December 31, 2022;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d.

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 16, 2023   By: /s/ Beatriz Blanco    
      Beatriz Blanco  
      President and Principal Executive Officer  

 

 

 

 
 EX-31.2 3 ex_488288.htm EXHIBIT 31.2 ex_488288.htm

EXHIBIT 31.2

 

SECTION 302 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

 

I, Andrea Young, certify that:

 

1. I have reviewed this Annual Report of United-Guardian, Inc. on Form 10-K for the year ended December 31, 2022;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d.

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 16, 2023   By: /s/ Andrea Young  
      Andrea Young  
      Principal Financial Officer  

 

 

 

 

 
 EX-32 4 ex_488286.htm EXHIBIT 32 ex_488286.htm

EXHIBIT 32

 

CERTIFICATIONS PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the annual report of United-Guardian, Inc. (the "Company") on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission (the "Report"), I, Beatriz Blanco, President and Principal Executive Officer of the Company, and I, Andrea Young, Principal Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(i) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 16, 2023           By: /s/ Beatriz Blanco  
      Beatriz Blanco  
      President & Principal Executive Officer  
         
         
    By: /s/ Andrea Young  
      Andrea Young  
      Principal Financial Officer  

 

 

 

 

 

 

 

 

        

 

 

 

 

 
 EX-101.SCH 5 ug-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Statements of Income link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Balance Sheets link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Statements of Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Statements of Stockholders' Equity (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note B - Cash and Cash Equivalents link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note C - Marketable Securities link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note D - Inventories link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note E - Income Taxes link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note F - Benefit Plans link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note G - Geographic and Other Information link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note H - Accrued Expenses link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note J - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note B - Cash and Cash Equivalents (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note C - Marketable Securities (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note D - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note E - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note G - Geographic and Other Information (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note H - Accrued Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies - Disaggregated Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies - Revenue by Geographic Region (Details) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies - Property, Plant, and Equipment Useful Lives (Details) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note B - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note C - Marketable Securities (Details Textual) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note C - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note C - Marketable Securities - Summary of Investments (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note D - Inventories (Details Textual) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note D - Inventories - Summary of Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note E - Income Taxes - Provision for Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note E - Income Taxes - Reconciliation of the Effective Income Tax Rate (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note E - Income Taxes - Deferred Tax Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note F - Benefit Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note G - Geographic and Other Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note G - Geographic and Other Information - Net Sales (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note G - Geographic and Other Information - Geographic Information (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note G - Geographic and Other Information - Sales to Major Customers (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note H - Accrued Expenses - Summary of Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities (Details Textual) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note J - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 6 ug-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 ug-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 ug-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Fair Value of Financial Instruments, Policy [Policy Text Block] Note To Financial Statement Details Textual Significant Accounting Policies ug_AccruedDistributionFeesCurrent Distribution fees Accrued distribution fees Note A - Nature of Business and Summary of Significant Accounting Policies us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Income taxes at statutory federal income tax rate Note B - Cash and Cash Equivalents Note C - Marketable Securities Note D - Inventories Note E - Income Taxes Note G - Geographic and Other Information Note H - Accrued Expenses US with Subsequent Shipment to Foreign Locations [Member] Represents products sold in the United States and subsequently shipped to foreign locations. Note A - Nature of Business and Summary of Significant Accounting Policies - Disaggregated Revenue (Details) Income Tax Disclosure [Text Block] Note A - Nature of Business and Summary of Significant Accounting Policies - Revenue by Geographic Region (Details) Discretionary Contributions Vesting Each Additional Year [Member] Represents discretionary contributions vesting each additional year of employment. Note A - Nature of Business and Summary of Significant Accounting Policies - Property, Plant, and Equipment Useful Lives (Details) ug_SalesReturnsAndAllowances Less: Discounts and allowances Total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions) and price reductions (allowance, price protection agreements) given by the entity. Returns and allowances are a deduction from gross revenue in arriving at net revenue. Discretionary Contributions Vesting at Two Years [Member] Represents discretionary contributions vesting after two years of employment. Note B - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) Gross Sales Gross Amount before sales allowance and return, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Note C - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note C - Marketable Securities - Summary of Investments (Details) Note D - Inventories - Summary of Inventories (Details) Note E - Income Taxes - Provision for Income Taxes (Details) Note E - Income Taxes - Reconciliation of the Effective Income Tax Rate (Details) Note E - Income Taxes - Deferred Tax Assets and Liabilities (Details) Earnings Per Share, Policy [Policy Text Block] Note G - Geographic and Other Information - Net Sales (Details) Note G - Geographic and Other Information - Geographic Information (Details) Note G - Geographic and Other Information - Sales to Major Customers (Details) Note H - Accrued Expenses - Summary of Accrued Expenses (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Income Tax, Policy [Policy Text Block] Trade-in received from sale of asset Amount of trade-in received from sale of assets. Equity securities, unrealized gain Accumulated amount of unrealized gain (loss) on equity securities. Proceeds from sales of marketable securities Proceeds from Sale and Maturity of Marketable Securities US Treasury Securities [Member] Equity securities, cost Research, Development, and Computer Software, Policy [Policy Text Block] Fixed Income Securities [Member] Depreciation and amortization us-gaap_AssetsCurrent Total current assets Net unrealized loss recognized during the reporting year on marketable securities still held at the reporting date ug_AllowanceForMaterialReturns Allowance for Material Returns The amount of allowance for material returns. Accrued Expenses [Member] Related to accrued expenses. Advertising Cost [Policy Text Block] Common stock, $.10 par value; 10,000,000 shares authorized; 4,594,319 shares issued and outstanding at December 31, 2022 and 2021, respectively us-gaap_PaymentsToAcquireMarketableSecurities Purchases of marketable securities Retirement Plan Name [Axis] Financial Instruments [Domain] Retirement Plan Name [Domain] Adjustments to reconcile net income to net cash provided by operating activities: Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Deferred revenue Contract with Customer, Liability, Current Six Raw Material Vendors [Member] Related to six raw materials vendors. Financial Instrument [Axis] Common stock, par value (in dollars per share) Stockholders' Equity, Policy [Policy Text Block] Accrued expenses Total accrued expenses Income taxes payable Statistical Measurement [Domain] Minimum [Member] Dividends payable Accounts payable Product and Service [Axis] Proceeds from sale of asset Product and Service [Domain] us-gaap_DeferredTaxAssetsNet Total deferred tax assets Statistical Measurement [Axis] us-gaap_AccruedBonusesCurrent Bonuses us-gaap_OtherAccruedLiabilitiesCurrent Other us-gaap_DeferredTaxAssetsLiabilitiesNet Net deferred tax asset Prepaid income taxes us-gaap_AccruedSalariesCurrent Payroll and related expenses us-gaap_PolicyTextBlockAbstract Accounting Policies Cash Flow, Supplemental Disclosures [Text Block] Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Geographical [Axis] Geographical [Domain] us-gaap_DeferredIncomeTaxLiabilities Total deferred tax liabilities Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Inventories (net) Total Inventories us-gaap_AccruedProfessionalFeesCurrent Audit fee us-gaap_AccruedMarketingCostsCurrent Sales rebates us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives Building improvements Net Sales Net sales us-gaap_InventoryValuationReserves Inventory Valuation Reserves us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross Unrealized loss on marketable securities ug_PaymentsForAccruedDividendsOnUnconvertedShares Payments for Accrued Dividends on Unconverted Shares The amount of cash outflow for payments for accrued dividends on unconverted shares. us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Acquisitions of property, plant and equipment Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block] Supplemental disclosure of non-cash items: Lubrajel [Member] Customer [Axis] us-gaap_DeferredTaxAssetsInventory Inventories Renacidin [Member] Represents the product line, Renacidin. Customer [Domain] Factory Equipment And Fixtures [Member] Taxes paid Net losses recognized during the year on marketable securities Current liabilities: Equity And Other Mutual Funds [Member] Equity And Other Mutual Funds Member us-gaap_Assets TOTAL ASSETS Supplemental disclosure of cash flow information us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Accrued expenses us-gaap_PropertyPlantAndEquipmentUsefulLife Property, plant, and equipment, useful lives (Year) Personal Care [Member] The products for personal care. Property, plant, and equipment: Pharmaceuticals [Member] Cash flows from operating activities: Industrial And Other [Member] Schedule of Segment Reporting Information, by Segment [Table Text Block] us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts Allowance for doubtful accounts Revenue [Policy Text Block] Statement [Line Items] Accounts receivable, allowance for doubtful accounts Customer A [Member] Represents customer A. us-gaap_NumberOfOperatingSegments Number of Operating Segments Accounts receivable, net of allowance for doubtful accounts of $20,063 in 2022 and $20,252 in 2021 Customer B [Member] Represents a second customer. All Other Customers [Member] Deferred income taxes, net Building [Member] Building Improvements [Member] us-gaap_MarketableSecuritiesCurrent Marketable securities Stockholders’ equity: Property, Plant and Equipment, Policy [Policy Text Block] Long-Lived Tangible Asset [Axis] us-gaap_NonoperatingIncomeExpense Total other (loss) income Segment Reporting Disclosure [Text Block] Long-Lived Tangible Asset [Domain] Current assets: Investment income Net income Net income Deferred tax assets us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Inventory, Policy [Policy Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net increase (decrease) in cash and cash equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities Commitments and contingencies Director [Member] us-gaap_OperatingIncomeLoss Income from operations us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities Other (loss) income: Prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash provided by (used in) investing activities us-gaap_DeferredTaxLiabilities Net deferred tax liability Cost of sales Cost of Goods and Services Sold, Total ug_DefinedContributionDiscretionaryContributionPlanVestingPeriod Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year) Represents the vesting period of discretionary contributions made under the defined contribution plan. us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities Company 401(k) contribution us-gaap_DeferredIncomeTaxLiabilitiesNet Deferred income taxes (net) us-gaap_InventoryWriteDown Reserve for inventory obsolescence Less accumulated depreciation us-gaap_PropertyPlantAndEquipmentNet Total property, plant, and equipment, net us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total us-gaap_PropertyPlantAndEquipmentGross Total property, plant and equipment Marketable Securities, Policy [Policy Text Block] Concentration Risk, Credit Risk, Policy [Policy Text Block] Land us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities Unrealized gain on marketable securities ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss Marketable securities, unrealized gain Amount of accumulated unrealized gain (loss) in debt securities classified as held to maturity and equity securities. us-gaap_Dividends Dividends, Total Dividends ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue Marketable securities Fair value of investment in debt securities classified as held to maturity and equity securities. Building and improvements ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost Marketable securities, cost Cost of investment in debt securities classified as held to maturity and equity securities. us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Depreciation on property, plant and equipment Factory equipment and fixtures us-gaap_DeferredTaxLiabilitiesPrepaidExpenses Prepaid expenses Other Liabilities Disclosure [Text Block] us-gaap_PaymentsOfDividends Dividends paid Deferred tax liabilities us-gaap_PaymentsOfDividendsCommonStock Payments of Ordinary Dividends, Common Stock us-gaap_CostsAndExpenses Total costs and expenses Vendor Concentration [Policy Text Block] Vendor concentration policy text block. Cash flows from investing activities: Scenario [Domain] Retained Earnings [Member] us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty Related Party Transaction, Expenses from Transactions with Related Party Equity securities Net loss on marketable securities us-gaap_CurrentStateAndLocalTaxExpenseBenefit State Scenario [Axis] us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Income taxes payable Accounting and Tax Services [Member] Represents accounting and tax services. us-gaap_RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction us-gaap_MarketableSecuritiesRealizedGainLoss Net loss on marketable securities us-gaap_CurrentFederalTaxExpenseBenefit Federal Common Stock [Member] Related Party Transactions Disclosure [Text Block] us-gaap_DeferredFederalIncomeTaxExpenseBenefit Federal Provision for income taxes Total provision for income taxes Provision for income taxes us-gaap_IncreaseDecreaseInAccruedLiabilities Accrued expenses ug_ConvertibleCommonStockSharesIssuableUponConversion Convertible Common Stock, Shares Issuable upon Conversion (in shares) Number of shares issuable upon the conversion of convertible common stock. Equity Components [Axis] Equity Component [Domain] CHINA us-gaap_CurrentIncomeTaxExpenseBenefit Total current provision for income taxes Accounts payable us-gaap_IncreaseDecreaseInAccountsPayable Gain (Loss) on Securities [Table Text Block] us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income before provision for income taxes us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount ICFR Auditor Attestation Flag us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Cash and cash equivalents Disaggregation of Revenue [Table Text Block] Loans and Leases Receivable, Allowance for Loan Losses Policy [Policy Text Block] Document Annual Report Cash and Cash Equivalents, Policy [Policy Text Block] Balance Sheet Location [Axis] ug_DefinedContributionPlanEmployerDiscretionaryContributionAmountPerYearAuthorized Defined Contribution Plan, Employer Discretionary Contribution Amount Per Year Authorized Defined Contribution Plan, Employer Discretionary Contribution Amount Per Year, Authorized. Balance Sheet Location [Domain] Amendment Flag Entity Incorporation, State or Country Code us-gaap_UnrecognizedTaxBenefits Unrecognized Tax Benefits, Ending Balance Accounting Policies [Abstract] Distributors and Marketing Partners [Member] Represents distributors and marketing partners of the company. Document Transition Report City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Entity Interactive Data Current Dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid (in dollars per share) us-gaap_IncreaseDecreaseInContractWithCustomerLiability Deferred revenue us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Security Exchange Name Common stock, shares outstanding (in shares) Title of 12(b) Security Current Fiscal Year End Date (Decrease) increase in operating liabilities: Less: Net losses (gains) realized during the year on marketable securities sold during the period us-gaap_DebtAndEquitySecuritiesRealizedGainLoss Debt and Equity Securities, Realized Gain (Loss), Total Customer C [Member] Represents a third customer. Customer D [Member] Represents a fourth customer. us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Document Fiscal Period Focus Document Fiscal Year Focus Medical Lubricants [Member] Represents medical lubricants. Document Period End Date Entity File Number us-gaap_IncreaseDecreaseInPrepaidTaxes Prepaid income taxes Entity Emerging Growth Company Document Type R&D expenses Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development. Cosmetic Ingredients [Member] Represents information related to cosmetic ingredients. Entity Small Business Entity Shell Company Auditor Name Document Information [Line Items] Document Information [Table] Entity Public Float Shipping and Handling [Member] Entity Filer Category Auditor Firm ID Entity Current Reporting Status Entity Voluntary Filers Auditor Location Entity Well-known Seasoned Issuer us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Impairment, Long-Lived Asset, Held-for-Use, Total Previous President and CEO [Member] Represents previous President and CEO. Consulting Services [Member] Represents consulting services. Purchase of Used Vehicle [Member] Represents purchase of used vehicle. us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Entity Tax Identification Number Non-US [Member] Entity Central Index Key Entity Registrant Name Product Concentration Risk [Member] Entity [Domain] Cost of Goods and Services Sold, Shipping and Handling Cost, Policy [Policy Text Block] Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs. Customer Concentration Risk [Member] Legal Entity [Axis] Statement [Table] Entity Address, Address Line One Statement of Financial Position [Abstract] Supplier Concentration Risk [Member] Weighted average shares (basic and diluted) (in shares) Other, net, percent Entity Address, City or Town Geographic Concentration Risk [Member] us-gaap_EffectiveIncomeTaxRateContinuingOperations Provision for income taxes, percent Entity Address, Postal Zip Code Earnings per common share (basic and diluted) (in dollars per share) Entity Address, State or Province Concentration Risk Type [Axis] Concentration Risk Type [Domain] us-gaap_AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss, Ending Balance Cost of Goods and Service, Product and Service Benchmark [Member] Statement of Cash Flows [Abstract] Entity Common Stock, Shares Outstanding Statement of Stockholders' Equity [Abstract] Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] ug_AccruedReserveForOutdatedMaterial Reserve for outdated material returns Carrying value on reserves for outdated material. Marketable Securities [Table Text Block] ug_AccruedAnnualReportExpensesCurrent Annual report expenses The carrying value of accrued annual report expenses classified as current liabilities. Income Statement [Abstract] us-gaap_AdvertisingExpense Advertising Expense Revenue Benchmark [Member] Revenue from External Customers by Geographic Areas [Table Text Block] Revenue, Product and Service Benchmark [Member] Accounts Receivable [Member] Schedule of Accrued Liabilities [Table Text Block] us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsDividends Non-taxable dividends, percent Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Local Phone Number Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] us-gaap_TableTextBlock Notes Tables us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment Research & development credits, percent us-gaap_GainLossOnDispositionOfAssets1 Loss (gain) on sale of asset Related Party [Axis] Related Party [Domain] us-gaap_ProvisionForDoubtfulAccounts Allowance for doubtful accounts Other, net Cash flows from financing activities: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Income taxes at statutory federal income tax rate of 21%, percent us-gaap_DividendsPayableCurrentAndNoncurrent Dividends Payable ug_DeferredTaxAssetsAccountsPayable Accounts payable Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accounts payable. Operating expenses ug_DeferredTaxLiabilitiesAccountsReceivable Accounts receivable Amount of deferred tax consequences attributable to taxable temporary differences derived from accounts receivable. Raw materials Dividend Declared [Member] us-gaap_LiabilitiesAndStockholdersEquity TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Dividend Paid [Member] us-gaap_CashUninsuredAmount Cash, Uninsured Amount Finished products Work in process UNITED STATES Related Party Transaction [Axis] Dividends [Axis] DC Plan [Member] Represents DC plan. Related Party Transaction [Domain] Dividends [Domain] Decrease (increase) in operating assets: Retained earnings Research and development Costs and expenses: Demand Deposits [Member] LUBRAJEL and RENACIDIN IRRIGATION [Member] Refers to the products LUBREJEL and RENACIDIN IRRIGATION. Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] ASI [Member] Refers to information regarding the entity ASI, which is located in Canada. us-gaap_StockholdersEquity Total stockholders’ equity Balance Balance us-gaap_IncomeTaxReconciliationDeductionsDividends Non-taxable dividends us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Inventory Disclosure [Text Block] Schedule of Cash and Cash Equivalents [Table Text Block] Schedule of Inventory, Current [Table Text Block] Class of Stock [Axis] us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment Research & development credits ug_NumberOfCustomers Number of Customers The number of customers affecting an entity's concentration risk. Cash and Cash Equivalents Disclosure [Text Block] ug_NumberOfVendors Number of Vendors The number of vendors affecting an entity's concentration risk. Retirement Benefits [Text Block] Proerty Plant and Equipment, Useful Lives [Table Text Block] Schedule of periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment). us-gaap_DeferredIncomeTaxExpenseBenefit Total deferred benefit from income taxes Deferred income taxes State taxes, net of federal benefit EX-101.PRE 9 ug-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2022
Mar. 01, 2023
Jun. 30, 2022
Document Information [Line Items]      
Entity Central Index Key 0000101295    
Entity Registrant Name UNITED GUARDIAN INC    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Document Transition Report false    
Entity File Number 1-10526    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 11-1719724    
Entity Address, Address Line One 230 Marcus Blvd.    
Entity Address, City or Town Hauppauge    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 11788    
City Area Code 631    
Local Phone Number 273-0900    
Title of 12(b) Security Common Stock, $.10 par value    
Trading Symbol UG    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Filer Category Non-accelerated Filer    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Public Float     $ 68,868,800
Entity Common Stock, Shares Outstanding   4,594,319  
Auditor Firm ID 23    
Auditor Name Baker Tilly US, LLP    
Auditor Location Uniondale, NY    
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Statements of Income - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Net sales $ 12,698,503 $ 13,929,629
Costs and expenses:    
Cost of sales 5,996,376 5,747,931
Operating expenses 2,174,127 2,035,970
Research and development 490,770 478,642
Total costs and expenses 8,661,273 8,262,543
Income from operations 4,037,230 5,667,086
Other (loss) income:    
Investment income 236,695 233,857
Net loss on marketable securities (1,046,245) (23,018)
Total other (loss) income (809,550) 210,839
Income before provision for income taxes 3,227,680 5,877,925
Provision for income taxes 658,168 1,219,383
Net income $ 2,569,512 $ 4,658,542
Earnings per common share (basic and diluted) (in dollars per share) $ 0.56 $ 1.01
Weighted average shares (basic and diluted) (in shares) 4,594,319 4,594,319
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 830,452 $ 531,213
Marketable securities 5,653,516 7,635,463
Accounts receivable, net of allowance for doubtful accounts of $20,063 in 2022 and $20,252 in 2021 1,427,576 1,813,346
Inventories (net) 1,672,012 1,410,789
Prepaid expenses and other current assets 201,846 192,579
Prepaid income taxes 185,228  
Total current assets 9,970,630 11,583,390
Deferred income taxes, net 110,544  
Property, plant, and equipment:    
Land 69,000 69,000
Factory equipment and fixtures 4,585,055 4,605,742
Building and improvements 2,895,742 2,853,718
Total property, plant and equipment 7,549,797 7,528,460
Less accumulated depreciation 6,990,636 6,869,598
Total property, plant, and equipment, net 559,161 658,862
TOTAL ASSETS 10,640,335 12,242,252
Current liabilities:    
Accounts payable 30,415 410,894
Accrued expenses 1,322,056 1,627,390
Deferred revenue 0 190,164
Income taxes payable   88,738
Dividends payable 21,220 20,575
Total current liabilities 1,373,691 2,337,761
Deferred income taxes (net)   83,222
Commitments and contingencies
Stockholders’ equity:    
Common stock, $.10 par value; 10,000,000 shares authorized; 4,594,319 shares issued and outstanding at December 31, 2022 and 2021, respectively 459,432 459,432
Retained earnings 8,807,212 9,361,837
Total stockholders’ equity 9,266,644 9,821,269
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 10,640,335 $ 12,242,252
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheets (Parentheticals) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Accounts receivable, allowance for doubtful accounts $ 20,063 $ 20,252
Common stock, par value (in dollars per share) $ 0.10 $ 0.10
Common stock, shares authorized (in shares) 10,000,000 10,000,000
Common stock, shares issued (in shares) 4,594,319 4,594,319
Common stock, shares outstanding (in shares) 4,594,319 4,594,319
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Statements of Stockholders' Equity - USD ($)
Dividend Declared [Member]
Retained Earnings [Member]
Dividend Declared [Member]
Dividend Paid [Member]
Retained Earnings [Member]
Dividend Paid [Member]
Common Stock [Member]
Retained Earnings [Member]
Total
Balance (in shares) at Dec. 31, 2020         4,594,319    
Balance at Dec. 31, 2020         $ 459,432 $ 9,894,875 $ 10,354,307
Net income           4,658,542 4,658,542
Dividends $ (1,547) $ (1,547) $ (5,190,033) $ (5,190,033)     (5,191,580)
Balance (in shares) at Dec. 31, 2021         4,594,319    
Balance at Dec. 31, 2021         $ 459,432 9,361,837 9,821,269
Net income           2,569,512 2,569,512
Dividends $ (645) $ (645) $ (3,123,492) $ (3,123,492)     (3,124,137)
Balance (in shares) at Dec. 31, 2022         4,594,319    
Balance at Dec. 31, 2022         $ 459,432 $ 8,807,212 $ 9,266,644
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Statements of Stockholders' Equity (Parentheticals) - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dividend Declared [Member]    
Dividends declared per share (in dollars per share) $ 0.68 $ 1.13
Dividend Paid [Member]    
Dividends declared per share (in dollars per share) $ 0.68 $ 1.13
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:    
Net income $ 2,569,512 $ 4,658,542
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 135,396 145,977
Loss (gain) on sale of asset 2,445 (14,799)
Net loss on marketable securities 1,046,245 23,018
Allowance for doubtful accounts (189) 6,235
Reserve for inventory obsolescence 29,000  
Deferred income taxes (193,766) (68,462)
Decrease (increase) in operating assets:    
Accounts receivable 385,959 (431,883)
Inventories (290,223) 4,984
Prepaid expenses and other current assets (9,267) (31,371)
Prepaid income taxes (185,228) 99,107
(Decrease) increase in operating liabilities:    
Accounts payable (380,479) 379,094
Accrued expenses (305,334) 263,933
Deferred revenue (190,164) 190,164
Income taxes payable (88,738) 88,738
Net cash provided by operating activities 2,525,169 5,313,277
Cash flows from investing activities:    
Acquisitions of property, plant and equipment (75,179) (116,375)
Proceeds from sale of asset 37,039  
Purchases of marketable securities (1,931,969) (4,219,760)
Proceeds from sales of marketable securities 2,867,671 4,152,660
Net cash provided by (used in) investing activities 897,562 (183,475)
Cash flows from financing activities:    
Dividends paid (3,123,492) (5,190,033)
Net cash used in financing activities (3,123,492) (5,190,033)
Net increase (decrease) in cash and cash equivalents 299,239 (60,231)
Cash and cash equivalents, beginning of year 531,213 591,444
Cash and cash equivalents, end of year 830,452 531,213
Supplemental disclosure of cash flow information    
Taxes paid 1,125,000 1,100,000
Supplemental disclosure of non-cash items:    
Dividends Payable $ 645 1,547
Trade-in received from sale of asset   $ 29,000
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Note A - Nature of Business and Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

NOTE A - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Business

 

United-Guardian, Inc. (the "Company") is a Delaware corporation that, through its Guardian Laboratories division, manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. It also conducts research and product development, primarily related to the development of new and unique cosmetic ingredients. The Company’s research and development department also modifies, refines, and expands the uses for existing products, with the goal of further developing the market for the Company's products. Two major product lines, Lubrajel® and Renacidin® Irrigation Solution (“Renacidin”) together accounted for approximately 92% and 93% of the Company’s sales for the years ended December 31, 2022 and December 31, 2021, respectively. Lubrajel accounted for approximately 59% and 64% of the Company’s sales for the years ended December 31, 2022 and December 31, 2021, respectively, and Renacidin accounted for approximately 33% and 29% of the Company’s sales for the years ended December 31, 2022 and December 31, 2021, respectively.

 

Impact of the Coronavirus Pandemic, Global Supply Chain Instability and Inflation

 

While the coronavirus pandemic continues to impact certain areas of the Company’s operations, the current impact on the Company’s financial performance is coming primarily from 1) higher raw material costs and increased shipping costs, which had an impact on the Company’s gross profit margins during 2022 and 2) a decrease in cosmetic ingredient sales in China due to China’s zero-COVID mandate that was in effect for a substantial part of 2022.

 

The pandemic did not affect the Company’s ability to obtain raw materials but due to supply chain instability, the Company experienced longer lead times and higher prices for many of its raw materials. The increased raw material prices had an impact on the Company’s gross profit margins in 2022 and may continue to have an impact on gross profit margins in upcoming quarters. In response to the rising raw material prices the Company has instituted price increases on many of its products, which will help to reduce the impact on the Company’s gross margins in the future.

 

As a result of the lingering effects of the coronavirus pandemic as described above, combined with global supply chain instability, there continues to be uncertainty in regard to its future potential impact on the Company’s operations or financial results. The Company believes that it is still unable to provide an accurate estimate or projection as to what the future impact of the pandemic will be on its future operations or financial results.

 

While it is unknown whether inflation will continue to increase or will begin to decrease during 2023, continued inflation is likely to result in further increases in raw material costs, shipping costs, and internal labor costs, which could impact the Company’s results of operations.

 

Use of Estimates

 

In preparing financial statements in conformity with a Generally Accepted Accounting Principles in the United States of America (“US GAAP”), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for bad debts, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities and the allocation of overhead.

 

 

Accounts Receivable and Reserves

 

The carrying amount of accounts receivable is reduced by a valuation allowance that reflects the Company’s best estimate of the amounts that will not be collected. The reserve for accounts receivable comprises the allowance for doubtful accounts. In addition to reviewing delinquent accounts receivable, the Company considers many factors in estimating this reserve, including historical data, experience, customer types and credit worthiness, and economic trends. At December 31, 2022 and 2021, the allowance for doubtful accounts receivable amounted to $20,063 and $20,252, respectively. From time to time, the Company adjusts its assumptions for anticipated changes in any of these or other factors expected to affect collectability.

 

Revenue Recognition

 

The Company records revenue in accordance with ASC Topic 606 “Revenue from Contracts with Customers.” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company’s principal source of revenue is product sales.

 

The Company’s sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period in which the revenue is recognized. Such deductions, primarily related to the sale of the Company’s pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with the Company’s current participation in Medicare programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period.

 

During 2022 and 2021, the Company participated in various government drug rebate programs related to the sale of Renacidin®, its most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (“FSS”), and the Medicare Part D Coverage Gap Discount Program (“CGDP”). These programs require the Company to sell its product at a discounted price. The Company’s sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized.

 

As long as a valid purchase order has been received and future collection of the sale amount is reasonably assured, the Company recognizes revenue from sales of its products when those products are shipped, which is when the Company’s performance obligation is satisfied. The Company’s cosmetic products are shipped “Ex-Works” from the Company’s facility in Hauppauge, NY, and the risk of loss and responsibility for the shipment passes to the customer upon shipment. Sales of the Company’s non-pharmaceutical medical products are deemed final upon shipment, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective. Sales of the Company’s pharmaceutical products are final upon shipment unless (a) they are found to be defective; (b) the product is damaged in shipping; (c) the product cannot be sold because it is too close to its expiration date; or (d) the product has expired (but it is not more than one year after the expiration date). This return policy conforms to standard pharmaceutical industry practice. The Company estimates an allowance for outdated material returns based on previous years’ historical returns of its pharmaceutical products.

 

The Company does not make sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is not contingent upon the customer being able to sell the goods to a third party.

 

 

Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606-10-32-8. At December 31, 2022 and 2021, the Company had an allowance of $369,154 and $313,904, respectively, for possible outdated material returns, which is included in accrued expenses.

 

The timing between recognition of revenue for product sales and the receipt of payment is not significant. The Company’s standard credit terms, which vary depending on the customer, range between 30 and 60 days. The Company uses its judgment on a case-by-case basis to determine its ability to collect outstanding receivables and provides allowances for any receivables for which collection has become doubtful. Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken.

 

At December 31, 2021, the Company recorded an advance payment from one of its customers in the amount of $190,164, which was recorded as deferred revenue on the balance sheet. The related performance obligation associated with this payment was satisfied in the first quarter of 2022. No such advanced payment exists at December 31, 2022.

 

The Company has distribution agreements with certain distributors of its pharmaceutical products that entitles those distributors to distribution and services-related fees. The Company records distribution fees, and estimates of distribution fees, as offsets to revenue.

 

Disaggregated net sales by product class are as follows:

 

  

Years ended December 31,

 
  2022  2021 
         

Cosmetic ingredients

 $5,167,909  $6,872,714 

Pharmaceuticals

  4,943,605   4,735,324 

Medical lubricants

  2,470,163   2,171,204 

Industrial and other

  116,826   150,387 

Total Net Sales

 $12,698,503  $13,929,629 

 

The Company’s cosmetic ingredients are currently marketed worldwide by five distributors, of which the United States (“U.S.”)-based ASI purchases the largest volume. For the years ended December 31, 2022 and 2021, approximately 25% and 20%, respectively, of the Company’s sales were to (a) its foreign-based distributors (which does not include ASI), which marketed and distributed the Company’s cosmetic ingredients to customers outside the U.S, and (b) a few foreign customers for the Company’s medical lubricants sold directly by the Company.

 

Disaggregated sales by geographic region are as follows:

 

  Years ended December 31, 
  

2022

  

2021

 
         

United States*

 $9,537,124  $11,159,341 

Other countries

  3,161,379   2,770,288 

Net Sales

 $12,698,503  $13,929,629 

 

* Although a significant percentage of ASI’s purchases from the Company are sold to foreign customers, all sales to ASI are considered U.S. sales for financial reporting purposes, since all shipments to ASI are shipped to ASI’s warehouses in the U.S. A certain percentage of those products are subsequently shipped by ASI to its foreign customers. Based on sales information provided to the Company by ASI, 66% of ASI’s sales in 2022 were to customers in foreign countries, compared with 74% in 2021. ASI’s largest foreign market in both 2022 and 2021 was China, which accounted for approximately 38% of ASI’s sales in 2022 and 42% of sales in 2021.

 

 

 

Cash and Cash Equivalents

 

For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at the time of purchase. The Company deposits cash and cash equivalents with high credit quality financial institutions and believes that any amounts in excess of insurance limitations to be at minimal risk. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of $250,000. At December 31, 2022, approximately $105,000 exceeded the FDIC limit.

 

Dividends

 

On May 10, 2022, the Company’s Board of Directors declared a semi-annual cash dividend of $0.37 per share, which was paid on June 1, 2022 to all stockholders of record as of May 23, 2022. On November 15, 2022, the Company’s Board of Directors declared a semi-annual cash dividend of $0.31 per share, which was paid on December 7, 2022, to all stockholders of record as of November 28, 2022. In 2022, the Company declared a total of $3,124,137 in dividends, of which $3,123,492 was paid. The balance of $645 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment.

 

On May 18, 2021, the Company’s Board of Directors declared a semi-annual cash dividend of $0.48 per share, which was paid on June 7, 2021 to all stockholders of record as of May 31, 2021. On November 16, 2021, the Company’s Board of Directors declared a semi-annual cash dividend of $0.65 per share which was paid on December 7, 2021 to all stockholders of record as of November 29, 2021. In 2021, the Company declared a total of $5,191,580 in dividends, of which $5,190,033 was paid. The balance of $1,547 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment.

 

Marketable Securities

 

The Company’s marketable securities include investments in equity and fixed income mutual funds. The Company’s marketable equity securities are reported at fair value with the related unrealized and realized gains and losses included in net income. Realized gains or losses on mutual funds are determined on a specific identification basis. The Company evaluates its investments periodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extent to which fair value had been below cost basis, the financial condition of the issuer and the Company’s ability and intent to hold the investment for a period of time which may be sufficient for anticipated recovery of market value. The Company would record an impairment charge to the extent that the cost of the available-for-sale securities exceeds the estimated fair value of the securities and the decline in value is determined to be other-than-temporary. During 2022 and 2021, the Company did not record an impairment charge regarding its investment in marketable securities because management believes, based on its evaluation of the circumstances, that the decline in fair value below the cost of certain of the Company’s marketable securities is temporary.

 

Inventories

 

Inventories are valued at the lower of cost and net realizable value. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Inventory costs include material, labor and factory overhead.

 

 

Property, Plant and Equipment

 

Property, plant and equipment are carried at cost, less accumulated depreciation. Major replacements and betterments are capitalized, while routine maintenance and repairs are expensed as incurred. Assets are depreciated under both accelerated and straight-line methods. Depreciation charged as a result of using accelerated methods was not materially different than that which would result from using the straight-line method for all periods presented. Certain factory equipment and fixtures are constructed by the Company using purchased materials and in-house labor. Such assets are capitalized and depreciated on a basis consistent with the Company's purchased fixed assets.

 

Estimated useful lives are as follows: 

 

Factory equipment and fixtures  

5 - 7 years  

           Building

40 years  

Building improvements  

Lesser of useful life or 20 years

 

Impairment of Long-Lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairments were necessary at December 31, 2022 and 2021.

 

Fair Value of Financial Instruments

 

Management of the Company believes that the fair value of financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, approximates their carrying value due to their short payment terms and liquid nature.

 

Concentration of Credit Risk

 

Accounts receivable potentially exposes the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether any credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its accounts receivable credit risk has been reduced.

 

For the year ended December 31, 2022, four of the Company’s pharmaceutical wholesalers and cosmetic ingredient distributors accounted for approximately 72% of the Company’s gross sales during the year and approximately 81% of its outstanding accounts receivable at December 31, 2022. For the year ended December 31, 2021, the same four pharmaceutical wholesalers and cosmetic ingredient distributors accounted for a total of approximately 75% of the Company’s gross sales during the year and 80% of its outstanding accounts receivable at December 31, 2021.

 

 

Vendor Concentration

 

Most of the principal raw materials used by the Company consist of common industrial organic and inorganic chemicals and are available in ample supply from numerous sources. However, there are some raw materials used by the Company that are not readily available or require long lead times. During 2022, the Company periodically experienced longer lead times due to shipping delays and supply chain issues related to the pandemic. The Company has six major raw material vendors that collectively accounted for approximately 90% and 94% of the raw material purchases by the Company in 2022 and 2021, respectively.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to the temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized.

 

Uncertain tax positions are accounted for utilizing a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As of December 31, 2022 and 2021, the Company did not have any unrecognized income tax benefits. It is the Company’s policy to recognize interest and penalties related to taxes as interest expense as incurred. During the years ended December 31, 2022 and 2021, the Company did not record any tax-related interest or penalties. The Company’s tax returns for 2019 and all subsequent years are subject to examination by the United States Internal Revenue Service and by the State of New York.

 

Research and Development

 

Research and development expenses are expenditures incurred in connection with in-house research on new and existing products. It includes payroll and payroll related expenses, outside laboratory expenditures, lab supplies, and equipment depreciation.

 

Shipping and Handling Expenses

 

Shipping and handling costs are classified in operating expenses in the accompanying statements of income. Shipping and handling costs were approximately $97,000 and $82,000 for the years ended December 31, 2022 and 2021, respectively.

 

Advertising Expenses

 

Advertising costs are expensed as incurred. For the years ended December 31, 2022 and 2021, the Company incurred approximately $19,000 and $31,000, respectively, in advertising expense, which primarily relates to the internet marketing of Renacidin, one of the Company’s pharmaceutical products.

 

 

Earnings Per Share Information

 

Basic earnings per share are computed by dividing net income by the weighted average number of common shares outstanding during the year. Diluted earnings per share would include the dilutive effect of outstanding stock options, if any.

 

New Accounting Standards

 

In June 2016, the FASB issued ASU-2016-13 “Financial Instruments – Credit Losses”. This guidance affects organizations that hold financial assets and net investments in leases that are not accounted for at fair value with changes in fair value reported in net income. The guidance requires organizations to measure all expected credit losses for financial instruments at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. It is effective for fiscal years beginning after December 15, 2022. The Company does not expect that the implementation of this standard will have a material effect on its’ financial statements.
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Note B - Cash and Cash Equivalents
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Cash and Cash Equivalents Disclosure [Text Block]

NOTE B – CASH AND CASH EQUIVALENTS

 

Cash and cash equivalents include currency on hand, demand deposits with banks or financial institutions, and short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. The following table summarizes the Company’s cash and cash equivalents:

 

  Years ended December 31, 
  2022  2021 
         

Demand Deposits

 $333,275  $531,213 

U.S. Treasury Bills (original 2-month maturity)

  497,177   --- 

Total cash and cash equivalents

 $830,452  $531,213 

 
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Note C - Marketable Securities
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

NOTE C - MARKETABLE SECURITIES

 

Marketable securities include investments in fixed income and equity mutual funds with maturities greater than 3 months, which are reported at their fair values.

 

The disaggregated net gains and losses on the marketable securities recognized in the income statement for the years ended December 31, 2022 and 2021 are as follows:

 

  Years ended December 31,    
  2022  2021 
       

Net losses recognized during the year on marketable securities

 $(1,046,245

)

 $(23,018

)

Less: Net losses (gains) realized during the year on marketable securities sold during the period

  364,074   (111,917

)

 

Net unrealized loss recognized during the reporting year on marketable securities still held at the reporting date

 $(682,171

)

 $(134,935

)

 

 

 

The fair values of the Company’s marketable securities are determined in accordance with US GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by US GAAP, which prioritizes the inputs used in measuring fair value as follows:

 

•    Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

•    Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

 

•    Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

The Company’s marketable equity securities, which are considered available-for-sale securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs using quoted prices (unadjusted) for identical assets in active markets. The following tables summarize the Company’s investments:

 

December 31, 2022

 

          Unrealized 
  Cost  Fair Value  (Loss)Gain 
             

Equity Securities

            

Fixed income mutual funds

 $5,449,227  $4,924,497  $(524,730

)

Equity and other mutual funds

  717,165   729,019   11,854 

Total equity securities

  6,166,392   5,653,516   (512,876

)

Total marketable securities

 $6,166,392  $5,653,516  $(512,876

)

 

December 31, 2021

 

          Unrealized 
    Cost  Fair Value  Gain 
             

Equity Securities

            

Fixed income mutual funds

 $6,814,420  $6,873,333  $58,913 

Equity and other mutual funds

  651,748   762,130   110,382 

Total equity securities

  7,466,168   7,635,463   169,295 

Total marketable securities

 $7,466,168  $7,635,463  $169,295 

 

Investment income is recognized when earned and consists principally of dividend income from equity and fixed income mutual funds and interest income on United States Treasury Bills. Realized gains and losses on sales of investments are determined on a specific identification basis.

 

Proceeds from the sale and redemption of marketable securities amounted to $2,867,671 for the year ended December 31, 2022, which included realized losses of $364,074. Proceeds from the sale and redemption of marketable securities for the year ended December 31, 2021 amounted to $4,152,660, which included realized gains of $111,917.

 

 
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Note D - Inventories
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Inventory Disclosure [Text Block]

NOTE D – INVENTORIES 

 

Inventories consist of the following:

 

  

December 31,

 
  

2022

  

2021

 
         

Raw materials

 $601,125  $494,348 

Work in process

  16,520   119,069 

Finished products

  1,054,367   797,372 

Total Inventories

 $1,672,012  $1,410,789 

 

Inventories are valued at the lower of cost and net realizable value. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out method. Finished product inventories at December 31, 2022 and December 31, 2021 are net of a reserve of $64,000 and $35,000, respectively.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Note E - Income Taxes
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

NOTE E – INCOME TAXES

 

The provision for income taxes consists of the following:

 

  

Years ended December 31,

 

Current

 

2022

  

2021

 

Federal

 $850,344  $1,287,749 

State

  1,590   96 

Total current provision for income taxes

  851,934   1,287,845 

 

Deferred

        

Federal

  (193,766

)

  (68,462

)

State

  ---   --- 

Total deferred benefit from income taxes

  (193,766

)

  (68,462

)

         

Total provision for income taxes

 $658,168  $1,219,383 

 

The following is a reconciliation of the Company’s effective income tax rate to the Federal statutory rate:         

 

  

Years ended December 31,

 
  2022  2021 
   ($)  

Tax rate

   ($)  

Tax rate

 
                 

Income taxes at statutory federal income tax rate

 $677,813   21.0

%

 $1,234,364   21.0

%

State taxes, net of federal benefit

  1,256   ---   76   --- 

Research & development credits

  (10,000

)

  (0.3)  (10,000

)

  (0.2

)

Non-taxable dividends

  (6,300

)

  (0.2)  (2,923

)

  (0.1

)

Other, net

  (4,601

)

  (0.1)  (2,134

)

  --- 

Provision for income taxes

 $658,168   20.4

%

 $1,219,383   20.7

%

 

 

The tax effects of temporary differences which comprise the deferred tax assets and liabilities are as follows:

 

  

December 31, .

 
  

2022

  

2021

 
         

Deferred tax assets

        

Allowance for doubtful accounts

 $4,213  $4,253 

Inventories

  13,440   7,350 

Accounts payable

  6,367   86,288 

R&D expenses

  92,756   --- 

Unrealized loss on marketable securities

  107,704   --- 

Accrued expenses

  277,326   339,884 

Total deferred tax assets

 $501,806  $437,775 

Deferred tax liabilities

        

Accounts receivable

  (304,004

)

  (385,056

)

Prepaid expenses

  (42,446

)

  (38,918

)

Depreciation on property, plant and equipment

  (44,812

)

  (61,471

)

Unrealized gain on marketable securities

  ---   (35,552

)

Total deferred tax liabilities

  (391,262

)

  (520,997

)

Net deferred tax asset (liability)

 $110,544  $(83,222

)

 
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Note F - Benefit Plans
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Retirement Benefits [Text Block]

NOTE F - BENEFIT PLANS

 

Defined Contribution Plan

 

The Company sponsors a 401(k) defined contribution plan ("DC Plan") that provides for a dollar-for-dollar employer matching contribution of the first 4% of each employee's pay. Employees become fully vested in employer matching contributions immediately. Company 401(k) matching contributions were approximately $81,000 and $80,000 for the years ended December 31, 2022 and 2021, respectively.

 

The Company also makes discretionary contributions to each employee's account based on a "pay-to-pay" safe-harbor formula that qualifies the 401(k) Plan under current IRS regulations. For the years ended December 31, 2022 and 2021, respectively, the Company’s Board of Directors authorized discretionary contributions in the amount of $109,000 to be allocated among all eligible employees. Employees become vested in the discretionary contributions as follows: 20% after two years of employment, and 20% for each year of employment thereafter until the employee becomes fully vested after six years of employment. The discretionary contribution for 2022 will be paid in February 2023. The amount paid in February 2023 has been reduced by an amount paid to Ken Globus upon his retirement from the Company during 2022. The remaining contribution payable is included in accrued expenses at December 31, 2022.
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Note G - Geographic and Other Information
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

NOTE G - GEOGRAPHIC and OTHER INFORMATION

 

Through its Guardian Laboratories division, the Company conducts research, product development, manufacturing, and marketing of cosmetic ingredients, personal and health care products, pharmaceuticals, non-pharmaceutical medical products, and proprietary specialty industrial products. All the products that the Company markets, exception for Renacidin, are produced at its facility in Hauppauge, New York. Renacidin, a urological product, is manufactured for the Company by an outside contract manufacturer. The Company’s R&D department not only develops new products but also modifies and refines existing products, with the goal of expanding the potential markets for the Company’s products. Many of the cosmetic ingredients manufactured by the Company, particularly its Lubrajel line of water-based moisturizing and lubricating gels, are currently used by many of the major multinational personal care products companies.

 

 

The Company operates in one business segment. The Company’s products are separated into four distinct product categories: cosmetic ingredients, pharmaceuticals, medical lubricants, and industrial products. Each product category is marketed differently. The cosmetic ingredients are marketed through a global network of distributors. These distributors purchase product outright from the Company and provide the marketing functions for these products on behalf of the Company. They in turn receive their compensation for those efforts by re-selling those products at a markup to their customers. This enables the Company to aggressively have its products marketed without the high cost of maintaining its own in-house marketing staff. The Company has written marketing arrangements with only one of its global distributors, ASI, and that contract renews every two years unless cancelled for any reason by either party at least 60 days prior to the expiration of the two-year marketing period in effect at that time. The current marketing period with ASI ends on December 31, 2023. The Company’s other distributors are not under any contractual obligation to market the Company’s cosmetic ingredients, and the Company has the ability to cancel those marketing arrangements at any time upon reasonable notice. All sales of the Company’s cosmetic ingredients are final other than product later determined to be defective, and the Company does not make any sales on consignment.

 

No prior regulatory approval is needed by the Company to sell any products other than its pharmaceutical products. The end users of its products may or may not need regulatory approvals, depending on the intended claims and uses of those products.

 

The pharmaceutical products include a urological product and a topical bioticide that are sold to end users primarily through distribution agreements with the major drug wholesalers. For these products, the Company does the marketing, and the drug wholesalers supply the product to the end users, such as hospitals and pharmacies. The Company’s marketing effort for Renacidin, its most important drug product, centers around a separate Renacidin website. There is currently no active marketing effort for Clorpactin. Both of these products were originally developed in the 1950s. Clorpactin pre-dated the need for a formal New Drug Application (“NDA”), and the current sterile liquid form of Renacidin is marketed under an NDA that was approved by the FDA in 1990.

 

The medical lubricants are not pharmaceutical products. They consist primarily of water-based lubricating gels, which are marketed by the Company directly to manufacturers that incorporate them into urologic catheters and other medical devices and products that they sell. These products are distinguished from the pharmaceutical products in that, unlike the pharmaceutical products, the Company is not required to obtain regulatory approval prior to marketing them. Approvals are the responsibility of the companies that market the products in which the Company’s products are used, which are typically classified as medical devices. However, the Company is responsible for manufacturing these products in accordance with current Good Manufacturing Practices for medical devices, and its manufacturing facility is subject to regular FDA oversight.

 

The industrial products are also marketed by the Company directly to manufacturers, and generally do not require that the Company obtain regulatory approval. However, the manufacturers of the finished products may have to obtain such regulatory approvals before marketing these products. The Company plans on discontinuing the sales of its industrial products in the second quarter of 2023.

 

The following tables present the significant concentrations of the Company’s sales. Although a significant percentage of Customer A’s purchases from the Company are sold to foreign customers, in table “b” below all sales to Customer A are included in “The United States” sales revenue because all shipments to Customer A are delivered to Customer A's warehouses in the U.S.

 

 

In addition, there are four customers for the Company’s medical lubricants that take delivery of their shipments in the U.S. but potentially ship some of that product to manufacturing facilities outside the U.S. Since the Company makes those shipments to U.S. locations, sales to those customers are also included in the “The United States” revenue number in the table below.

 

 

(a)

Net Sales

 

   Years ended December 31, 
   2022   2021  
         

Cosmetic Ingredients

 $5,388,365  $6,872,714 

Pharmaceuticals

  5,929,216   5,748,244 

Medical Lubricants

  2,471,555   2,175,822 

Industrial and other

  116,826   150,387 

Gross Sales

  13,905,962   14,947,167 

Less: Discounts and allowances

  (1,207,459

)

  (1,017,538

)

Net Sales

 $12,698,503  $13,929,629 

 

 

(b)

Geographic Information

 

  

Years ended December 31,

 
  

2022

  

2021

 
         

United States

 $9,537,124  $11,159,341 

Other countries

  3,161,379   2,770,288 

Net Sales

 $12,698,503  $13,929,629 

 

 

(c)

Gross Sales to Major Customers

 

 

  Years ended December 31, 
  

2022

  

2021

 
         

Customer A

 $4,284,799  $5,641,279 

Customer B

  2,527,743   2,526,869 

Customer C

  1,613,597   1,522,882 

Customer D

  1,553,885   1,488,301 

All other customers

  3,925,938   3,767,836 

Total Gross Sales

 $13,905,962  $14,947,167 

 
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Note H - Accrued Expenses
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Other Liabilities Disclosure [Text Block]

NOTE H - ACCRUED EXPENSES

 

Accrued expenses at December 31, 2022 and 2021 consist of:

 

  

2022

  

2021

 
         

Bonuses

 $175,496  $348,000 

Distribution fees

  395,536   359,550 

Payroll and related expenses

  53,475   292,560 

Company 401(k) contribution

  94,326   109,000 

Annual report expenses

  68,349   64,038 

Audit fee

  66,500   61,500 

Reserve for outdated material returns

  369,154   313,904 

Sales rebates

  80,926   56,857 

Other

  18,294   21,981 

Total accrued expenses

 $1,322,056  $1,627,390 

 

 
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Cash Flow, Supplemental Disclosures [Text Block]

NOTE I - SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES

 

As of December 31, 2022, the Company had a number of unconverted Guardian Chemical shares that would convert to approximately 447 shares of United-Guardian, Inc. common stock if all of the remaining holders of those Guardian shares converted their Guardian stock to United-Guardian stock. The Company’s transfer agent continues to try to locate the holders of those shares in anticipation of escheating them to the appropriate state jurisdictions. The Company is currently accruing dividends on the 447 shares that have not yet been exchanged or designated for escheatment as of December 31, 2022, and the Company will continue to do so as dividends are declared.
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Note J - Related Party Transactions
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]

NOTE J - RELATED PARTY TRANSACTIONS

 

During the years ended December 31, 2022 and 2021, the Company paid PKF O’Connor Davies $14,500 and $19,500, respectively, for accounting and tax services. Lawrence Maietta, a partner at PKF O’Connor Davies, is a director of the Company.

 

For the year ended December 31, 2022, the Company paid Ken Globus, the Company’s previous President and CEO, $20,000 for consulting services subsequent to his departure from the Company. The Company’s consulting agreement with Ken Globus expires on May 31, 2023. Ken Globus is a director of the Company and currently serves as Chairman of the Board of Directors. In addition, in November 2022, Ken Globus purchased a used vehicle from the Company for $37,039.

 

 
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Use of Estimates, Policy [Policy Text Block]

Use of Estimates

 

In preparing financial statements in conformity with a Generally Accepted Accounting Principles in the United States of America (“US GAAP”), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for bad debts, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities and the allocation of overhead.

 

 
Loans and Leases Receivable, Allowance for Loan Losses Policy [Policy Text Block]

Accounts Receivable and Reserves

 

The carrying amount of accounts receivable is reduced by a valuation allowance that reflects the Company’s best estimate of the amounts that will not be collected. The reserve for accounts receivable comprises the allowance for doubtful accounts. In addition to reviewing delinquent accounts receivable, the Company considers many factors in estimating this reserve, including historical data, experience, customer types and credit worthiness, and economic trends. At December 31, 2022 and 2021, the allowance for doubtful accounts receivable amounted to $20,063 and $20,252, respectively. From time to time, the Company adjusts its assumptions for anticipated changes in any of these or other factors expected to affect collectability.

 
Revenue [Policy Text Block]

Revenue Recognition

 

The Company records revenue in accordance with ASC Topic 606 “Revenue from Contracts with Customers.” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company’s principal source of revenue is product sales.

 

The Company’s sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period in which the revenue is recognized. Such deductions, primarily related to the sale of the Company’s pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with the Company’s current participation in Medicare programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period.

 

During 2022 and 2021, the Company participated in various government drug rebate programs related to the sale of Renacidin®, its most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (“FSS”), and the Medicare Part D Coverage Gap Discount Program (“CGDP”). These programs require the Company to sell its product at a discounted price. The Company’s sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized.

 

As long as a valid purchase order has been received and future collection of the sale amount is reasonably assured, the Company recognizes revenue from sales of its products when those products are shipped, which is when the Company’s performance obligation is satisfied. The Company’s cosmetic products are shipped “Ex-Works” from the Company’s facility in Hauppauge, NY, and the risk of loss and responsibility for the shipment passes to the customer upon shipment. Sales of the Company’s non-pharmaceutical medical products are deemed final upon shipment, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective. Sales of the Company’s pharmaceutical products are final upon shipment unless (a) they are found to be defective; (b) the product is damaged in shipping; (c) the product cannot be sold because it is too close to its expiration date; or (d) the product has expired (but it is not more than one year after the expiration date). This return policy conforms to standard pharmaceutical industry practice. The Company estimates an allowance for outdated material returns based on previous years’ historical returns of its pharmaceutical products.

 

The Company does not make sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is not contingent upon the customer being able to sell the goods to a third party.

 

 

Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606-10-32-8. At December 31, 2022 and 2021, the Company had an allowance of $369,154 and $313,904, respectively, for possible outdated material returns, which is included in accrued expenses.

 

The timing between recognition of revenue for product sales and the receipt of payment is not significant. The Company’s standard credit terms, which vary depending on the customer, range between 30 and 60 days. The Company uses its judgment on a case-by-case basis to determine its ability to collect outstanding receivables and provides allowances for any receivables for which collection has become doubtful. Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken.

 

At December 31, 2021, the Company recorded an advance payment from one of its customers in the amount of $190,164, which was recorded as deferred revenue on the balance sheet. The related performance obligation associated with this payment was satisfied in the first quarter of 2022. No such advanced payment exists at December 31, 2022.

 

The Company has distribution agreements with certain distributors of its pharmaceutical products that entitles those distributors to distribution and services-related fees. The Company records distribution fees, and estimates of distribution fees, as offsets to revenue.

 

Disaggregated net sales by product class are as follows:

 

  

Years ended December 31,

 
  2022  2021 
         

Cosmetic ingredients

 $5,167,909  $6,872,714 

Pharmaceuticals

  4,943,605   4,735,324 

Medical lubricants

  2,470,163   2,171,204 

Industrial and other

  116,826   150,387 

Total Net Sales

 $12,698,503  $13,929,629 

 

The Company’s cosmetic ingredients are currently marketed worldwide by five distributors, of which the United States (“U.S.”)-based ASI purchases the largest volume. For the years ended December 31, 2022 and 2021, approximately 25% and 20%, respectively, of the Company’s sales were to (a) its foreign-based distributors (which does not include ASI), which marketed and distributed the Company’s cosmetic ingredients to customers outside the U.S, and (b) a few foreign customers for the Company’s medical lubricants sold directly by the Company.

 

Disaggregated sales by geographic region are as follows:

 

  Years ended December 31, 
  

2022

  

2021

 
         

United States*

 $9,537,124  $11,159,341 

Other countries

  3,161,379   2,770,288 

Net Sales

 $12,698,503  $13,929,629 

 

* Although a significant percentage of ASI’s purchases from the Company are sold to foreign customers, all sales to ASI are considered U.S. sales for financial reporting purposes, since all shipments to ASI are shipped to ASI’s warehouses in the U.S. A certain percentage of those products are subsequently shipped by ASI to its foreign customers. Based on sales information provided to the Company by ASI, 66% of ASI’s sales in 2022 were to customers in foreign countries, compared with 74% in 2021. ASI’s largest foreign market in both 2022 and 2021 was China, which accounted for approximately 38% of ASI’s sales in 2022 and 42% of sales in 2021.

 

 

 
Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

 

For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at the time of purchase. The Company deposits cash and cash equivalents with high credit quality financial institutions and believes that any amounts in excess of insurance limitations to be at minimal risk. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of $250,000. At December 31, 2022, approximately $105,000 exceeded the FDIC limit.

 
Stockholders' Equity, Policy [Policy Text Block]

Dividends

 

On May 10, 2022, the Company’s Board of Directors declared a semi-annual cash dividend of $0.37 per share, which was paid on June 1, 2022 to all stockholders of record as of May 23, 2022. On November 15, 2022, the Company’s Board of Directors declared a semi-annual cash dividend of $0.31 per share, which was paid on December 7, 2022, to all stockholders of record as of November 28, 2022. In 2022, the Company declared a total of $3,124,137 in dividends, of which $3,123,492 was paid. The balance of $645 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment.

 

On May 18, 2021, the Company’s Board of Directors declared a semi-annual cash dividend of $0.48 per share, which was paid on June 7, 2021 to all stockholders of record as of May 31, 2021. On November 16, 2021, the Company’s Board of Directors declared a semi-annual cash dividend of $0.65 per share which was paid on December 7, 2021 to all stockholders of record as of November 29, 2021. In 2021, the Company declared a total of $5,191,580 in dividends, of which $5,190,033 was paid. The balance of $1,547 is payable to stockholders whose old Guardian Chemical shares have not yet been exchanged to United-Guardian, Inc. shares and are pending escheatment.

 
Marketable Securities, Policy [Policy Text Block]

Marketable Securities

 

The Company’s marketable securities include investments in equity and fixed income mutual funds. The Company’s marketable equity securities are reported at fair value with the related unrealized and realized gains and losses included in net income. Realized gains or losses on mutual funds are determined on a specific identification basis. The Company evaluates its investments periodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extent to which fair value had been below cost basis, the financial condition of the issuer and the Company’s ability and intent to hold the investment for a period of time which may be sufficient for anticipated recovery of market value. The Company would record an impairment charge to the extent that the cost of the available-for-sale securities exceeds the estimated fair value of the securities and the decline in value is determined to be other-than-temporary. During 2022 and 2021, the Company did not record an impairment charge regarding its investment in marketable securities because management believes, based on its evaluation of the circumstances, that the decline in fair value below the cost of certain of the Company’s marketable securities is temporary.

 
Inventory, Policy [Policy Text Block]

Inventories

 

Inventories are valued at the lower of cost and net realizable value. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Inventory costs include material, labor and factory overhead.

 

 
Property, Plant and Equipment, Policy [Policy Text Block]

Property, Plant and Equipment

 

Property, plant and equipment are carried at cost, less accumulated depreciation. Major replacements and betterments are capitalized, while routine maintenance and repairs are expensed as incurred. Assets are depreciated under both accelerated and straight-line methods. Depreciation charged as a result of using accelerated methods was not materially different than that which would result from using the straight-line method for all periods presented. Certain factory equipment and fixtures are constructed by the Company using purchased materials and in-house labor. Such assets are capitalized and depreciated on a basis consistent with the Company's purchased fixed assets.

 

Estimated useful lives are as follows: 

 

Factory equipment and fixtures  

5 - 7 years  

           Building

40 years  

Building improvements  

Lesser of useful life or 20 years

 
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-Lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairments were necessary at December 31, 2022 and 2021.

 
Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

 

Management of the Company believes that the fair value of financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, approximates their carrying value due to their short payment terms and liquid nature.

 
Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk

 

Accounts receivable potentially exposes the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether any credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its accounts receivable credit risk has been reduced.

 

For the year ended December 31, 2022, four of the Company’s pharmaceutical wholesalers and cosmetic ingredient distributors accounted for approximately 72% of the Company’s gross sales during the year and approximately 81% of its outstanding accounts receivable at December 31, 2022. For the year ended December 31, 2021, the same four pharmaceutical wholesalers and cosmetic ingredient distributors accounted for a total of approximately 75% of the Company’s gross sales during the year and 80% of its outstanding accounts receivable at December 31, 2021.

 

 
Vendor Concentration [Policy Text Block]

Vendor Concentration

 

Most of the principal raw materials used by the Company consist of common industrial organic and inorganic chemicals and are available in ample supply from numerous sources. However, there are some raw materials used by the Company that are not readily available or require long lead times. During 2022, the Company periodically experienced longer lead times due to shipping delays and supply chain issues related to the pandemic. The Company has six major raw material vendors that collectively accounted for approximately 90% and 94% of the raw material purchases by the Company in 2022 and 2021, respectively.

 
Income Tax, Policy [Policy Text Block]

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to the temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized.

 

Uncertain tax positions are accounted for utilizing a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As of December 31, 2022 and 2021, the Company did not have any unrecognized income tax benefits. It is the Company’s policy to recognize interest and penalties related to taxes as interest expense as incurred. During the years ended December 31, 2022 and 2021, the Company did not record any tax-related interest or penalties. The Company’s tax returns for 2019 and all subsequent years are subject to examination by the United States Internal Revenue Service and by the State of New York.

 
Research, Development, and Computer Software, Policy [Policy Text Block]

Research and Development

 

Research and development expenses are expenditures incurred in connection with in-house research on new and existing products. It includes payroll and payroll related expenses, outside laboratory expenditures, lab supplies, and equipment depreciation.

 
Cost of Goods and Services Sold, Shipping and Handling Cost, Policy [Policy Text Block]

Shipping and Handling Expenses

 

Shipping and handling costs are classified in operating expenses in the accompanying statements of income. Shipping and handling costs were approximately $97,000 and $82,000 for the years ended December 31, 2022 and 2021, respectively.

 
Advertising Cost [Policy Text Block]

Advertising Expenses

 

Advertising costs are expensed as incurred. For the years ended December 31, 2022 and 2021, the Company incurred approximately $19,000 and $31,000, respectively, in advertising expense, which primarily relates to the internet marketing of Renacidin, one of the Company’s pharmaceutical products.

 

 
Earnings Per Share, Policy [Policy Text Block]

Earnings Per Share Information

 

Basic earnings per share are computed by dividing net income by the weighted average number of common shares outstanding during the year. Diluted earnings per share would include the dilutive effect of outstanding stock options, if any.

 
New Accounting Pronouncements, Policy [Policy Text Block]

New Accounting Standards

 

In June 2016, the FASB issued ASU-2016-13 “Financial Instruments – Credit Losses”. This guidance affects organizations that hold financial assets and net investments in leases that are not accounted for at fair value with changes in fair value reported in net income. The guidance requires organizations to measure all expected credit losses for financial instruments at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. It is effective for fiscal years beginning after December 15, 2022. The Company does not expect that the implementation of this standard will have a material effect on its’ financial statements.
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Note A - Nature of Business and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Disaggregation of Revenue [Table Text Block]
  

Years ended December 31,

 
  2022  2021 
         

Cosmetic ingredients

 $5,167,909  $6,872,714 

Pharmaceuticals

  4,943,605   4,735,324 

Medical lubricants

  2,470,163   2,171,204 

Industrial and other

  116,826   150,387 

Total Net Sales

 $12,698,503  $13,929,629 
Revenue from External Customers by Geographic Areas [Table Text Block]
  Years ended December 31, 
  

2022

  

2021

 
         

United States*

 $9,537,124  $11,159,341 

Other countries

  3,161,379   2,770,288 

Net Sales

 $12,698,503  $13,929,629 
Proerty Plant and Equipment, Useful Lives [Table Text Block]

Factory equipment and fixtures  

5 - 7 years  

           Building

40 years  

Building improvements  

Lesser of useful life or 20 years
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Note B - Cash and Cash Equivalents (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Cash and Cash Equivalents [Table Text Block]
  Years ended December 31, 
  2022  2021 
         

Demand Deposits

 $333,275  $531,213 

U.S. Treasury Bills (original 2-month maturity)

  497,177   --- 

Total cash and cash equivalents

 $830,452  $531,213 
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Note C - Marketable Securities (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Gain (Loss) on Securities [Table Text Block]
  Years ended December 31,    
  2022  2021 
       

Net losses recognized during the year on marketable securities

 $(1,046,245

)

 $(23,018

)

Less: Net losses (gains) realized during the year on marketable securities sold during the period

  364,074   (111,917

)

 

Net unrealized loss recognized during the reporting year on marketable securities still held at the reporting date

 $(682,171

)

 $(134,935

)
Marketable Securities [Table Text Block]
          Unrealized 
  Cost  Fair Value  (Loss)Gain 
             

Equity Securities

            

Fixed income mutual funds

 $5,449,227  $4,924,497  $(524,730

)

Equity and other mutual funds

  717,165   729,019   11,854 

Total equity securities

  6,166,392   5,653,516   (512,876

)

Total marketable securities

 $6,166,392  $5,653,516  $(512,876

)

          Unrealized 
    Cost  Fair Value  Gain 
             

Equity Securities

            

Fixed income mutual funds

 $6,814,420  $6,873,333  $58,913 

Equity and other mutual funds

  651,748   762,130   110,382 

Total equity securities

  7,466,168   7,635,463   169,295 

Total marketable securities

 $7,466,168  $7,635,463  $169,295 
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Note D - Inventories (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Inventory, Current [Table Text Block]
  

December 31,

 
  

2022

  

2021

 
         

Raw materials

 $601,125  $494,348 

Work in process

  16,520   119,069 

Finished products

  1,054,367   797,372 

Total Inventories

 $1,672,012  $1,410,789 
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Note E - Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
  

Years ended December 31,

 

Current

 

2022

  

2021

 

Federal

 $850,344  $1,287,749 

State

  1,590   96 

Total current provision for income taxes

  851,934   1,287,845 

Deferred

        

Federal

  (193,766

)

  (68,462

)

State

  ---   --- 

Total deferred benefit from income taxes

  (193,766

)

  (68,462

)

         

Total provision for income taxes

 $658,168  $1,219,383 
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
  

Years ended December 31,

 
  2022  2021 
   ($)  

Tax rate

   ($)  

Tax rate

 
                 

Income taxes at statutory federal income tax rate

 $677,813   21.0

%

 $1,234,364   21.0

%

State taxes, net of federal benefit

  1,256   ---   76   --- 

Research & development credits

  (10,000

)

  (0.3)  (10,000

)

  (0.2

)

Non-taxable dividends

  (6,300

)

  (0.2)  (2,923

)

  (0.1

)

Other, net

  (4,601

)

  (0.1)  (2,134

)

  --- 

Provision for income taxes

 $658,168   20.4

%

 $1,219,383   20.7

%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
  

December 31, .

 
  

2022

  

2021

 
         

Deferred tax assets

        

Allowance for doubtful accounts

 $4,213  $4,253 

Inventories

  13,440   7,350 

Accounts payable

  6,367   86,288 

R&D expenses

  92,756   --- 

Unrealized loss on marketable securities

  107,704   --- 

Accrued expenses

  277,326   339,884 

Total deferred tax assets

 $501,806  $437,775 

Deferred tax liabilities

        

Accounts receivable

  (304,004

)

  (385,056

)

Prepaid expenses

  (42,446

)

  (38,918

)

Depreciation on property, plant and equipment

  (44,812

)

  (61,471

)

Unrealized gain on marketable securities

  ---   (35,552

)

Total deferred tax liabilities

  (391,262

)

  (520,997

)

Net deferred tax asset (liability)

 $110,544  $(83,222

)
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Note G - Geographic and Other Information (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
   Years ended December 31, 
   2022   2021  
         

Cosmetic Ingredients

 $5,388,365  $6,872,714 

Pharmaceuticals

  5,929,216   5,748,244 

Medical Lubricants

  2,471,555   2,175,822 

Industrial and other

  116,826   150,387 

Gross Sales

  13,905,962   14,947,167 

Less: Discounts and allowances

  (1,207,459

)

  (1,017,538

)

Net Sales

 $12,698,503  $13,929,629 
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
  

Years ended December 31,

 
  

2022

  

2021

 
         

United States

 $9,537,124  $11,159,341 

Other countries

  3,161,379   2,770,288 

Net Sales

 $12,698,503  $13,929,629 
Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]
  Years ended December 31, 
  

2022

  

2021

 
         

Customer A

 $4,284,799  $5,641,279 

Customer B

  2,527,743   2,526,869 

Customer C

  1,613,597   1,522,882 

Customer D

  1,553,885   1,488,301 

All other customers

  3,925,938   3,767,836 

Total Gross Sales

 $13,905,962  $14,947,167 
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Note H - Accrued Expenses (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Accrued Liabilities [Table Text Block]
  

2022

  

2021

 
         

Bonuses

 $175,496  $348,000 

Distribution fees

  395,536   359,550 

Payroll and related expenses

  53,475   292,560 

Company 401(k) contribution

  94,326   109,000 

Annual report expenses

  68,349   64,038 

Audit fee

  66,500   61,500 

Reserve for outdated material returns

  369,154   313,904 

Sales rebates

  80,926   56,857 

Other

  18,294   21,981 

Total accrued expenses

 $1,322,056  $1,627,390 
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Note A - Nature of Business and Summary of Significant Accounting Policies (Details Textual)
 12 Months Ended
Nov. 15, 2022
$ / shares
May 10, 2022
$ / shares
Nov. 16, 2021
$ / shares
May 18, 2021
$ / shares
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Accounts Receivable, Allowance for Credit Loss, Ending Balance         $ 20,063 $ 20,252
Contract with Customer, Liability, Current         0 190,164
Cash, Uninsured Amount         105,000  
Common Stock, Dividends, Per Share, Cash Paid (in dollars per share) | $ / shares $ 0.31 $ 0.37 $ 0.65 $ 0.48    
Dividends, Total         3,124,137 5,191,580
Payments of Ordinary Dividends, Common Stock         3,123,492 5,190,033
Dividends Payable         645 1,547
Impairment, Long-Lived Asset, Held-for-Use, Total         $ 0 $ 0
Number of Vendors         6 6
Unrecognized Tax Benefits, Ending Balance         $ 0 $ 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total         0 0
Cost of Goods and Services Sold, Total         5,996,376 5,747,931
Advertising Expense         $ 19,000 $ 31,000
Distributors and Marketing Partners [Member]            
Number of Customers         4 4
Accrued Expenses [Member]            
Allowance for Material Returns         $ 369,154 $ 313,904
Shipping and Handling [Member]            
Cost of Goods and Services Sold, Total         $ 97,000 $ 82,000
Revenue Benchmark [Member] | Product Concentration Risk [Member] | LUBRAJEL and RENACIDIN IRRIGATION [Member]            
Concentration Risk, Percentage         92.00% 93.00%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Lubrajel [Member]            
Concentration Risk, Percentage         59.00% 64.00%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Renacidin [Member]            
Concentration Risk, Percentage         33.00% 29.00%
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Personal Care [Member] | Non-US [Member]            
Concentration Risk, Percentage         25.00% 20.00%
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | ASI [Member] | Non-US [Member]            
Concentration Risk, Percentage         66.00% 74.00%
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | ASI [Member] | CHINA            
Concentration Risk, Percentage         38.00% 42.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Distributors and Marketing Partners [Member]            
Concentration Risk, Percentage         72.00% 75.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Distributors and Marketing Partners [Member]            
Concentration Risk, Percentage         81.00% 80.00%
Cost of Goods and Service, Product and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Six Raw Material Vendors [Member]            
Concentration Risk, Percentage         90.00% 94.00%
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Note A - Nature of Business and Summary of Significant Accounting Policies - Disaggregated Revenue (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Net Sales $ 12,698,503 $ 13,929,629
Cosmetic Ingredients [Member]    
Net Sales 5,167,909 6,872,714
Pharmaceuticals [Member]    
Net Sales 4,943,605 4,735,324
Medical Lubricants [Member]    
Net Sales 2,470,163 2,171,204
Industrial And Other [Member]    
Net Sales $ 116,826 $ 150,387
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Note A - Nature of Business and Summary of Significant Accounting Policies - Revenue by Geographic Region (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Net Sales $ 12,698,503 $ 13,929,629
UNITED STATES    
Net Sales [1] 9,537,124 11,159,341
Non-US [Member]    
Net Sales $ 3,161,379 $ 2,770,288
[1] Although a significant percentage of ASI’s purchases from the Company are sold to foreign customers, all sales to ASI are considered U.S. sales for financial reporting purposes, since all shipments to ASI are shipped to ASI’s warehouses in the U.S. A certain percentage of those products are subsequently shipped by ASI to its foreign customers. Based on sales information provided to the Company by ASI, 66% of ASI’s sales in 2022 were to customers in foreign countries, compared with 74% in 2021. ASI’s largest foreign market in both 2022 and 2021 was China, which accounted for approximately 38% of ASI’s sales in 2022 and 42% of sales in 2021.
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Note A - Nature of Business and Summary of Significant Accounting Policies - Property, Plant, and Equipment Useful Lives (Details)
 12 Months Ended
Dec. 31, 2022
Factory Equipment And Fixtures [Member]  
Property, plant, and equipment, useful lives (Year) 7 years
Factory Equipment And Fixtures [Member] | Minimum [Member]  
Property, plant, and equipment, useful lives (Year) 5 years
Building [Member]  
Property, plant, and equipment, useful lives (Year) 40 years
Building Improvements [Member]  
Building improvements Lesser of useful life or 20 years
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Note B - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Cash and cash equivalents $ 830,452 $ 531,213
Demand Deposits [Member]    
Cash and cash equivalents 333,275 $ 531,213
US Treasury Securities [Member]    
Cash and cash equivalents $ 497,177  
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Note C - Marketable Securities (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Proceeds from Sale and Maturity of Marketable Securities $ 2,867,671 $ 4,152,660
Debt and Equity Securities, Realized Gain (Loss), Total $ (364,074) $ 111,917
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Note C - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Net losses recognized during the year on marketable securities $ (1,046,245) $ (23,018)
Less: Net losses (gains) realized during the year on marketable securities sold during the period (364,074) 111,917
Net unrealized loss recognized during the reporting year on marketable securities still held at the reporting date $ (682,171) $ (134,935)
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Note C - Marketable Securities - Summary of Investments (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Equity securities, cost $ 6,166,392 $ 7,466,168
Equity securities 5,653,516 7,635,463
Equity securities, unrealized gain (512,876) 169,295
Marketable securities, cost 6,166,392 7,466,168
Marketable securities 5,653,516 7,635,463
Marketable securities, unrealized gain (512,876) 169,295
Fixed Income Securities [Member]    
Equity securities, cost 5,449,227 6,814,420
Equity securities 4,924,497 6,873,333
Equity securities, unrealized gain (524,730) 58,913
Equity And Other Mutual Funds [Member]    
Equity securities, cost 717,165 651,748
Equity securities 729,019 762,130
Equity securities, unrealized gain $ 11,854 $ 110,382
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Note D - Inventories (Details Textual) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Inventory Valuation Reserves $ 64,000 $ 35,000
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Note D - Inventories - Summary of Inventories (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Raw materials $ 601,125 $ 494,348
Work in process 16,520 119,069
Finished products 1,054,367 797,372
Total Inventories $ 1,672,012 $ 1,410,789
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Note E - Income Taxes - Provision for Income Taxes (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Federal $ 850,344 $ 1,287,749
State 1,590 96
Total current provision for income taxes 851,934 1,287,845
Federal (193,766) (68,462)
Total deferred benefit from income taxes (193,766) (68,462)
Total provision for income taxes $ 658,168 $ 1,219,383
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Note E - Income Taxes - Reconciliation of the Effective Income Tax Rate (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income taxes at statutory federal income tax rate $ 677,813 $ 1,234,364
Income taxes at statutory federal income tax rate of 21%, percent 21.00% 21.00%
State taxes, net of federal benefit $ 1,256 $ 76
Research & development credits $ (10,000) $ (10,000)
Research & development credits, percent (0.30%) (0.20%)
Non-taxable dividends $ (6,300) $ (2,923)
Non-taxable dividends, percent (0.20%) (0.10%)
Other, net $ (4,601) $ (2,134)
Other, net, percent (0.10%)  
Provision for income taxes $ 658,168 $ 1,219,383
Provision for income taxes, percent 20.40% 20.70%
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Note E - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Deferred tax assets    
Allowance for doubtful accounts $ 4,213 $ 4,253
Inventories 13,440 7,350
Accounts payable 6,367 86,288
R&D expenses 92,756  
Unrealized loss on marketable securities 107,704  
Accrued expenses 277,326 339,884
Total deferred tax assets 501,806 437,775
Deferred tax liabilities    
Accounts receivable (304,004) (385,056)
Prepaid expenses (42,446) (38,918)
Depreciation on property, plant and equipment (44,812) (61,471)
Unrealized gain on marketable securities   (35,552)
Total deferred tax liabilities (391,262) (520,997)
Net deferred tax asset $ 110,544  
Net deferred tax liability   $ (83,222)
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Note F - Benefit Plans (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Defined Contribution Plan, Employer Discretionary Contribution Amount $ 81,000 $ 80,000
Defined Contribution Plan, Employer Discretionary Contribution Amount Per Year Authorized $ 109,000 $ 109,000
DC Plan [Member]    
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay 4.00%  
DC Plan [Member] | Discretionary Contributions Vesting at Two Years [Member]    
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage 20.00%  
Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year) 2 years  
DC Plan [Member] | Discretionary Contributions Vesting Each Additional Year [Member]    
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage 20.00%  
Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year) 6 years  
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Note G - Geographic and Other Information (Details Textual)
 12 Months Ended
Dec. 31, 2022
Number of Operating Segments 1
Geographic Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member] | Medical Lubricants [Member] | US with Subsequent Shipment to Foreign Locations [Member]  
Number of Customers 4
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Note G - Geographic and Other Information - Net Sales (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Gross Sales $ 13,905,962 $ 14,947,167
Less: Discounts and allowances (1,207,459) (1,017,538)
Net Sales 12,698,503 13,929,629
Cosmetic Ingredients [Member]    
Gross Sales 5,388,365 6,872,714
Net Sales 5,167,909 6,872,714
Pharmaceuticals [Member]    
Gross Sales 5,929,216 5,748,244
Net Sales 4,943,605 4,735,324
Medical Lubricants [Member]    
Gross Sales 2,471,555 2,175,822
Net Sales 2,470,163 2,171,204
Industrial And Other [Member]    
Gross Sales 116,826 150,387
Net Sales $ 116,826 $ 150,387
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Note G - Geographic and Other Information - Geographic Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Net Sales $ 12,698,503 $ 13,929,629
UNITED STATES    
Net Sales [1] 9,537,124 11,159,341
Non-US [Member]    
Net Sales $ 3,161,379 $ 2,770,288
[1] Although a significant percentage of ASI’s purchases from the Company are sold to foreign customers, all sales to ASI are considered U.S. sales for financial reporting purposes, since all shipments to ASI are shipped to ASI’s warehouses in the U.S. A certain percentage of those products are subsequently shipped by ASI to its foreign customers. Based on sales information provided to the Company by ASI, 66% of ASI’s sales in 2022 were to customers in foreign countries, compared with 74% in 2021. ASI’s largest foreign market in both 2022 and 2021 was China, which accounted for approximately 38% of ASI’s sales in 2022 and 42% of sales in 2021.
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Note G - Geographic and Other Information - Sales to Major Customers (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Gross Sales $ 13,905,962 $ 14,947,167
Customer A [Member]    
Gross Sales 4,284,799 5,641,279
Customer B [Member]    
Gross Sales 2,527,743 2,526,869
Customer C [Member]    
Gross Sales 1,613,597 1,522,882
Customer D [Member]    
Gross Sales 1,553,885 1,488,301
All Other Customers [Member]    
Gross Sales $ 3,925,938 $ 3,767,836
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Note H - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Bonuses $ 175,496 $ 348,000
Distribution fees 395,536 359,550
Payroll and related expenses 53,475 292,560
Company 401(k) contribution 94,326 109,000
Annual report expenses 68,349 64,038
Audit fee 66,500 61,500
Reserve for outdated material returns 369,154 313,904
Sales rebates 80,926 56,857
Other 18,294 21,981
Total accrued expenses $ 1,322,056 $ 1,627,390
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities (Details Textual)
 12 Months Ended
Dec. 31, 2022
USD ($)
shares
Convertible Common Stock, Shares Issuable upon Conversion (in shares) | shares 447
Payments for Accrued Dividends on Unconverted Shares | $ $ 447
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Note J - Related Party Transactions (Details Textual) - USD ($)
 1 Months Ended 12 Months Ended
Nov. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Director [Member] | Accounting and Tax Services [Member]      
Related Party Transaction, Expenses from Transactions with Related Party   $ 14,500 $ 19,500
Previous President and CEO [Member] | Consulting Services [Member]      
Related Party Transaction, Amounts of Transaction   $ 20,000  
Previous President and CEO [Member] | Purchase of Used Vehicle [Member]      
Related Party Transaction, Amounts of Transaction $ 37,039    
XML 56 ug20221231_10k_htm.xml IDEA: XBRL DOCUMENT 0000101295 2022-01-01 2022-12-31 0000101295 2022-06-30 0000101295 2023-03-01 0000101295 2021-01-01 2021-12-31 0000101295 2022-12-31 0000101295 2021-12-31 0000101295 us-gaap:CommonStockMember 2020-12-31 0000101295 us-gaap:RetainedEarningsMember 2020-12-31 0000101295 2020-12-31 0000101295 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000101295 us-gaap:DividendDeclaredMember 2021-01-01 2021-12-31 0000101295 us-gaap:DividendDeclaredMember us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000101295 us-gaap:DividendPaidMember 2021-01-01 2021-12-31 0000101295 us-gaap:DividendPaidMember us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000101295 us-gaap:CommonStockMember 2021-12-31 0000101295 us-gaap:RetainedEarningsMember 2021-12-31 0000101295 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000101295 us-gaap:DividendDeclaredMember 2022-01-01 2022-12-31 0000101295 us-gaap:DividendDeclaredMember us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000101295 us-gaap:DividendPaidMember 2022-01-01 2022-12-31 0000101295 us-gaap:DividendPaidMember us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000101295 us-gaap:CommonStockMember 2022-12-31 0000101295 us-gaap:RetainedEarningsMember 2022-12-31 0000101295 ug:LUBRAJELAndRENACIDINIRRIGATIONMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-12-31 0000101295 ug:LUBRAJELAndRENACIDINIRRIGATIONMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-12-31 0000101295 ug:LubrajelMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-12-31 0000101295 ug:LubrajelMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-12-31 0000101295 ug:RenacidinMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-12-31 0000101295 ug:RenacidinMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-12-31 0000101295 ug:AccruedExpensesMember 2022-12-31 0000101295 ug:AccruedExpensesMember 2021-12-31 0000101295 ug:CosmeticIngredientsMember 2022-01-01 2022-12-31 0000101295 ug:CosmeticIngredientsMember 2021-01-01 2021-12-31 0000101295 ug:PharmaceuticalsMember 2022-01-01 2022-12-31 0000101295 ug:PharmaceuticalsMember 2021-01-01 2021-12-31 0000101295 ug:MedicalLubricantsMember 2022-01-01 2022-12-31 0000101295 ug:MedicalLubricantsMember 2021-01-01 2021-12-31 0000101295 ug:IndustrialAndOtherMember 2022-01-01 2022-12-31 0000101295 ug:IndustrialAndOtherMember 2021-01-01 2021-12-31 0000101295 ug:PersonalCareMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000101295 ug:PersonalCareMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000101295 country:US 2022-01-01 2022-12-31 0000101295 country:US 2021-01-01 2021-12-31 0000101295 us-gaap:NonUsMember 2022-01-01 2022-12-31 0000101295 us-gaap:NonUsMember 2021-01-01 2021-12-31 0000101295 ug:ASIMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000101295 ug:ASIMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000101295 ug:ASIMember country:CN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000101295 ug:ASIMember country:CN us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000101295 2022-05-10 2022-05-10 0000101295 2022-11-15 2022-11-15 0000101295 2021-05-18 2021-05-18 0000101295 2021-11-16 2021-11-16 0000101295 srt:MinimumMember ug:FactoryEquipmentAndFixturesMember 2022-01-01 2022-12-31 0000101295 ug:FactoryEquipmentAndFixturesMember 2022-01-01 2022-12-31 0000101295 us-gaap:BuildingMember 2022-01-01 2022-12-31 0000101295 us-gaap:BuildingImprovementsMember 2022-01-01 2022-12-31 0000101295 ug:DistributorsAndMarketingPartnersMember 2022-01-01 2022-12-31 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000101295 ug:DistributorsAndMarketingPartnersMember 2021-01-01 2021-12-31 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000101295 ug:SixRawMaterialVendorsMember us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-12-31 0000101295 ug:SixRawMaterialVendorsMember us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-12-31 0000101295 us-gaap:ShippingAndHandlingMember 2022-01-01 2022-12-31 0000101295 us-gaap:ShippingAndHandlingMember 2021-01-01 2021-12-31 0000101295 us-gaap:DemandDepositsMember 2022-12-31 0000101295 us-gaap:DemandDepositsMember 2021-12-31 0000101295 us-gaap:USTreasurySecuritiesMember 2022-12-31 0000101295 us-gaap:FixedIncomeSecuritiesMember 2022-12-31 0000101295 ug:EquityAndOtherMutualFundsMember 2022-12-31 0000101295 us-gaap:FixedIncomeSecuritiesMember 2021-12-31 0000101295 ug:EquityAndOtherMutualFundsMember 2021-12-31 0000101295 ug:DCPlanMember 2022-01-01 2022-12-31 0000101295 ug:DiscretionaryContributionsVestingAtTwoYearsMember ug:DCPlanMember 2022-01-01 2022-12-31 0000101295 ug:DiscretionaryContributionsVestingEachAdditionalYearMember ug:DCPlanMember 2022-01-01 2022-12-31 0000101295 ug:MedicalLubricantsMember ug:USWithSubsequentShipmentToForeignLocationsMember us-gaap:SalesRevenueProductLineMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000101295 ug:CustomerAMember 2022-01-01 2022-12-31 0000101295 ug:CustomerAMember 2021-01-01 2021-12-31 0000101295 ug:CustomerBMember 2022-01-01 2022-12-31 0000101295 ug:CustomerBMember 2021-01-01 2021-12-31 0000101295 ug:CustomerCMember 2022-01-01 2022-12-31 0000101295 ug:CustomerCMember 2021-01-01 2021-12-31 0000101295 ug:CustomerDMember 2022-01-01 2022-12-31 0000101295 ug:CustomerDMember 2021-01-01 2021-12-31 0000101295 ug:AllOtherCustomersMember 2022-01-01 2022-12-31 0000101295 ug:AllOtherCustomersMember 2021-01-01 2021-12-31 0000101295 ug:AccountingAndTaxServicesMember srt:DirectorMember 2022-01-01 2022-12-31 0000101295 ug:AccountingAndTaxServicesMember srt:DirectorMember 2021-01-01 2021-12-31 0000101295 ug:ConsultingServicesMember ug:PreviousPresidentAndCeoMember 2022-01-01 2022-12-31 0000101295 ug:PurchaseOfUsedVehicleMember ug:PreviousPresidentAndCeoMember 2022-11-01 2022-11-30 iso4217:USD shares thunderdome:item iso4217:USD shares pure utr:Y 0000101295 UNITED GUARDIAN INC false --12-31 FY 2022 20063 20252 0.10 0.10 10000000 10000000 4594319 4594319 4594319 4594319 1.13 1.13 0.68 0.68 P5Y P7Y P40Y 0 4 6 0 0 0 0 109000 P2Y P6Y 10-K true 2022-12-31 false 1-10526 DE 11-1719724 230 Marcus Blvd. Hauppauge NY 11788 631 273-0900 Common Stock, $.10 par value UG NASDAQ No No Yes Yes true false Non-accelerated Filer false false 68868800 4594319 23 Baker Tilly US, LLP Uniondale, NY 12698503 13929629 5996376 5747931 2174127 2035970 490770 478642 8661273 8262543 4037230 5667086 236695 233857 -1046245 -23018 -809550 210839 3227680 5877925 658168 1219383 2569512 4658542 0.56 1.01 4594319 4594319 830452 531213 5653516 7635463 1427576 1813346 1672012 1410789 201846 192579 185228 9970630 11583390 110544 69000 69000 4585055 4605742 2895742 2853718 7549797 7528460 6990636 6869598 559161 658862 10640335 12242252 30415 410894 1322056 1627390 190164 88738 21220 20575 1373691 2337761 83222 459432 459432 8807212 9361837 9266644 9821269 10640335 12242252 4594319 459432 9894875 10354307 4658542 4658542 1547 1547 5190033 5190033 4594319 459432 9361837 9821269 2569512 2569512 645 645 3123492 3123492 4594319 459432 8807212 9266644 2569512 4658542 135396 145977 -2445 14799 -1046245 -23018 -189 6235 29000 -193766 -68462 -385959 431883 290223 -4984 9267 31371 185228 -99107 -380479 379094 -305334 263933 -190164 190164 -88738 88738 2525169 5313277 75179 116375 37039 1931969 4219760 2867671 4152660 897562 -183475 3123492 5190033 -3123492 -5190033 299239 -60231 531213 591444 830452 531213 1125000 1100000 645 1547 29000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE A - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT </b><b>ACCOUNTING POLICIES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Nature of Business</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">United-Guardian, Inc. (the "Company") is a Delaware corporation that, through its Guardian Laboratories division, manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. It also conducts research and product development, primarily related to the development of new and unique cosmetic ingredients. The Company’s research and development department also modifies, refines, and expands the uses for existing products, with the goal of further developing the market for the Company's products. Two major product lines, Lubrajel® and Renacidin®<sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup>Irrigation Solution (“Renacidin”) together accounted for approximately 92% and 93% of the Company’s sales for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>respectively. Lubrajel accounted for approximately 59% and 64% of the Company’s sales for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>respectively, and Renacidin accounted for approximately 33% and 29% of the Company’s sales for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Impact of the Coronavirus Pandemic, Global Supply Chain Instability and Inflation</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">While the coronavirus pandemic continues to impact certain areas of the Company’s operations, the current impact on the Company’s financial performance is coming primarily from <em style="font: inherit;">1</em>) higher raw material costs and increased shipping costs, which had an impact on the Company’s gross profit margins during <em style="font: inherit;">2022</em> and <em style="font: inherit;">2</em>) a decrease in cosmetic ingredient sales in China due to China’s <em style="font: inherit;">zero</em>-COVID mandate that was in effect for a substantial part of <em style="font: inherit;">2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The pandemic did <em style="font: inherit;">not</em> affect the Company’s ability to obtain raw materials but due to supply chain instability, the Company experienced longer lead times and higher prices for many of its raw materials. The increased raw material prices had an impact on the Company’s gross profit margins in <em style="font: inherit;">2022</em> and <em style="font: inherit;"> may </em>continue to have an impact on gross profit margins in upcoming quarters. In response to the rising raw material prices the Company has instituted price increases on many of its products, which will help to reduce the impact on the Company’s gross margins in the future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As a result of the lingering effects of the coronavirus pandemic as described above, combined with global supply chain instability, there continues to be uncertainty in regard to its future potential impact on the Company’s operations or financial results. The Company believes that it is still unable to provide an accurate estimate or projection as to what the future impact of the pandemic will be on its future operations or financial results.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">While it is unknown whether inflation will continue to increase or will begin to decrease during <em style="font: inherit;">2023,</em> continued inflation is likely to result in further increases in raw material costs, shipping costs, and internal labor costs, which could impact the Company’s results of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Use of Estimates</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In preparing financial statements in conformity with a Generally Accepted Accounting Principles in the United States of America (“US GAAP”), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for bad debts, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities and the allocation of overhead.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Accounts Receivable and Reserves</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The carrying amount of accounts receivable is reduced by a valuation allowance that reflects the Company’s best estimate of the amounts that will <em style="font: inherit;">not</em> be collected. The reserve for accounts receivable comprises the allowance for doubtful accounts. In addition to reviewing delinquent accounts receivable, the Company considers many factors in estimating this reserve, including historical data, experience, customer types and credit worthiness, and economic trends. At <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> the allowance for doubtful accounts receivable amounted to $20,063 and $20,252, respectively. From time to time, the Company adjusts its assumptions for anticipated changes in any of these or other factors expected to affect collectability.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Revenue Recognition</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company records revenue in accordance with ASC Topic <em style="font: inherit;">606</em> “Revenue from Contracts with Customers.” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company’s principal source of revenue is product sales.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period in which the revenue is recognized. Such deductions, primarily related to the sale of the Company’s pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with the Company’s current participation in Medicare programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">During <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> the Company participated in various government drug rebate programs related to the sale of Renacidin®, its most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (“FSS”), and the Medicare Part D Coverage Gap Discount Program (“CGDP”). These programs require the Company to sell its product at a discounted price. The Company’s sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As long as a valid purchase order has been received and future collection of the sale amount is reasonably assured, the Company recognizes revenue from sales of its products when those products are shipped, which is when the Company’s performance obligation is satisfied. The Company’s cosmetic products are shipped “Ex-Works” from the Company’s facility in Hauppauge, NY, and the risk of loss and responsibility for the shipment passes to the customer upon shipment. Sales of the Company’s non-pharmaceutical medical products are deemed final upon shipment, and there is <em style="font: inherit;">no</em> obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective. Sales of the Company’s pharmaceutical products are final upon shipment unless (a) they are found to be defective; (b) the product is damaged in shipping; (c) the product cannot be sold because it is too close to its expiration date; or (d) the product has expired (but it is <em style="font: inherit;">not</em> more than <em style="font: inherit;">one</em> year after the expiration date). This return policy conforms to standard pharmaceutical industry practice. The Company estimates an allowance for outdated material returns based on previous years’ historical returns of its pharmaceutical products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company does <em style="font: inherit;">not</em> make sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is <em style="font: inherit;">not</em> contingent upon the customer being able to sell the goods to a <em style="font: inherit;">third</em> party.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic <em style="font: inherit;">606</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">32</em>-<em style="font: inherit;">8.</em> At <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> the Company had an allowance of $369,154 and $313,904, respectively, for possible outdated material returns, which is included in accrued expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The timing between recognition of revenue for product sales and the receipt of payment is <em style="font: inherit;">not</em> significant. The Company’s standard credit terms, which vary depending on the customer, range between <em style="font: inherit;">30</em> and <em style="font: inherit;">60</em> days. The Company uses its judgment on a case-by-case basis to determine its ability to collect outstanding receivables and provides allowances for any receivables for which collection has become doubtful. Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">At <em style="font: inherit;"> December 31, 2021, </em>the Company recorded an advance payment from <em style="font: inherit;">one</em> of its customers in the amount of $190,164, which was recorded as deferred revenue on the balance sheet. The related performance obligation associated with this payment was satisfied in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2022.</em> No such advanced payment exists at <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has distribution agreements with certain distributors of its pharmaceutical products that entitles those distributors to distribution and services-related fees. The Company records distribution fees, and estimates of distribution fees, as offsets to revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Disaggregated net sales by product class are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Years ended December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2022</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2021</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cosmetic ingredients</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,167,909</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,872,714</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Pharmaceuticals</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,943,605</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,735,324</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Medical lubricants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,470,163</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,171,204</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Industrial and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">116,826</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">150,387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total Net Sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,698,503</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,929,629</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s cosmetic ingredients are currently marketed worldwide by <em style="font: inherit;">five</em> distributors, of which the United States (“U.S.”)-based ASI purchases the largest volume. For the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> approximately 25% and 20%, respectively, of the Company’s sales were to (a) its foreign-based distributors (which does <em style="font: inherit;">not</em> include ASI), which marketed and distributed the Company’s cosmetic ingredients to customers outside the U.S, and (b) a few foreign customers for the Company’s medical lubricants sold directly by the Company.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Disaggregated sales by geographic region are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Years ended December 31,</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2022</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">United States*</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9,537,124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11,159,341</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other countries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,161,379</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,770,288</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net Sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,698,503</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,929,629</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 28pt;text-indent:-28pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">* Although a significant percentage of ASI’s purchases from the Company are sold to foreign customers, all sales to ASI are considered U.S. sales for financial reporting purposes, since all shipments to ASI are shipped to ASI’s warehouses in the U.S. A certain percentage of those products are subsequently shipped by ASI to its foreign customers. Based on sales information provided to the Company by ASI, 66% of ASI’s sales in <em style="font: inherit;">2022</em> were to customers in foreign countries, compared with 74% in <em style="font: inherit;">2021.</em> ASI’s largest foreign market in both <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021</em> was China, which accounted for approximately 38% of ASI’s sales in <em style="font: inherit;">2022</em> and 42% of sales in <em style="font: inherit;">2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Cash and Cash Equivalents</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of <em style="font: inherit;">three</em> months or less at the time of purchase. The Company deposits cash and cash equivalents with high credit quality financial institutions and believes that any amounts in excess of insurance limitations to be at minimal risk. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of <em style="font: inherit;">$250,000.</em> At <em style="font: inherit;"> December 31, 2022, </em>approximately $105,000 exceeded the FDIC limit.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Dividends</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> May 10, 2022, </em>the Company’s Board of Directors declared a semi-annual cash dividend of $0.37 per share, which was paid on <em style="font: inherit;"> June 1, 2022 </em>to all stockholders of record as of <em style="font: inherit;"> May 23, 2022. </em>On <em style="font: inherit;"> November 15, 2022, </em>the Company’s Board of Directors declared a semi-annual cash dividend of $0.31 per share, which was paid on <em style="font: inherit;"> December 7, 2022, </em>to all stockholders of record as of <em style="font: inherit;"> November 28, 2022. </em>In <em style="font: inherit;">2022,</em> the Company declared a total of $3,124,137 in dividends, of which $3,123,492 was paid. The balance of $645 is payable to stockholders whose old Guardian Chemical shares have <em style="font: inherit;">not</em> yet been exchanged to United-Guardian, Inc. shares and are pending escheatment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> May 18, 2021, </em>the Company’s Board of Directors declared a semi-annual cash dividend of $0.48 per share, which was paid on <em style="font: inherit;"> June 7, 2021 </em>to all stockholders of record as of <em style="font: inherit;"> May 31, 2021. </em>On <em style="font: inherit;"> November 16, 2021, </em>the Company’s Board of Directors declared a semi-annual cash dividend of $0.65 per share which was paid on <em style="font: inherit;"> December 7, 2021 </em>to all stockholders of record as of <em style="font: inherit;"> November 29, 2021. </em>In <em style="font: inherit;">2021,</em> the Company declared a total of $5,191,580 in dividends, of which $5,190,033 was paid. The balance of $1,547 is payable to stockholders whose old Guardian Chemical shares have <em style="font: inherit;">not</em> yet been exchanged to United-Guardian, Inc. shares and are pending escheatment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Marketable Securities </span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s marketable securities include investments in equity and fixed income mutual funds. The Company’s marketable equity securities are reported at fair value with the related unrealized and realized gains and losses included in net income. Realized gains or losses on mutual funds are determined on a specific identification basis. The Company evaluates its investments periodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extent to which fair value had been below cost basis, the financial condition of the issuer and the Company’s ability and intent to hold the investment for a period of time which <em style="font: inherit;"> may </em>be sufficient for anticipated recovery of market value. The Company would record an impairment charge to the extent that the cost of the available-for-sale securities exceeds the estimated fair value of the securities and the decline in value is determined to be other-than-temporary. During <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> the Company did <em style="font: inherit;">not</em> record an impairment charge regarding its investment in marketable securities because management believes, based on its evaluation of the circumstances, that the decline in fair value below the cost of certain of the Company’s marketable securities is temporary.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Inventories</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Inventories are valued at the lower of cost and net realizable value. Cost is determined using the average cost method, which approximates cost determined by the <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out (“FIFO”) method. Inventory costs include material, labor and factory overhead.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Property, Plant and Equipment</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Property, plant and equipment are carried at cost, less accumulated depreciation. Major replacements and betterments are capitalized, while routine maintenance and repairs are expensed as incurred. Assets are depreciated under both accelerated and straight-line methods. Depreciation charged as a result of using accelerated methods was <em style="font: inherit;">not</em> materially different than that which would result from using the straight-line method for all periods presented. Certain factory equipment and fixtures are constructed by the Company using purchased materials and in-house labor. Such assets are capitalized and depreciated on a basis consistent with the Company's purchased fixed assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Estimated useful lives are as follows: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%; margin-left: 30%; margin-right: 30%;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c95657689">Factory equipment and fixtures  </span></p> </td><td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c95657690">5 - 7 years  </span></p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -27pt;"><em style="font: inherit;">           Building</em></p> </td><td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c95657692">40 years  </span></p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Building improvements  </em></p> </td><td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lesser of useful life or 20 years</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Impairment of Long-Lived Assets</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairments were necessary at <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Fair Value of Financial Instruments</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Management of the Company believes that the fair value of financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, approximates their carrying value due to their short payment terms and liquid nature.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Concentration of Credit Risk</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Accounts receivable potentially exposes the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether any credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its accounts receivable credit risk has been reduced.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the year ended <em style="font: inherit;"> December 31, 2022, </em><span style="-sec-ix-hidden:c95656233">four</span> of the Company’s pharmaceutical wholesalers and cosmetic ingredient distributors accounted for approximately 72% of the Company’s gross sales during the year and approximately 81% of its outstanding accounts receivable at <em style="font: inherit;"> December 31, 2022. </em>For the year ended <em style="font: inherit;"> December 31, 2021, </em>the same four pharmaceutical wholesalers and cosmetic ingredient distributors accounted for a total of approximately 75% of the Company’s gross sales during the year and 80% of its outstanding accounts receivable at <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Vendor Concentration</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Most of the principal raw materials used by the Company consist of common industrial organic and inorganic chemicals and are available in ample supply from numerous sources. However, there are some raw materials used by the Company that are <em style="font: inherit;">not</em> readily available or require long lead times. During <em style="font: inherit;">2022,</em> the Company periodically experienced longer lead times due to shipping delays and supply chain issues related to the pandemic. The Company has six major raw material vendors that collectively accounted for approximately 90% and 94% of the raw material purchases by the Company in <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Income Taxes</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to the temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than <em style="font: inherit;">not</em> that some portion or all the deferred tax assets will <em style="font: inherit;">not</em> be realized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Uncertain tax positions are accounted for utilizing a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> the Company did <span style="-sec-ix-hidden:c95656250"><span style="-sec-ix-hidden:c95656268">not</span></span> have any unrecognized income tax benefits. It is the Company’s policy to recognize interest and penalties related to taxes as interest expense as incurred. During the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> the Company did <span style="-sec-ix-hidden:c95656252"><span style="-sec-ix-hidden:c95656269">not</span></span> record any tax-related interest or penalties. The Company’s tax returns for <em style="font: inherit;">2019</em> and all subsequent years are subject to examination by the United States Internal Revenue Service and by the State of New York.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Research and Development </span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Research and development expenses are expenditures incurred in connection with in-house research on new and existing products. It includes payroll and payroll related expenses, outside laboratory expenditures, lab supplies, and equipment depreciation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Shipping and Handling Expenses</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Shipping and handling costs are classified in operating expenses in the accompanying statements of income. Shipping and handling costs were approximately $97,000 and $82,000 for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Advertising Expenses</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Advertising costs are expensed as incurred. For the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> the Company incurred approximately $19,000 and $31,000, respectively, in advertising expense, which primarily relates to the internet marketing of Renacidin, <em style="font: inherit;">one</em> of the Company’s pharmaceutical products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Earnings Per Share Information</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Basic earnings per share are computed by dividing net income by the weighted average number of common shares outstanding during the year. Diluted earnings per share would include the dilutive effect of outstanding stock options, if any.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b/></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">New Accounting Standards</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU-<em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> “Financial Instruments – Credit Losses”. This guidance affects organizations that hold financial assets and net investments in leases that are <em style="font: inherit;">not</em> accounted for at fair value with changes in fair value reported in net income. The guidance requires organizations to measure all expected credit losses for financial instruments at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. It is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2022. </em>The Company does <em style="font: inherit;">not</em> expect that the implementation of this standard will have a material effect on its’ financial statements.</p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"/> 0.92 0.93 0.59 0.64 0.33 0.29 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Use of Estimates</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In preparing financial statements in conformity with a Generally Accepted Accounting Principles in the United States of America (“US GAAP”), management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for bad debts, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities and the allocation of overhead.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Accounts Receivable and Reserves</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The carrying amount of accounts receivable is reduced by a valuation allowance that reflects the Company’s best estimate of the amounts that will <em style="font: inherit;">not</em> be collected. The reserve for accounts receivable comprises the allowance for doubtful accounts. In addition to reviewing delinquent accounts receivable, the Company considers many factors in estimating this reserve, including historical data, experience, customer types and credit worthiness, and economic trends. At <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> the allowance for doubtful accounts receivable amounted to $20,063 and $20,252, respectively. From time to time, the Company adjusts its assumptions for anticipated changes in any of these or other factors expected to affect collectability.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/> 20063 20252 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Revenue Recognition</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company records revenue in accordance with ASC Topic <em style="font: inherit;">606</em> “Revenue from Contracts with Customers.” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company’s principal source of revenue is product sales.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period in which the revenue is recognized. Such deductions, primarily related to the sale of the Company’s pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with the Company’s current participation in Medicare programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">During <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> the Company participated in various government drug rebate programs related to the sale of Renacidin®, its most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (“FSS”), and the Medicare Part D Coverage Gap Discount Program (“CGDP”). These programs require the Company to sell its product at a discounted price. The Company’s sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As long as a valid purchase order has been received and future collection of the sale amount is reasonably assured, the Company recognizes revenue from sales of its products when those products are shipped, which is when the Company’s performance obligation is satisfied. The Company’s cosmetic products are shipped “Ex-Works” from the Company’s facility in Hauppauge, NY, and the risk of loss and responsibility for the shipment passes to the customer upon shipment. Sales of the Company’s non-pharmaceutical medical products are deemed final upon shipment, and there is <em style="font: inherit;">no</em> obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective. Sales of the Company’s pharmaceutical products are final upon shipment unless (a) they are found to be defective; (b) the product is damaged in shipping; (c) the product cannot be sold because it is too close to its expiration date; or (d) the product has expired (but it is <em style="font: inherit;">not</em> more than <em style="font: inherit;">one</em> year after the expiration date). This return policy conforms to standard pharmaceutical industry practice. The Company estimates an allowance for outdated material returns based on previous years’ historical returns of its pharmaceutical products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company does <em style="font: inherit;">not</em> make sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is <em style="font: inherit;">not</em> contingent upon the customer being able to sell the goods to a <em style="font: inherit;">third</em> party.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic <em style="font: inherit;">606</em>-<em style="font: inherit;">10</em>-<em style="font: inherit;">32</em>-<em style="font: inherit;">8.</em> At <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> the Company had an allowance of $369,154 and $313,904, respectively, for possible outdated material returns, which is included in accrued expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The timing between recognition of revenue for product sales and the receipt of payment is <em style="font: inherit;">not</em> significant. The Company’s standard credit terms, which vary depending on the customer, range between <em style="font: inherit;">30</em> and <em style="font: inherit;">60</em> days. The Company uses its judgment on a case-by-case basis to determine its ability to collect outstanding receivables and provides allowances for any receivables for which collection has become doubtful. Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">At <em style="font: inherit;"> December 31, 2021, </em>the Company recorded an advance payment from <em style="font: inherit;">one</em> of its customers in the amount of $190,164, which was recorded as deferred revenue on the balance sheet. The related performance obligation associated with this payment was satisfied in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2022.</em> No such advanced payment exists at <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has distribution agreements with certain distributors of its pharmaceutical products that entitles those distributors to distribution and services-related fees. The Company records distribution fees, and estimates of distribution fees, as offsets to revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Disaggregated net sales by product class are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Years ended December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2022</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2021</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cosmetic ingredients</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,167,909</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,872,714</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Pharmaceuticals</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,943,605</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,735,324</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Medical lubricants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,470,163</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,171,204</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Industrial and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">116,826</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">150,387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total Net Sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,698,503</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,929,629</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s cosmetic ingredients are currently marketed worldwide by <em style="font: inherit;">five</em> distributors, of which the United States (“U.S.”)-based ASI purchases the largest volume. For the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> approximately 25% and 20%, respectively, of the Company’s sales were to (a) its foreign-based distributors (which does <em style="font: inherit;">not</em> include ASI), which marketed and distributed the Company’s cosmetic ingredients to customers outside the U.S, and (b) a few foreign customers for the Company’s medical lubricants sold directly by the Company.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Disaggregated sales by geographic region are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Years ended December 31,</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2022</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">United States*</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9,537,124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11,159,341</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other countries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,161,379</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,770,288</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net Sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,698,503</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,929,629</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 28pt;text-indent:-28pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">* Although a significant percentage of ASI’s purchases from the Company are sold to foreign customers, all sales to ASI are considered U.S. sales for financial reporting purposes, since all shipments to ASI are shipped to ASI’s warehouses in the U.S. A certain percentage of those products are subsequently shipped by ASI to its foreign customers. Based on sales information provided to the Company by ASI, 66% of ASI’s sales in <em style="font: inherit;">2022</em> were to customers in foreign countries, compared with 74% in <em style="font: inherit;">2021.</em> ASI’s largest foreign market in both <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021</em> was China, which accounted for approximately 38% of ASI’s sales in <em style="font: inherit;">2022</em> and 42% of sales in <em style="font: inherit;">2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/> 369154 313904 190164 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Years ended December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2022</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2021</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cosmetic ingredients</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,167,909</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,872,714</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Pharmaceuticals</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,943,605</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,735,324</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Medical lubricants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,470,163</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,171,204</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Industrial and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">116,826</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">150,387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total Net Sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,698,503</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,929,629</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> 5167909 6872714 4943605 4735324 2470163 2171204 116826 150387 12698503 13929629 0.25 0.20 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Years ended December 31,</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2022</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">United States*</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9,537,124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11,159,341</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other countries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,161,379</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,770,288</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net Sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,698,503</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,929,629</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> 9537124 11159341 3161379 2770288 12698503 13929629 0.66 0.74 0.38 0.42 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Cash and Cash Equivalents</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of <em style="font: inherit;">three</em> months or less at the time of purchase. The Company deposits cash and cash equivalents with high credit quality financial institutions and believes that any amounts in excess of insurance limitations to be at minimal risk. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of <em style="font: inherit;">$250,000.</em> At <em style="font: inherit;"> December 31, 2022, </em>approximately $105,000 exceeded the FDIC limit.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/> 105000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Dividends</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> May 10, 2022, </em>the Company’s Board of Directors declared a semi-annual cash dividend of $0.37 per share, which was paid on <em style="font: inherit;"> June 1, 2022 </em>to all stockholders of record as of <em style="font: inherit;"> May 23, 2022. </em>On <em style="font: inherit;"> November 15, 2022, </em>the Company’s Board of Directors declared a semi-annual cash dividend of $0.31 per share, which was paid on <em style="font: inherit;"> December 7, 2022, </em>to all stockholders of record as of <em style="font: inherit;"> November 28, 2022. </em>In <em style="font: inherit;">2022,</em> the Company declared a total of $3,124,137 in dividends, of which $3,123,492 was paid. The balance of $645 is payable to stockholders whose old Guardian Chemical shares have <em style="font: inherit;">not</em> yet been exchanged to United-Guardian, Inc. shares and are pending escheatment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> May 18, 2021, </em>the Company’s Board of Directors declared a semi-annual cash dividend of $0.48 per share, which was paid on <em style="font: inherit;"> June 7, 2021 </em>to all stockholders of record as of <em style="font: inherit;"> May 31, 2021. </em>On <em style="font: inherit;"> November 16, 2021, </em>the Company’s Board of Directors declared a semi-annual cash dividend of $0.65 per share which was paid on <em style="font: inherit;"> December 7, 2021 </em>to all stockholders of record as of <em style="font: inherit;"> November 29, 2021. </em>In <em style="font: inherit;">2021,</em> the Company declared a total of $5,191,580 in dividends, of which $5,190,033 was paid. The balance of $1,547 is payable to stockholders whose old Guardian Chemical shares have <em style="font: inherit;">not</em> yet been exchanged to United-Guardian, Inc. shares and are pending escheatment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/> 0.37 0.31 3124137 3123492 645 0.48 0.65 5191580 5190033 1547 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Marketable Securities </span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s marketable securities include investments in equity and fixed income mutual funds. The Company’s marketable equity securities are reported at fair value with the related unrealized and realized gains and losses included in net income. Realized gains or losses on mutual funds are determined on a specific identification basis. The Company evaluates its investments periodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extent to which fair value had been below cost basis, the financial condition of the issuer and the Company’s ability and intent to hold the investment for a period of time which <em style="font: inherit;"> may </em>be sufficient for anticipated recovery of market value. The Company would record an impairment charge to the extent that the cost of the available-for-sale securities exceeds the estimated fair value of the securities and the decline in value is determined to be other-than-temporary. During <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> the Company did <em style="font: inherit;">not</em> record an impairment charge regarding its investment in marketable securities because management believes, based on its evaluation of the circumstances, that the decline in fair value below the cost of certain of the Company’s marketable securities is temporary.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Inventories</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Inventories are valued at the lower of cost and net realizable value. Cost is determined using the average cost method, which approximates cost determined by the <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out (“FIFO”) method. Inventory costs include material, labor and factory overhead.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Property, Plant and Equipment</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Property, plant and equipment are carried at cost, less accumulated depreciation. Major replacements and betterments are capitalized, while routine maintenance and repairs are expensed as incurred. Assets are depreciated under both accelerated and straight-line methods. Depreciation charged as a result of using accelerated methods was <em style="font: inherit;">not</em> materially different than that which would result from using the straight-line method for all periods presented. Certain factory equipment and fixtures are constructed by the Company using purchased materials and in-house labor. Such assets are capitalized and depreciated on a basis consistent with the Company's purchased fixed assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Estimated useful lives are as follows: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%; margin-left: 30%; margin-right: 30%;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c95657689">Factory equipment and fixtures  </span></p> </td><td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c95657690">5 - 7 years  </span></p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -27pt;"><em style="font: inherit;">           Building</em></p> </td><td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c95657692">40 years  </span></p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Building improvements  </em></p> </td><td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lesser of useful life or 20 years</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/> <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%; margin-left: 30%; margin-right: 30%;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c95657689">Factory equipment and fixtures  </span></p> </td><td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c95657690">5 - 7 years  </span></p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -27pt;"><em style="font: inherit;">           Building</em></p> </td><td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c95657692">40 years  </span></p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Building improvements  </em></p> </td><td style="vertical-align: bottom; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lesser of useful life or 20 years</p> </td></tr> </tbody></table> Lesser of useful life or 20 years <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Impairment of Long-Lived Assets</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairments were necessary at <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/> 0 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Fair Value of Financial Instruments</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Management of the Company believes that the fair value of financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, approximates their carrying value due to their short payment terms and liquid nature.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Concentration of Credit Risk</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Accounts receivable potentially exposes the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether any credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its accounts receivable credit risk has been reduced.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the year ended <em style="font: inherit;"> December 31, 2022, </em><span style="-sec-ix-hidden:c95656233">four</span> of the Company’s pharmaceutical wholesalers and cosmetic ingredient distributors accounted for approximately 72% of the Company’s gross sales during the year and approximately 81% of its outstanding accounts receivable at <em style="font: inherit;"> December 31, 2022. </em>For the year ended <em style="font: inherit;"> December 31, 2021, </em>the same four pharmaceutical wholesalers and cosmetic ingredient distributors accounted for a total of approximately 75% of the Company’s gross sales during the year and 80% of its outstanding accounts receivable at <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/> 0.72 0.81 4 0.75 0.80 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Vendor Concentration</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Most of the principal raw materials used by the Company consist of common industrial organic and inorganic chemicals and are available in ample supply from numerous sources. However, there are some raw materials used by the Company that are <em style="font: inherit;">not</em> readily available or require long lead times. During <em style="font: inherit;">2022,</em> the Company periodically experienced longer lead times due to shipping delays and supply chain issues related to the pandemic. The Company has six major raw material vendors that collectively accounted for approximately 90% and 94% of the raw material purchases by the Company in <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/> 6 0.90 0.94 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Income Taxes</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to the temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than <em style="font: inherit;">not</em> that some portion or all the deferred tax assets will <em style="font: inherit;">not</em> be realized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Uncertain tax positions are accounted for utilizing a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> the Company did <span style="-sec-ix-hidden:c95656250"><span style="-sec-ix-hidden:c95656268">not</span></span> have any unrecognized income tax benefits. It is the Company’s policy to recognize interest and penalties related to taxes as interest expense as incurred. During the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> the Company did <span style="-sec-ix-hidden:c95656252"><span style="-sec-ix-hidden:c95656269">not</span></span> record any tax-related interest or penalties. The Company’s tax returns for <em style="font: inherit;">2019</em> and all subsequent years are subject to examination by the United States Internal Revenue Service and by the State of New York.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Research and Development </span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Research and development expenses are expenditures incurred in connection with in-house research on new and existing products. It includes payroll and payroll related expenses, outside laboratory expenditures, lab supplies, and equipment depreciation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Shipping and Handling Expenses</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Shipping and handling costs are classified in operating expenses in the accompanying statements of income. Shipping and handling costs were approximately $97,000 and $82,000 for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/> 97000 82000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Advertising Expenses</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Advertising costs are expensed as incurred. For the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> the Company incurred approximately $19,000 and $31,000, respectively, in advertising expense, which primarily relates to the internet marketing of Renacidin, <em style="font: inherit;">one</em> of the Company’s pharmaceutical products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/> 19000 31000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Earnings Per Share Information</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Basic earnings per share are computed by dividing net income by the weighted average number of common shares outstanding during the year. Diluted earnings per share would include the dilutive effect of outstanding stock options, if any.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">New Accounting Standards</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU-<em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> “Financial Instruments – Credit Losses”. This guidance affects organizations that hold financial assets and net investments in leases that are <em style="font: inherit;">not</em> accounted for at fair value with changes in fair value reported in net income. The guidance requires organizations to measure all expected credit losses for financial instruments at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. It is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2022. </em>The Company does <em style="font: inherit;">not</em> expect that the implementation of this standard will have a material effect on its’ financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE B </b>–<b> CASH AND CASH EQUIVALENTS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Cash and cash equivalents include currency on hand, demand deposits with banks or financial institutions, and short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. The following table summarizes the Company’s cash and cash equivalents:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="6" style="text-align: center;">Years ended December 31,</td><td> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2022</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">2021</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Demand Deposits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">333,275</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">531,213</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. Treasury Bills (original 2-month maturity)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">497,177</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">---</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">830,452</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">531,213</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="6" style="text-align: center;">Years ended December 31,</td><td> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2022</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">2021</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Demand Deposits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">333,275</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">531,213</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. Treasury Bills (original 2-month maturity)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">497,177</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">---</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">830,452</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">531,213</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 333275 531213 497177 830452 531213 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE C - MARKETABLE SECURITIES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Marketable securities include investments in fixed income and equity mutual funds with maturities greater than <em style="font: inherit;">3</em> months, which are reported at their fair values.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The disaggregated net gains and losses on the marketable securities recognized in the income statement for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="6" rowspan="1" style="text-align: center;">Years ended December 31,   </td><td> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2022</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2021</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td> </td><td> </td><td colspan="2" style="text-align: center;"> </td><td> </td><td> </td><td colspan="2" style="text-align: center;"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net losses recognized during the year on marketable securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,046,245</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(23,018</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Less: Net losses (gains) realized during the year on marketable securities sold during the period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">364,074</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(111,917</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:-4pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;"><b>Net unrealized loss recognized during the reporting year on marketable securities still held at the reporting date</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(682,171</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(134,935</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:-4pt;">)</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The fair values of the Company’s marketable securities are determined in accordance with US GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the <em style="font: inherit;">three</em>-tier value hierarchy, as prescribed by US GAAP, which prioritizes the inputs used in measuring fair value as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;">•    Level <em style="font: inherit;">1</em> - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;">•    Level <em style="font: inherit;">2</em> - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;">•    Level <em style="font: inherit;">3</em> – inputs to the valuation methodology are unobservable and significant to the fair value measurement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s marketable equity securities, which are considered available-for-sale securities, are re-measured to fair value on a recurring basis and are valued using Level <em style="font: inherit;">1</em> inputs using quoted prices (unadjusted) for identical assets in active markets. The following tables summarize the Company’s investments:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; "><em style="font: inherit;"> December 31, 2022</em></span></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:-18pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Unrealized</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">Cost</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">Fair Value</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(Loss)Gain</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; "><b>Equity Securities</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fixed income mutual funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,449,227</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,924,497</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(524,730</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Equity and other mutual funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">717,165</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">729,019</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,854</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total equity securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,166,392</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,653,516</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(512,876</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b>Total marketable securities</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,166,392</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,653,516</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(512,876</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; "><em style="font: inherit;"> December 31, 2021</em></span></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:-18pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Unrealized</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> Cost</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">Fair Value</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">Gain</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 43%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; "><b>Equity Securities</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fixed income mutual funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,814,420</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,873,333</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">58,913</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Equity and other mutual funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">651,748</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">762,130</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">110,382</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total equity securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,466,168</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,635,463</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">169,295</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b>Total marketable securities</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,466,168</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,635,463</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">169,295</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Investment income is recognized when earned and consists principally of dividend income from equity and fixed income mutual funds and interest income on United States Treasury Bills. Realized gains and losses on sales of investments are determined on a specific identification basis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Proceeds from the sale and redemption of marketable securities amounted to $2,867,671 for the year ended <em style="font: inherit;"> December 31, 2022, </em>which included realized losses of $364,074. Proceeds from the sale and redemption of marketable securities for the year ended <em style="font: inherit;"> December 31, 2021 </em>amounted to $4,152,660, which included realized gains of $111,917.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="6" rowspan="1" style="text-align: center;">Years ended December 31,   </td><td> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2022</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2021</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td> </td><td> </td><td colspan="2" style="text-align: center;"> </td><td> </td><td> </td><td colspan="2" style="text-align: center;"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net losses recognized during the year on marketable securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,046,245</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(23,018</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Less: Net losses (gains) realized during the year on marketable securities sold during the period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">364,074</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(111,917</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:-4pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;"><b>Net unrealized loss recognized during the reporting year on marketable securities still held at the reporting date</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(682,171</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(134,935</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:-4pt;">)</p> </td></tr> </tbody></table> -1046245 -23018 -364074 111917 -682171 -134935 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Unrealized</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">Cost</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">Fair Value</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(Loss)Gain</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; "><b>Equity Securities</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fixed income mutual funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,449,227</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,924,497</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(524,730</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Equity and other mutual funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">717,165</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">729,019</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,854</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total equity securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,166,392</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,653,516</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(512,876</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b>Total marketable securities</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,166,392</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,653,516</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(512,876</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Unrealized</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> Cost</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">Fair Value</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">Gain</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 43%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; "><b>Equity Securities</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fixed income mutual funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,814,420</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,873,333</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">58,913</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Equity and other mutual funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">651,748</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">762,130</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">110,382</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total equity securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,466,168</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,635,463</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">169,295</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b>Total marketable securities</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,466,168</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,635,463</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">169,295</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 5449227 4924497 -524730 717165 729019 11854 6166392 5653516 -512876 6166392 5653516 -512876 6814420 6873333 58913 651748 762130 110382 7466168 7635463 169295 7466168 7635463 169295 2867671 -364074 4152660 111917 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE D </b>–<b> INVENTORIES</b> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Inventories consist of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2022</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">601,125</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">494,348</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Work in process</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">16,520</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">119,069</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished products</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,054,367</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">797,372</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><b>Total Inventories</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,672,012</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,410,789</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Inventories are valued at the lower of cost and net realizable value. Cost is determined using the average cost method, which approximates cost determined by the <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out method. Finished product inventories at <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021 </em>are net of a reserve of $64,000 and $35,000, respectively.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2022</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">601,125</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">494,348</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Work in process</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">16,520</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">119,069</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished products</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,054,367</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">797,372</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><b>Total Inventories</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,672,012</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,410,789</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> 601125 494348 16520 119069 1054367 797372 1672012 1410789 64000 35000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE E </b>–<b> INCOME TAXES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The provision for income taxes consists of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Years ended December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Current</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">2022</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">850,344</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,287,749</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,590</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current provision for income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">851,934</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,287,845</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(193,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(68,462</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">---</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">---</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred benefit from income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(193,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(68,462</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b>Total provision for income taxes</b> <b> </b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">658,168</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,219,383</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following is a reconciliation of the Company’s effective income tax rate to the Federal statutory rate:         </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Years ended December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2022</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">2021</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">($)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Tax rate</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">($)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Tax rate</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Income taxes at statutory federal income tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">677,813</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,234,364</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">State taxes, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,256</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">---</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">76</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">---</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research &amp; development credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(10,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(0.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(10,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(0.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-taxable dividends</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(6,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(0.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(2,923</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(0.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,601</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(0.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,134</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">---</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>Provision for income taxes</b> <b> </b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">658,168</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,219,383</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The tax effects of temporary differences which comprise the deferred tax assets and liabilities are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">December 31, .</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2022</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Allowance for doubtful accounts</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,213</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,253</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Inventories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">13,440</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7,350</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,367</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">86,288</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">R&amp;D expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">92,756</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">---</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Unrealized loss on marketable securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">107,704</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">---</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">277,326</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">339,884</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">501,806</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">437,775</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax liabilities</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(304,004</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(385,056</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(42,446</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(38,918</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Depreciation on property, plant and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(44,812</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(61,471</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Unrealized gain on marketable securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">---</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(35,552</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(391,262</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(520,997</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b>Net deferred tax asset (liability)</b> <b> </b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">110,544</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(83,222</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Years ended December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Current</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">2022</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">850,344</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,287,749</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,590</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current provision for income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">851,934</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,287,845</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(193,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(68,462</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">---</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">---</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred benefit from income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(193,766</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(68,462</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b>Total provision for income taxes</b> <b> </b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">658,168</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,219,383</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> 850344 1287749 1590 96 851934 1287845 -193766 -68462 -193766 -68462 658168 1219383 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Years ended December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2022</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">2021</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">($)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Tax rate</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">($)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Tax rate</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Income taxes at statutory federal income tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">677,813</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,234,364</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">State taxes, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,256</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">---</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">76</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">---</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research &amp; development credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(10,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(0.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(10,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(0.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-taxable dividends</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(6,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(0.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(2,923</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(0.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,601</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(0.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,134</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">---</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>Provision for income taxes</b> <b> </b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">658,168</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,219,383</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> </tbody></table> 677813 0.210 1234364 0.210 1256 76 10000 0.003 10000 0.002 6300 0.002 2923 0.001 -4601 -0.001 -2134 658168 0.204 1219383 0.207 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">December 31, .</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2022</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Allowance for doubtful accounts</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,213</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,253</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Inventories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">13,440</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7,350</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,367</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">86,288</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">R&amp;D expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">92,756</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">---</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Unrealized loss on marketable securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">107,704</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">---</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">277,326</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">339,884</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">501,806</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">437,775</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax liabilities</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(304,004</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(385,056</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(42,446</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(38,918</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Depreciation on property, plant and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(44,812</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(61,471</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Unrealized gain on marketable securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">---</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(35,552</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(391,262</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(520,997</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b>Net deferred tax asset (liability)</b> <b> </b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">110,544</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(83,222</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> </tbody></table> 4213 4253 13440 7350 6367 86288 92756 107704 277326 339884 501806 437775 304004 385056 42446 38918 44812 61471 35552 391262 520997 110544 83222 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE F - BENEFIT PLANS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><span style="text-decoration: underline; ">Defined Contribution Plan</span></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company sponsors a <em style="font: inherit;">401</em>(k) defined contribution plan ("DC Plan") that provides for a dollar-for-dollar employer matching contribution of the <em style="font: inherit;">first</em> 4% of each employee's pay. Employees become fully vested in employer matching contributions immediately. Company <em style="font: inherit;">401</em>(k) matching contributions were approximately $81,000 and $80,000 for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company also makes discretionary contributions to each employee's account based on a "pay-to-pay" safe-harbor formula that qualifies the <em style="font: inherit;">401</em>(k) Plan under current IRS regulations. For the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively, the Company’s Board of Directors authorized discretionary contributions in the amount of $109,000 to be allocated among all eligible employees. Employees become vested in the discretionary contributions as follows: 20% after <span style="-sec-ix-hidden:c95656445">two</span> years of employment, and 20% for each year of employment thereafter until the employee becomes fully vested after <span style="-sec-ix-hidden:c95656447">six</span> years of employment. The discretionary contribution for <em style="font: inherit;">2022</em> will be paid in <em style="font: inherit;"> February 2023. </em>The amount paid in <em style="font: inherit;"> February 2023 </em>has been reduced by an amount paid to Ken Globus upon his retirement from the Company during <em style="font: inherit;">2022.</em> The remaining contribution payable is included in accrued expenses at <em style="font: inherit;"> December 31, 2022.</em></p> 0.04 81000 80000 109000 0.20 0.20 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE G - GEOGRAPHIC and OTHER INFORMATION </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Through its Guardian Laboratories division, the Company conducts research, product development, manufacturing, and marketing of cosmetic ingredients, personal and health care products, pharmaceuticals, non-pharmaceutical medical products, and proprietary specialty industrial products. All the products that the Company markets, exception for Renacidin, are produced at its facility in Hauppauge, New York. Renacidin, a urological product, is manufactured for the Company by an outside contract manufacturer. The Company’s R&amp;D department <em style="font: inherit;">not</em> only develops new products but also modifies and refines existing products, with the goal of expanding the potential markets for the Company’s products. Many of the cosmetic ingredients manufactured by the Company, particularly its Lubrajel line of water-based moisturizing and lubricating gels, are currently used by many of the major multinational personal care products companies.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company operates in one business segment. The Company’s products are separated into <em style="font: inherit;">four</em> distinct product categories: cosmetic ingredients, pharmaceuticals, medical lubricants, and industrial products. Each product category is marketed differently. The cosmetic ingredients are marketed through a global network of distributors. These distributors purchase product outright from the Company and provide the marketing functions for these products on behalf of the Company. They in turn receive their compensation for those efforts by re-selling those products at a markup to their customers. This enables the Company to aggressively have its products marketed without the high cost of maintaining its own in-house marketing staff. The Company has written marketing arrangements with only <em style="font: inherit;">one</em> of its global distributors, ASI, and that contract renews every <em style="font: inherit;">two</em> years unless cancelled for any reason by either party at least <em style="font: inherit;">60</em> days prior to the expiration of the <em style="font: inherit;">two</em>-year marketing period in effect at that time. The current marketing period with ASI ends on <em style="font: inherit;"> December 31, 2023. </em>The Company’s other distributors are <em style="font: inherit;">not</em> under any contractual obligation to market the Company’s cosmetic ingredients, and the Company has the ability to cancel those marketing arrangements at any time upon reasonable notice. All sales of the Company’s cosmetic ingredients are final other than product later determined to be defective, and the Company does <em style="font: inherit;">not</em> make any sales on consignment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><em style="font: inherit;">No</em> prior regulatory approval is needed by the Company to sell any products other than its pharmaceutical products. The end users of its products <em style="font: inherit;"> may </em>or <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> need regulatory approvals, depending on the intended claims and uses of those products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The pharmaceutical products include a urological product and a topical bioticide that are sold to end users primarily through distribution agreements with the major drug wholesalers. For these products, the Company does the marketing, and the drug wholesalers supply the product to the end users, such as hospitals and pharmacies. The Company’s marketing effort for Renacidin, its most important drug product, centers around a separate Renacidin website. There is currently <em style="font: inherit;">no</em> active marketing effort for Clorpactin. Both of these products were originally developed in the <em style="font: inherit;">1950s.</em> Clorpactin pre-dated the need for a formal New Drug Application (“NDA”), and the current sterile liquid form of Renacidin is marketed under an NDA that was approved by the FDA in <em style="font: inherit;">1990.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">The medical lubricants are <em style="font: inherit;">not</em> pharmaceutical products. They consist primarily of water-based lubricating gels, which are marketed by the Company directly to manufacturers that incorporate them into urologic catheters and other medical devices and products that they sell. These products are distinguished from the pharmaceutical products in that, unlike the pharmaceutical products, the Company is <em style="font: inherit;">not</em> required to obtain regulatory approval prior to marketing them. Approvals are the responsibility of the companies that market the products in which the Company’s products are used, which are typically classified as medical devices. However, the Company is responsible for manufacturing these products in accordance with current Good Manufacturing Practices for medical devices, and its manufacturing facility is subject to regular FDA oversight.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The industrial products are also marketed by the Company directly to manufacturers, and generally do <em style="font: inherit;">not</em> require that the Company obtain regulatory approval. However, the manufacturers of the finished products <em style="font: inherit;"> may </em>have to obtain such regulatory approvals before marketing these products. The Company plans on discontinuing the sales of its industrial products in the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2023.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following tables present the significant concentrations of the Company’s sales. Although a significant percentage of Customer A’s purchases from the Company are sold to foreign customers, in table “b” below all sales to Customer A are included in “The United States” sales revenue because all shipments to Customer A are delivered to Customer A's warehouses in the U.S.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition, there are four customers for the Company’s medical <b>lubricants</b> that take delivery of their shipments in the U.S. but potentially ship some of that product to manufacturing facilities outside the U.S. Since the Company makes those shipments to U.S. locations, sales to those customers are also included in the “The United States” revenue number in the table below.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(a)</p> </td><td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 97%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-decoration: underline; ">Net Sales</span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="5" rowspan="1" style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">Years ended December 31,</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2022</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2021 </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cosmetic Ingredients</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,388,365</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,872,714</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Pharmaceuticals</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,929,216</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,748,244</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Medical Lubricants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,471,555</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,175,822</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Industrial and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">116,826</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">150,387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gross Sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">13,905,962</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">14,947,167</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Discounts and allowances</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,207,459</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,017,538</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>Net Sales</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,698,503</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,929,629</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>(b)</b></p> </td><td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 97%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-decoration: underline; ">Geographic Information </span></b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Years ended December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2022</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9,537,124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11,159,341</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other countries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,161,379</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,770,288</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net Sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,698,503</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,929,629</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>(c)</b></p> </td><td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 97%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-decoration: underline; ">Gross Sales to Major Customers</span></b></p> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" rowspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">Years ended December 31,</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2022</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer A</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,284,799</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,641,279</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer B</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,527,743</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,526,869</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer C</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,613,597</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,522,882</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer D</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,553,885</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,488,301</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">All other customers</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,925,938</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,767,836</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total Gross Sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,905,962</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,947,167</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 1 4 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="5" rowspan="1" style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">Years ended December 31,</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2022</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2021 </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cosmetic Ingredients</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,388,365</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,872,714</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Pharmaceuticals</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,929,216</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,748,244</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Medical Lubricants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,471,555</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,175,822</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Industrial and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">116,826</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">150,387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Gross Sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">13,905,962</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">14,947,167</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Discounts and allowances</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,207,459</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,017,538</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>Net Sales</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,698,503</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,929,629</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> 5388365 6872714 5929216 5748244 2471555 2175822 116826 150387 13905962 14947167 1207459 1017538 12698503 13929629 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Years ended December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2022</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9,537,124</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11,159,341</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other countries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,161,379</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,770,288</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net Sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,698,503</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,929,629</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> 9537124 11159341 3161379 2770288 12698503 13929629 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" rowspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">Years ended December 31,</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2022</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer A</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,284,799</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,641,279</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer B</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,527,743</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,526,869</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer C</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,613,597</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,522,882</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Customer D</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,553,885</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,488,301</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">All other customers</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,925,938</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,767,836</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total Gross Sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,905,962</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,947,167</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> 4284799 5641279 2527743 2526869 1613597 1522882 1553885 1488301 3925938 3767836 13905962 14947167 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE H - ACCRUED EXPENSES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Accrued expenses at <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> consist of:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2022</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Bonuses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">175,496</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">348,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Distribution fees</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">395,536</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">359,550</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Payroll and related expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">53,475</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">292,560</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Company 401(k) contribution</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">94,326</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">109,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Annual report expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">68,349</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">64,038</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Audit fee</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">66,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">61,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Reserve for outdated material returns</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">369,154</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">313,904</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Sales rebates</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">80,926</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">56,857</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18,294</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">21,981</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,322,056</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,627,390</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><a href="#" id="Notes_end" title="Notes end"/></p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 20%; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2022</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Bonuses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">175,496</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">348,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Distribution fees</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">395,536</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">359,550</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Payroll and related expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">53,475</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">292,560</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Company 401(k) contribution</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">94,326</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">109,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Annual report expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">68,349</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">64,038</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Audit fee</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">66,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">61,500</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Reserve for outdated material returns</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">369,154</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">313,904</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Sales rebates</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">80,926</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">56,857</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18,294</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">21,981</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,322,056</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,627,390</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> 175496 348000 395536 359550 53475 292560 94326 109000 68349 64038 66500 61500 369154 313904 80926 56857 18294 21981 1322056 1627390 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOTE I - SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION AND </b><b>NON-CASH INVESTING AND FINANCING ACTIVITIES</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> December 31, 2022, </em>the Company had a number of unconverted Guardian Chemical shares that would convert to approximately 447 shares of United-Guardian, Inc. common stock if all of the remaining holders of those Guardian shares converted their Guardian stock to United-Guardian stock. The Company’s transfer agent continues to try to locate the holders of those shares in anticipation of escheating them to the appropriate state jurisdictions. The Company is currently accruing dividends on the 447 shares that have <em style="font: inherit;">not</em> yet been exchanged or designated for escheatment as of <em style="font: inherit;"> December 31, 2022, </em>and the Company will continue to do so as dividends are declared.</p> 447 447 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE J - RELATED PARTY TRANSACTIONS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">During the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> the Company paid PKF O’Connor Davies $14,500 and $19,500, respectively, for accounting and tax services. Lawrence Maietta, a partner at PKF O’Connor Davies, is a director of the Company.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the year ended <em style="font: inherit;"> December 31, 2022, </em>the Company paid Ken Globus, the Company’s previous President and CEO, $20,000 for consulting services subsequent to his departure from the Company. The Company’s consulting agreement with Ken Globus expires on <em style="font: inherit;"> May 31, 2023. </em>Ken Globus is a director of the Company and currently serves as Chairman of the Board of Directors. In addition, in <em style="font: inherit;"> November 2022, </em>Ken Globus purchased a used vehicle from the Company for $37,039.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> 14500 19500 20000 37039 Although a significant percentage of ASI’s purchases from the Company are sold to foreign customers, all sales to ASI are considered U.S. sales for financial reporting purposes, since all shipments to ASI are shipped to ASI’s warehouses in the U.S. A certain percentage of those products are subsequently shipped by ASI to its foreign customers. Based on sales information provided to the Company by ASI, 66% of ASI’s sales in 2022 were to customers in foreign countries, compared with 74% in 2021. ASI’s largest foreign market in both 2022 and 2021 was China, which accounted for approximately 38% of ASI’s sales in 2022 and 42% of sales in 2021. EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

@&ULQ9QO;^(Z%L:_ MBL5>K>9*[4 2_LZVE2BQ,ZS:W@JF=U^L]H6;N."=$+.)H>W5_?#7#BDAP;C- MS)&V+UH(Q[\X/<=/["7Z2[N=A4NVHMEGL6:) M^N1)I"LJU=MTT<[6*:-1WF@5M]U.I]]>49ZTKB[R;??IU878R)@G[#Y%V6:U MHNGK-8O%\V7+:;UMF/'%4NH-[:N+-5VP.9,/Z_M4O6OO*1%?L23C(D$I>[IL MC9TO@3?2#?*(WSE[S@Y>(WTHCT)\UV^FT66KHWO$8A9*C:#JSY9-6!QKDNK' M_PIH:[]/W?#P]1N=Y >O#N:19FPBXG_Q2"XO6\,6BM@3W<1R)IZ_LN* >IH7 MBCC+?Z/G(K;30N$FDV)5-%8]6/%D]Y>^%/^(@P9N[T0#MVC@UAMT3S3PB@;> M1_?0+1IT/[J'7M&@5V_@GFC0+QKT/]I@4#08Y,G:_7?SU/A4TJN+5#RC5$2\CA#W]B+W-#XUXNV5#W4 M^VF'16_(KC?NB=XX+KH5B5QF""<1BZJ MCJT_?&Y;\=W[5J)=V+[&3F],^1V M7!?]@MHH6]*498:^3>RD6_J*G,Y'0/Y'NM3/28Z=A#_0I>%'0,0.\EGX&7E. M<7 /,J231VQ>IEW.[)[A%M65HQD+&M_0Q9F=H'"L9I4G( MD!)D-$E9Q"6Z$5EVIHM'5^8UC?7GAN.XMNY/R_^7;$U#=ME2^IZQ=,M:5W__ MF]/O_,-4-Y P'Q*&(6%D!^OE,'V&VU[I\YUWT=X>5H@IRNVY^ZA* 73W!="U M%L!$B4*JSEI*'.4237)99.D9NN'TD<=_9,TVQYAAX2GF3J=!2A\4J/?%-6K9RF M686$^9 P# DCO>.<=7J=3CVU0/NL%$!_7P#]=X;Z:J6FJ',IPN]GR.=;'K$D M4J)^SU(TU^J0=@4U!U6@XCUW](PT0$0K)+!P3Z# VL&#W+V34@: MFQ)@)30=O) P'Q*&(6%D<#1X/L[(Z0T[9F4>[M,ZM*;UGKZJ M):B:A*FEP&^IFF#I9<%!K@\'KBGE5GK3E$/"?$@8AH21H2GE7G?DUE)^'*=2 MWNEXGCGEHWW*1Q\;R4IL7_6LVY17*Z)I7B%A/B0,0\+(Z"A?_6[MI!$Q9)(OS&[[5TZPL8VK+5Q9'YVHY=?Z0,8MZ MV_?1-.>@-!^4AD%II* =+H[J4R]K2#7G!Q:/8\WYW6;UJ.9&2K=_5X-9I,8I MD9W1.*>0-!^4AD%II*!5QG(]I[:0:D[=,J>N-:)326 MVHC5ONTTD4P=4>[4IAL6V=0F,JJ MTO) B*CPZ%5/>:@2/Q>Q-=&@1A@HS0>E85 :<8ZMKMYHU/<&1T)O"!QT!Z,# M:Z&:]-(5<^RVV#C:LE3R3 L[?EFS)#,+.Z@I!DKS06D8E$8*VJ%JZ_73T7 ^ M#O.8 M=DCO: )*\T%I&)1&0&D!%*U:1*7KYMAMMW*6_W9]Q#S/![7>0&D^* V#THAS M;*MUZ_)@"ZEFM33='+OK5DS?WD3_'1T ]=A :3XH#8/2""@M@*)5*Z;T[!R[ M:5>]+GY+U3J TQC-F-RDB5D20"T\4)H/2L.@-%+0*M.!_LCI'>F"(<[Q1IT3 MXN"69IYK-_/F2[Y>ZUF"GC-\5;]B_<:F$'9@TU2#TGQ0&@:E$5!: $6KEDWI M![IV/_#'5Y!V<./R 34)06D8E$8*VJ$"C ;'ZPM#V- ]N;YP2[/0M9N%,[9E MR89IWRAJJ:XHIZM0]H6YID+IV@Q1 4V8LH2&/>&(7%5 G%93F@](P*(V T@(H M6K7:2B?5M3NI/R JH*8J*,T'I6%0&BEH5;GPZE\I,$:YHQ.B4EJKKMU:M8I* MP,0BI>LE#]_1%548F4AHC"8T98W:J%$9OQ?-I0 M8NS=:OQ--U##%Y2&06D$E!9 T:K%5QJ^WGN&;U.)L0,;EPVHT0M*PZ T4M!J MZY_Z?4+&J,&)59)7VKS>3]B\/ZHQDZ_3N[&Q1$ ]75":#TK#H#0"2@N@:-62 M._AB-K2G:PQ<:% ^KW@M(P*(V T@(H6K402[_7@_9[[<#&90/J]X+2,"B->"8G M=U"_AF2.ZIW0F]+O]>Q^K^&!'_\/Q0$U@T%I/B@-@]((*"V HE5+L32#/6@S MV YL7#:@9C H#8/2B&>R>8?Z_OKRQZGKC['-"?DIG6'/[@R?O$'J;'^QZ6"C M>58TWZS7,7]7H^;\! MM&]L!S8N&U#?&)2&06G$,SG"]2O?YB!O5/FI"5/[X+E]:CJSR!_)F*%\[K-[ MQ-U^Z_ZQC^/\88>U[<3Y$NP>WEAB=L^25%.>!4\R%+,GA=1SLQ9*=X]GW+V1 M8IT_'?!12#6GRE\N&8U8J@/4YT]"R+@?[AV1>_0502P,$% @ -$UW M5OP.U0), P /@L !D !X;"]W;W)K&ULK59= MCYLX%/TK%EM54ZD=P"009I-(^=AJ1^JTT43=/E3[X, -6 -V:IND^^]K&X8F M&8)V1O.2V.:>PSD^PK[C Q;*G0"26E!9N-CS0KF85ZJ@#%8"R:HLB?AO#@4_3!S? M>5RXIUFNS((['>](!FM07W400%),I0$/VWAP44A6'2.GXTI$[[3@,\'C^R?[3FM9D- MD;#@Q3>:JGSBC!R4PI94A;KGA[^A,30T? DOI/U%AZ;625UD92(L!2MZWC-^IIFC&YI0IA" MLR3A%5.496C%"YI0D)IC227),@$949"B>]@#JP!=+4$16LAWNN+K>HFNWKP; MNTIK-PK-'YW/,W?VQ MYH["(,9QB..V\$3=H%4WZ%6WX+($11-TRW2^*06F)/I^!^4&Q+]=BGOIS-ET M(W MUH6C"$?^H#N5L-46]FI;Y42?9 E4.AE2] ?2R_3<0%Z)[,1TU)J.7AY(]&2C M!_$@"+WA62 ==5$P#/"%0$:MME&OMCO]:>@DT*=J(^Q!V9])+]ES,WDELA/? M<>L[?GDF\9.]QH/(\\/SLZNCSH]\[%W(Q/=^7W%>K[I;ENJ+5% =S$Q?:5]4 M#J(WEWZ^YP;S6FRG[H\N>/_EV338DPO##TY;G!!F +]?,MUS]-,S O:EGGZ"U!+ P04 " T37=6 M!*EZ$T$$ "."P &0 'AL+W=O=OH M[??M?KN6=D=;J1YUBFC@*<^$'GNI,<6Y[^LXQ9SIEBQ0T,Y*JIP9 M>E5K7Q<*6>) >>:'[7;/SQD7WF3DUF[59"1+DW&!MPITF>=,/5]@)K=C+_!> M%N[X.C5VP9^,"K;&!9J'XE;1F]^P)#Q'H;D4H' U]J;!^7QH[9W!GQRW>N<9 MK)*EE(_VY2H9>VT;$&88&\O Z&^#,\PR2T1A?*\YO<:E!>X^O[!_==I)RY)I MG,GL+YZ8=.P-/$APQZKSL ,(HC< 80T(#P&]-P!1#8@. 9TW )T:T'&9J:2X/,R989.1DEM0UIK8 M[(-+ID.3?"YLV1=&T2XGG)G<2(,PA<]PPTRI$.0*+DI-1EH#$PDLJL_!KB_X M6O 5CYDP,(UC60K#Q1IN9<9CCIHX[G"#HD18/L/O*->*%2F/:75M*_QQCH;Q M3'\BPX?%'#[^]FGD&Y)@ _'C.MQ9%6[X1KA!"-=2F%3#I4@PV2?P27N3@/ E M ;/P).,%>&T7]OOM<# X7H>!=[ P;((= M_NA[F68FE>4Z!09ZYY8M4,4H#+5?>_].%U2?)]1L"+&BC+E!4T#9H_6+A:8U$M-\%O: M([DV>BY<[,[I%&)4U"+$@6Y*C48HE$S*F/@=<;G4^+TDF^RY\4)=QSHF9]SH MU]);<$$)2X!:426/BVIJLLV)V#>4 !?J;C(KSC/H]=X?EN"%Q#4.V%+R++AQ M9W>:&&RO5-QF++;$-L];;E+H=][7#$%KCSQC:HW:- S4@Q_IFR;;I22<"UK%S MZ>],'J1Z[28X70FNVDJSV@R)%VXV.EB?T? 8'%F?#LYG@V/KP_.9&S;]?]U6 MD^HUI8X+2B&N*(1VJT\G6%737_5B9.'F(&ULO59M:]LP$/XKAP=C@ZQVG*1O2P))7UBA*:&E&V/L M@V*?$U%9;,[*@")7W)E,Z9I:E>AJ;0R-+**1=A'$6[8%R[Y%FR)5VBOB[FF6=BBI#Q':;B2 MH#$;!9/NX;0;.8?*XCO'M=D:@TMEH=2-FYREHR!RC%!@8AT$H]<='J$0#HEX MW#:@01O3.6Z/']%/J^0IF04S>*3$#Y[:U2C8#R#%C)7"7JKU-VP2&CB\1 E3 M/6'=V$8!)*6Q*F^,05[SK0!7+8V;9>*C5&K2S M)C0WJ%*MO(D<83)BU,DD25TG*YA+D2/.%H"&.NZ6_1]J$#/"?!Z&EO)P;,*DX3RM.MP-Q%,<>O%ZK:J_"ZS^#=TH_FR+5-KE/2(E3?N\T-O!K MAOD"]>^G4O<"NSUZ: J6X"B@36A0WV$P_OBANQM]]=#NM[3[7MJ;^A6;^N%C M#ATHZP**NH _D>DGJ^Y5WAOK#<*O]MF MLOL>PON##%X4?J^EN^=%FI9%/2@Y7OP M.D'/\D*K.W0L_<>$%^^-ZG:C3=.(7L>7;_%]\B#WXYQ3FT'MFDM;D8QZD*9S M^'EMPZUNEZ->5CW=0-60ZL;7KK;WADG=+3?F]:5CQO222P,",W*-=O;H$-!U M'Z\G5A55[UPH2YVX&J[H[H/:&=#W3%'_;"8N0'N;&O\%4$L#!!0 ( #1- M=U9\1H3G>@( * ' 9 >&PO=V]R:W-H965TNJB70W()*[@:>E[@E9963CNV[2YF.1:,YJ^!2$M64)97WY\#%9N+XSL.+ M*[8JM'GAIN.:KF .^KJ^E+AR>Y:"D@[ "A-=HJL[9F5--T+,6&2).-;":PM;%H=,,JT\6YEKC+ M$*?3'T(#.2X!D],\A.2.B_)X$7!'O@TY?#_5VXBY7IRQ/T MY0DL7_0,7^\V,P'\=[O/64L56RKS]:S3T]"+8K2QWG;P-"T._< /^[0=I6&O M-!Q4.L.O&W7.H!:*83?^7$"Y /EWG]!!)C,WSE1-,Y@X.!@4R#4XZ;LW?N)] MVM>0 Y'MF(YZT]'AVM-2)5MU#\,P&,6/VA.]JCUQKS0>5'H])S]QRJI&WI,Y M9(UDFL%PEP8)7]NE Y'M>$]Z[\GANI0\*7_T<>2/1H^Z-'CB:_VX6_/3W%T7 M5*Y8I0B')=)[)R.4(]O[H%UH4=N1NA :![0-"[Q"09H$W%\*'*O=PDSI_E). M_P%02P,$% @ -$UW5E53_>YP @ H 4 !D !X;"]W;W)K&ULC51=3^,P$/PKJ^@>0 +2I&D*J(U$6^Y#.DX5A;MG-]DT M%DY<;(?"_?I;.R&4TJ)[2>SUSNS,)M[11JH'72 :>"Y%I<=>8[)>,5UXR@Z[)D MZF6"0F[&7N"]!F[YJC VX">C-5OA LW]>JYHYWU?!Y32R M^2[A-\>-WEJ#=;*4\L%N?F1CKV<%H<#46 9&KR>5]("M]>O M[%^==_*R9!JG4OSAF2G&WKD'&>:L%N96;KYCZV=@^5(IM'O"ILD=7'B0UMK( ML@63@I)7S9L]MWW8 @3Q 4#8 L)=0'0 T&\!?6>T4>9LS9AAR4C)#2B;36QV MX7KCT.2&5_8K+HRB4TXXD_R2!F$*IW##U ,:MA0("TQKQ0U'#4+V9P].5XY!NJ;UG\M*TU:6J%!VH%(=S(RA0:KJL,L_<$/@GOU(>O MZB?AIXPS3,^@'YQ V O#/8*F_P\//I'3[YK9=WS1 ;ZYDBEBIB%7LH0%HUZR M*J/6&MO/%Y#Y_C;O:V53:> JV:OXE(3G\3 >DLZG;8&PO=V]R:W-H M965T MW62;6#AVSG8IW*^_M1-"*2GF<],T[6XXW2]Z8$L.2Q$M),@M+:^BP, M359"QU EPCB*AF'%N RF8Q^[T=.Q6EO!)=QH M8M95Q?33#(3:3 (:/ =N>5%:%PBGXYH5L ![5]]HG(5=E9Q7( U7DFA838)S M>C8?N'R?\)/#QFR-B5.R5.K>37[DDR!RA$! 9ET%AJ\'F(,0KA#2^-W6#+HM M'7![_%S]J]>.6I;,P%R)7SRWY20X"4@.*[86]E9MOD.KQQ/,E##^239M;A20 M;&VLJEHP,JBX;-[LL?5A"T"'>P!Q"XAW >D>0-("$B^T8>9E73#+IF.M-D2[ M;*SF!MX;CT8U7+I37%B-JQQQ=GJM+) Y.2)73-^#94L!9 '96G/+P6#\&K^D M;_@U&,)D3BZ5,1A&__OS#RXPQH4Y1.3=XH(SC1 MF%PI:4M#OL@<\M<%0A38J8R?5<[B=RM>0'9,$OJ9Q%$<]Q":_SNI?24COHE#SK)@P_/<"T[?4[WGL/4 M4"MMW>P#Y98+04I _&ULM9== MCZ,V%(;_BD6K:E?:'; ! ],DTFZFH\[%M*.-MKVH>D'(26(-X*QMDMG^^MK M$@($)=OI7$SX>,_KY_CKF,F!BV>Y!5#H)4MS.;6V2NUN;5LF6\AB><-WD.LW M:RZR6.E;L;'E3D"\*H.RU":.0^TL9KDUFY3/GL1LP@N5LAR>!))%EL7BZT=( M^6%J8>O;@T]LLU7F@3V;[.(-+$!]WCT)?6(/!@?9ND8FE27GS^;F836U'$,$*23*6,3Z9P]S2%/CI#F^U*96TZ8);%]_ M<[\OD]?)+&,)I^L0/OT*=4 F8\%26_]&AT@;40DDA M%<_J8$V0L;SZC5_JCF@%8.], *D#R*4!;AW@EHE69&5:=[&*9Q/!#T@8M78S M%V7?E-$Z&Y:;85PHH=\R':=FOW$%:([>H\=8/(.*ERF@!22%8(J!U,\7U?@B MOD8/^1ZDTF.H)'ISI\4LE6^UY//B#KWY\>W$5AK(V-I)W?C'JG%RIO$[2&Z0 MB]\AXA R$#Z_/!R?AMNZ&YJ^($U?D-+/.^/WRY>"J:](-NF_0PF7:BBORL@O MC!1+0T;W0FIVY"ZUY$.,586M-6V3WW7Q[3#V-<% MU/4]Z@XS>@VC=VUO%KG>:5+V#ZS01N\P0]!>#^:]CTD8=*'[.DPC$OG#S'[# M[(\RMQ;!);/ [T$,SX*^;G06T(:67D\[Q$DOG E]W>A,"!K.X'MZ]8+9$%PX M&_JZL=D0-MSA*/<]>]%L#WG"LY--\:]'R)8@_AXB'G4T-?E6[N($II8NNA+$ M'JS93S]@ZOP\M/V]DME)\E&3?/1:FV'4GUZ>%Q$2=$:IKZ,A]CSB# \3=HXU MS/GOVV'MT6Y>0VK0+N: D(:!J__.<+9J+?X?ML3:]'05$"]PG2YX7^B'$3Z' M?2R+^**Z^"%?H=_5%@1Z+%01I^B^R%?CJV'<^-KE\%INI]UPK+GXRJ)[?D7@ M@9J* TS][HCU==3'@7>F,.!C[<57%M]!RGX1#4CDX*A+.:"C!+OGUNVQVN+Q M&PO=V]R:W-H965T,D75+%/D>^4PQ;;5YMB4 DI,4RBZC$K&ZH]06)4AF)[H"Y2(';21#YYHCM94! MM@\@*6@2QS=4,JZB+ UW:Y.END;!%:P-L;64S+S<@]#M,II&YXL-/Y;H+VB6 M5NP(6\#':FV<1P>6/9>@+->*&#@LH^_3NU7B\T/"$X?6CFSBE>RT?O;.PWX9 MQ;XA$%"@9V#N:& %0G@BU\:_GC,:2GK@V#ZS_PC:G98=L[#2XB_?8[F,;B.R MAP.K!6YT^Q-Z/0O/5VAAPY>T7>[\6T2*VJ*6/=AU(+GJ3G;J_\,(,)U? "0] M(/DH8-8#9D%HUUF0E3-D66IT2XS/=FS>"/\FH)T:KOP4MVA@:\^#I_^#Z=.ZR X&00G@6]^@>^L\X4\,5&S\)8V8,$T8-\3 MU[$M IM?B2:[F<=QG-)FK.%MUFPQSNI:I:,Y^1WYQ8(& 0:EM!&)>>U@ 8S:0P?C;Q_2&E%8X7K]'OW.UFUI>B(*%8,^TTMNY M=^VA"M9DQ_2C:'] 7X\#+ 53[HG:SC=-/53NE!9U+S8$->7=F[SU?1@)POB$ M /<"_%E!U LB5VA'YLI:$DV*7(H62>MMHMF%ZXU3FVHHMU]QI:4YI4:GBU]" M UJB;^B>[X%K(2DH8ZVZCXK$^L/!Q1(TH4Q=&I>GU1)=?+G,?6TP;#"_[%/> M=BGQB91+**]0%'Y%.,!X0K[XO#S\*/=-\4,'\- ![.+%)^(]DM8T5(.DA*FI M:CIYXN1V*/9%&H0A3G)_/Z8^=HMG<11?#VX?Z**!+CI+]VR& %&.&BE*4)-\ M78!TE#A,$QP?!;OCG)J?K[*\E6[4D\"QL>I@R2.TNP M\=@OFV51AJ<1DP$Q.8OX6VC"QG_Q%&)R]/'"-,-!B \0)_SB,,BN#]OHCR;2 MWH8_B=Q0KA"#M5$&5YD)(;L;IC.T:-R0O@AM1MXMM^92!FD=S/E:F$'M#3OW MPS5?_ =02P,$% @ -$UW5J_S*"ZY @ @ !D !X;"]W;W)K&ULG97;/I13+3QOAL,L!,@&2:BW28D+37 MPEY $UNBDH#T[;N2'9>#H;0WM@[[[WZ[EK6]K9!O:@F@R7M9<-5WEEJO;EU7 M94LHJ;H1*^"X,Q>RI!JG\['0,$!63:>*#XVL (BL(X0HR?M4^G M"6F$N^,/[P\V=\QE1A6,1/&#Y7K9=U*'Y#"GZT(_B^U7J/.)C+],%,H^R;:R M33!BME9:E+48YR7CU9N^UW78$7CQ"8%?"_Q#07A"$-2"P"9:D=FTQE3304^* M+9'&&KV9@:V-56,VC)NO.-42=QGJ].";T$#NR1?RR#-1 GFA[Z!P.I%BP^RG MPI.ROWDU!DU9H:[1['4Z)E>?KGNN1A;CT3)\'U4I%[GD.^ M[\#%))I,_(],AOY9CV/(;DC@?29^Q_=;@$:7R[TS.$%3V,#Z"T_X>X <)"W: M*E,)(RLT?]EFD$:=( Q[[F:7]]C,\],D";N-W1Y8V("%9\&FFFIHPZID\6Z\ MJ-LY@#HVZL;M/%'#$YWE>1&:%GC4I02NR6KOW+'JW&ES[MJ0HR.:-/*ZP6$E MC\U,)=,P:B>/&_+X?S]Q?!3Q"W(E<7Q UF(7IV'LMX,E#5AR04GQ,@,L:DYF MP&'.-)E+4?ZUI,F%Y"UV9\C3ACR]@/S?#D%Z])_$4>K%Z0'PL9GG8V9I<$#L M[ERF)N,3E0O&%2E@CBX[ M-PE2R:K?5!,M5O;*G@F-#< .E]BB01H#W)\+O+;KB0G0-/W!;U!+ P04 M" T37=6MKD&-)X# !:# &0 'AL+W=O?A7T-FMJ2*PE(_[Z2 M[#@&C.G.+@\@R?<>G7,D2Y?I7LCO:@.@T5.17/.\C% M?N9A[WE@R=8;;0?\^;2D:W@$_:U\D*;G-R@I*X K)CB2D,V\]_AV@4.;X"+^ M9K!7K3:R4E9"?+>=S^G,"RPCR"'1%H*:GQTL(,\MDN'QHP;UFCEM8KO]C/[1 MB3=B5E3!0N3_L%1O9E[LH10RNLWU4NP_02UH9/$2D2OWC?9U;."A9*NT*.ID MPZ!@O/JE3[41K0020CK!.><7S%SLNZIIO.I%'LD;;1!LPWG MC?Q4:T =T@S[S1!2 _J)/H$QW"8G@"]"4Y>JMR?WV>(^N_G@[];4A:*?QDYK,746&G"&#"?HB MN-XH](&GD!X"^$99(X\\R[LCO8CWD Q0B*\1"0CI(+3X_73<0R=LW X=WO , M7NV:=B93C92F>JN%_(DR2$'2'+$F DGC:Y>'U10C-X5]2W?S:#R.<3CU=VUE MIV&8A,,P&C9Q!Q*&C83A_RO![AV"7U^C$F0"7'=)JJ:,6UR#@37\0-"%H ,U MHT;-J%?-H[8,G9AKQ,VI:<@^ZU@!AXQU\AUU>#N*COB>!HVC;K91PS;J9;L$ M!50F&_2&%N4[_T?* MO1NC'_PJ&(3!ZZZ#9G$QD9PD'NB+&WUQ+])7P6_,]J&K'%#*=BP%GG:N0GQJ M;Q2>+$)'%)F0L'L-)@W'R;_GV&M[/UZG>Q7_BXFXWW8M2Q;])KM?F"RB==M7$>S-M[7>K2IK S#/% MG0*Y V_^YA6.@G=]YI,7?:27V8,4.^8J.5-(M@Y\Z-SZ-=C!C36*<10?K\9I M'"9X$L9G]C]^N79Q_[U[GF__^E2HD\,K)Q@>\^X.&Q^Q]EM56@%R[8I7A1*Q MY;JJ:)K1ID!^[\K"H_$[6SB[ZN\%IJJZOU"Y9ERA'#(#&0S&QDM9%;)51XO2 MU8(KH4UEZ9H;4_R#M 'F>29,/5AW[ 3-WXGY+U!+ P04 " T37=6XTX; MA! $ "(#P &0 'AL+W=OK4-I#&&Q9@*X*DV3[3\CDF0HDJ2=O)?OTH69%?1*MND0%! M+$IWQ^.%-QG5[V[59"171O ";A72JSQGZN4S"+D9>\1[?7'' M'Y>F>N%/1B5[A'LP#^6MLB._C3+G.12:RP(I6(R]*W)Y39+*H;;XF\-&[SVC MBLI,RJ=J<#,?>[A"! (R4X5@]F<-UR!$%O_:-/88@]E*VUDWCA;!#DO MMK_LN4G$G@,)3SC0QH&>ZQ T#D%-=(NLIC5EADU&2FZ0JJQMM.JASDWM;=GP MHEK&>Z/L5V[]S.2+-(!^0P-T4V0R!_25/8.VPRDL0"F85R_0E=9@-&+%'/W) MV8P+;KBU>C\%P[C0'ZS]P_T4O?_UP\@W%E05VL\: )^W .@) %/(+E! /B** M*76X7Y_O3@[=?9N*-A^TS0>MXP4GXS6\C>7-:MXN3ML@H3M(=?0N=S><^':.L=[ M4Y(@#/$1L*Y5$D38#2QJ@47]26RRA4KVPF8"7.BBSKQQ$"='X+I&:4S3U(TN M;M'%O>CNWK&\_#1%\&QKOW;G+NY,/*1)%!_!ZYWG)S=JTK)(>ED\%%:E!/_7 M'DTAM496 JSN/-D*9!..-&0K55W0H$D2T.-5ZIH%P3!-0_6.A'V@%(W%%<2DJSZ"A3!C[JA?OHJ[CZ8@PP5!J$T3]7>,0DT1;4G%\*XPZ MI4^M6'V^LWYJP"LP$R)PR)*/-))QUVD[$.&4+!)YSI9OL0!TH.V%+!'F%Y:% MK.= N!"2I86RBB"E6?Y/;@HB*@I^:X-"4"@$ZPK-#0J-0J%A@.:1&5@C(DFO MP]D2N)96UO2#X<9H*S0TTVF\D%R=4J4G>^^91#B%5S# #*=4PC@AF8"=$4I" M$P&7>",7)-E5$A\N1K#S?+?C2N57:[MAX6.0^P@V^/ #.&.9C 6<9!%&JP9< M%7 9=7 7]2"P6AQAN \-?P\"+PAJ AK^OKIO":=1DM@P]IH;[4W53@1#A9+3 MR<(4J"9R#T[2><)ND<.(BI"C/E'=LBK93]DBDW6\YFX/C%O=D->]MN]Y7L>] MKH*MD?*J4BN8FB6FYM_'!&,E]0D)A_Y"QHS3[^OISW$V?T'@>T>_ GU0; 7I M08GTP(YT:'#!YS-,)\B_U 5HM:!?M<=B3D+L.NI=*I!?H]-[\:_KBO.) MC*V ;95@6W^,.9$# FMW6TY;&T*PGS M]KWF6E:M 3^2CL.2CL.M<@\_+$4MX J%U,00"9=+9BI;6.O&ZGW;NGDB8RM$ MM4NBVG]:-V)3X?2S3'U"2O**.E*7A#K&VC4E$ZQ5C#741Q)Q5!)QM#41>[8W M84Y2!3QE$>SHTJG]E-J]!W"K:ZZN.JR*CR3%]^ZO$=[?:*03$L;0CR)JQ)+\ M6V%K*'L8VW;44UE;):UR]_+_CZ8JXK!WE3W8QY(1W),1_-/&>L!]:W-GV36W M)<:M7-93Y#,SPP@(]7TIOP&7N^6$SZCJL@2G MRJ2W?ZAN'#R?9_*%9',S$DR85 .&>8S5#(A<"ZCS*5-C0;'0#LJILO<34$L# M!!0 ( #1-=U;_6+*NEP( , % 9 >&PO=V]R:W-H965T;Q263,@@'ONSA8['JK:%D+C08.JR9/K7 M% NUG03]X/%@*;+ MX)O K=E9@XMDI=2=VUREDZ#G!&&!W#H&1K\-SK H'!')N&\Y@\ZE ^ZN']D_ M^]@IEA4S.%/%=Y':?!)\""#%-:L+NU3;2VSC\0*Y*HS_PK:U[07 :V-5V8)) M02ED\V=^/(JSQGEL5CK;:@G36QN84/U:-)G)"N*(G5 M="L(9^,ORB)<-:/8*ZDS0U\DBFFSPE"4M[)CQ[E3Z.#C.?(C^&D?P11 M+XH.\)UTZ3CQ?(.7TE&7*XI;K>&F0DV!RPP2S.@56K,OWH9MY-G<^]_$_7&X MV2-@T D8'!2P4X:9DIS\ZB;]2V'NX,<D7AF\K\DQ)+FH7.1@%5 + MT .7<*VXU_.$W9>6@S&Z.7-J*L9Q$M @,:09@_CUJ_ZH]_% "8==!H?_6<*9 M;Q_4>RLW_*=R@[\J%^YT%;%D?G88X*J6MFFP[K0;3V=-5SZ9-[-MSG0F*&<% MK@G:.WY/WG4S+YJ-597OT96R)-DO<[7K($O2RYJJJ K5JY<"T;SUJFN7.)YD5O3LG%FDW;L7LPF?*.JLF'W LE- M75/Q[Q6K^';J8.=IX'.Y*I0><&>3-5VQ!Z:^K.\%]-P!)2]KULB2-TBPY=2Y MQ!=S'&N'UN*/DFWE7AOI4!:)H1JUBF- 2%OTPXX.N% >@=R['!J!K]W\-M .V9M6-=4 MT=E$\"T2VAK0=*-=F]8;HBD;O8T/2L#7$OS4["-7#-V@,W3#^$K0=5%FB#8Y M^J0*)M!MTPE%+_@9^@BJ>J 5D^CM-5.TK.0[&/WR<(W>OGDW<170T:!NUD]] MU4U-3DR-";KCC2HD^JW)67X(X$(<0S#D*9@K8D6\9MDY\O$OB'B$& C-_[\[ MMM#QA[7U6[S@!-Z-X%)V*V9:GES/BF4;+==UK!P:9-9J;(@3(\HFPP] M'(=^8J8<#I1#*^5!@B9VX6A23*(T"3W_B)W!T$\)+'QJ9A<-["(KNSF7-5-P M@FZ;E6!YR?2J_G7'Z@43?YL86^'T#7XAUS1C4P>N:,G$(W-F/_^$(^]7D[A? M">P@\GB(/'Z)U./1@H,2$C\*CS9F;!">P@:.SMTH[W$L'TW@>[ B>4 MX.AH5TR&<9"0X,2VX+W$B']<-+WO_K1P)?N1=ZQHDV'LASXYQ8_L^!$KOSNX M8$ QZ,-F(:#QO:O&CO9<\;P6VF'LN\2*7Y19>^_]12>0+\-PM#L&0\A2"2$G M=F>76K$]M]K5,TZ/P,_#T7&B,AGB&%+N*?7L\BBV)]+;)H?'I2A!0)?#<\^J M'RO>L_7S2FB'T>_R-+8GZN_I)QH_$'"4D-'E8["#UT9RXEV&=]D4V].I73WQ M^#UH9&>P,[%S]ZJ'FHE56U1)U#X*N[?W,#H4;I=MN7(T?J4+NK8JV<%TU> = M%:NRD:AB2X#TSF,@);H"J^LHOFYKE 574/&TS0**4B:T 7Q?8"AS M9_\!4$L#!!0 ( #1-=U;I+Y;]'@0 &<+ 9 >&PO=V]R:W-H965T M=23&V^>44F"&0]O*07J8D=P^= M>Q#V@C6U)5<2(?GO;R4[/B .O>OT!2QIOV_WV[6\.]Y)]4UGB 8>BESHB9<9 M4Y[[ODXR+)CNR!(%G:RE*IBAI=KXNE3(4@^R8S=\*?CDFUPB>:NO%&T\AN6E!ZCSL <(HA< 80T(CP&#%P!1#8B. ;T7 +T: MT'.9J:2X/"R88=.QDCM0UIK8[(-+ID.3?"YLV9=&T2DGG)E^E@;A$[R'3R@W MBI493X")%/XP&2JX$M6+92MT8+)_\':!AO%>KV\L%+&]GMY?+M@A/PNVWZ5R7+,&)1Q\?C>H>O>F; M5\&@^Z$M\[^([$!IOU':_^DZ7)R&?@W^;DM-!1KLU23N1\,@[!W5[KE=$ 3] M..H%[;4;-(H&IQ5)\?YN"5^OL5BA:@WQ),'_K=XO(CO0.FRT#G_^%@V?78XH M& 31,#XJQ'.[<#CLAJ-1>QU&WM%&W 0;_^A]F>4FD]M-!@PTWPB^Y@D3!DI4 M"0I#?17D&F;+JS>O1F$P_*"AW*HDHSZF8:UD ?05AKDL2B8>@2D$+?,4C 3Z M^E)'$W6'0*7/@.4Y:)L:>TZ4SCZ1U*!35)C"76?9J0T(#6LNF$@XRZEYEU(9 M+C;6>2G)]QD%*Q*L*#->4ILW![1VL\2TWFJ"W]$9R;71<^%B=TYGD*"B%B&. M=%-J-$*I9+I-B-\1;U<:OV_))G]LO*P>G6-RQHU^+KT#%Y2P%*@55?+X7G,B M]GM*@ MU/YD5YQD,!J^/2_!$XAH'["AY%MRXLR=-#'(KC.(V8XDEMGG><9/! ML/>Z9@@Z!^0Y4QO4IF&@6>L;O=-DNY*$&>4:%.H,==5UZBQ+G MD;S8$K*2U#UP4HJ4K6CT R66MAA\/FK;C\_G;HKT_W5;C:#7E#HN*(6XIA"ZG2'=8%6- M==7"R-(-.I1)*I5[S&@21F4-Z'PM:=BI%]9!,UM/_P%02P,$% @ -$UW M5B+$6 = P J@P !D !X;"]W;W)K&ULK5== M;]HP%/TK5C9-K;0VL?/= 5*!K>M#MZI5MX=I#VZXD*Q)S&Q3NG\_VTG#1T/4 M"EX@=NXY.><>P)?>DO$'D0)(]%3DI>A;J93S,]L620H%%:=L#J6Z,V6\H%(M M^R"9J4UZ)F]:S[HL87,LQ*N.1*+HJ#\WQ!RMNQ;V'K> MN,EFJ=0;]J WIS.X!7DWO^9J93L\8>].)RTK<L.57J WYFB]AN3"O:%G7.A9*%D*RH@8K!456 M5N_TJ6[$&@ '.P"D!I!M@+<#X-8 TSF[4F9LC:FD@QYG2\1UM6+3%Z8W!JW< M9*6.\59R=3=3.#GXQB2@"W2"+H#-.)VG68)H.4'?90H<79;5!T4W_ 3=TAP$ MD@Q=T3^,HY%1!UR@HS%(FN7B6!7=W8[1T?OCGBV5.OT,.ZF5#"LE9(<23- 5 M*V4JT.=R I-- EO9:KR19V]#TLDXAN04N?@C(@XA+8)&KX?C#CENTVK7\'D[ M^"XX$Z)J8EMW*K!OP/K+]SC ;NSX<:"D/ZZK;BGT8B_$0=@4;NCS&GU>I[[G M/-$Y^G4%Q3WPWVTZ.TGTK\Z9F-,$^I;Z61' '\$:?'B' ^=36P('(MOPZS=^ M_7WRJ,#!6IL]$GEA'&_%\;+.#SQ,PK@]C:!1%[PNC6%G&ITD;TWC0&0;?L/& M;[A/&N&++A.?A*'G;J716A=$P8XTHD9=]+HT1IUI=)*\-8T#D6WXC1N_\3YI MQ"^ZC /L^G&XE49+G4](%)'V-+"S.K6CR-\*I:W0BR+7P3M2(2N%I%/A>9[7@\-J-NB,IY/NS?$W&Q(_=:#N>EL(P"",WV(K'7IOZ5*MG9A@6*&&+4E9#4K/;#-SG M9LS"0 M&0 'AL+W=ORV#'#,1R)5$G/S['@F6.D9F]L9&\+Y'SSF2."Q. M4KWH ^<&O36BUHUHM9&=$W?)'A737-$R]/W A3\L@"G[<>*J?#\;>"%>+(WOF M6VZ^'1\5C,(Q2E4WO-6U;)'B^V5P'WU:1\[@%-]K?M)GU\BFLI/RQ0[^K)8! MMD1<\-+8$ S^7OF:"V$C <>_0]!@G-,:SZ]_1/_#)0_)[)CF:RG^J2MS6 9Y M@"J^9YTP3_+TF0\)41NOE$*[7W3JM5D:H++31C:#&0B:NNW_V=M0B#-#E%PQ MD,% ?M80#X;8)=J3N;0VS+#50LD34E8-T>R%JXUS0S9U:Y=Q:Q0\K<%G5G]) MP]%G]!NZ+TO5\0K]_@8[1',-M[;]TB*YGSZ]V7##:J%O0?=MNT$WO]PN0@- M-FQ8#I,_]).3*Y-O>'F'XNA71# A'OOZY^W11WL(91AK0<9:$!LX[E<5)CC$>91^XXI$KGN7:U-JH>M>Y?;_G M?L(^1'H^=4%I?$GHD5'072%,1L)DEO"1O2LI!&)M!6=;, -;A0];Q0>;3"AH MG&3T@G6J(@6AZ156.K+26=:U;(ZL?4<)CFY>;E$IV[&X/E0Z@2B2F%R6=:J* M<'%UX=,1-9U%O6_;C@FHZ%$J,UO0=#)_FL=)<4'I424XSOV0V0B9S4-V56WL MMO1Q9=,94WI6EI[+HXKHM>+E(U<^R_7$-5>O'$&K0]"_*KUJ:CK5 M>FN93X](6D0TN8#VR**XP(F?NABIBUGJ+1/P=E5\!Z!>NF(R;8Z+R7ZI?O;'+CRON?Q] #DI+BLF4=&HB*/KG"=-;%HENNK-+"F;&A2 MPX5GSM5\^7YAZKEN-!-^#$]]E$$+U'Q/] MP,BCZ\<[::"[N\L#?(!Q907P?"^A)P\#V^+'3[K5?U!+ P04 " T37=6 MH'186'@" I!0 &0 'AL+W=O0@+2AP(;22+0=6A] %1W;L^M<&PO'SFRG!8D?S]D.62=!7Q+; M=_?=]YWOG.^T>;85HH.76BH[3BKGFILTM;S"FMESW: BRUJ;FCG:FDUJ&X.L M#$&U3+/!X"JMF5!)D8>SA2ERW3HI%"X,V+:NF7F=H-2[<3),/@X>Q:9R_B M M\H9M<(GNJ5D8VJ4]2BEJ5%9H!0;7X^1V>#,9>?_@\%O@SNZMP2M9:?WL-_-R MG P\(93(G4=@]-OB%*7T0$3C;X>9]"E]X/[Z _TN:"]@.S[%P%9 M%Y %WC%18#ECCA6YT3LPWIO0_")(#=%$3BA_*4MGR"HHSA4/VB',X0R6;=-( MI'([)F$F+)?:M@8MZ#5,F:W@CNX/YBKV02BH*N%!JS/NK7.U1>N$VH3C.Z&8 MXGYWZZLNG""@XQDZ)J2%7_CB6B9/\M21 L\CY1W;262;?<%VF,&]5JZR\$.5 M6/X/D)+T7G_VH7^2'42<(3^'B^$I9(,L@Z?E#(Z/3L!6C*0?@+_HRWL1X$=? MP$\UU<4XL9((4UW75+:ET_SY%)8A!!1&AD[(&QQ]1B]FNCQ(+]UKWQK-)@RI!:Y;Y6(G]Z?].W ;V_^?>WQ$[IG9 M"&5!XII"!^?7E-G$P8P;IYLP#"OM:+3"LJ*W#(UW(/M:TT!T&Y^@?QV+=U!+ M P04 " T37=6\13L6S8# ",# &0 'AL+W=O)4#JQ(J<6Y;6 WK:>"&S2.E!VROOZ!SF("Z6XP%]NS")60)I)+QE B8#:QA MX]SOZ?EFPCV#M=QJ$[V3*>UI% M2"W<;C^Y?S1[Q[U,J801C[^Q4$4#JV>1$&9T&:L;OOX$^7[:VB_@L32?9)W- M[38M$BREXDDNQA4D+,V^Z2;GL"5 G]T"-Q>XSP6=/8)F+F@^%[3V"%JYH&7( M9%LQ''RJJ-<7?$V$GHUNNF%@&C5NGZ7ZM4^4P*<,=W$!,%81D M3(5Z)+>"II*:5R/)D0^*LEB26]BH)8V/9 '= M/0$;Y(JG*I+D,@TAW*$?_47O5AC8N/L"@?N$X,*M=+SFJU/2=$Z(Z[CNK@55 MRWT(4-[8*_=?+V]4[*99O-"F\6OM\V,"CQ07Y/L5)%,0/\@O,@P"ODP52^>$ MIB&YI1LR ;%B &;6-F;Z^E]Y MC5;;-+2; A60BI,IDWNORZG9 M ;SW_Y.T]R*OFEVG>5;.JU'E0@YE5I-9QLS>JM,2$'-3[TIB?IRS>J48+4KJ MH:DDGXV/L-3.*N,_-EF=?D7%G.'/30PSM'1.NTA+9+5OUE%\8:K!*5=86YIF MA'\70.@)^'S&L2+,.SI \0?$^PU02P,$% @ -$UW5N8EEPL? P 2!$ M T !X;"]S='EL97,N>&ULW5AM3]LP$/XKD1D32!-I&PC-:"MME9 F;1,2 M?-@WY#9.:\FQ,\=E+;]^/CM-7_ AQH>M+%6)?8_ON<=W%QQU4)N58+=SQDRT M+(6LAV1N3/4QCNOIG)6T/E,5DQ8IE"ZIL5,]B^M*,YK7X%2*N-?II'%)N22C M@5R4UZ6IHZE:2#,DYZTI\K;JQRMF0W)^\_[E0YNI=Y.]''XZ. M.O>G5_OV$P>O$"TK,.SFLQC#K=I7;+CRV1=SS&W"X#;C;*QA,FSCEN M\C8:%$INTI<0;[#LM&31 Q5#,J:"3S0'KX*67*R\N0>&J1)*1\;6S8;K@J5^ M]'#7SZ"D#4_)I=(NMH_@_TZ:Y7O >@8"N1"MP![QAM&@HL8P+:_MQ"UVQB=0 MU(SO5I55.--TU>U=D(V#N]D@$Z5SIMLP7;(VC0:"%2!'\]D<[D95,8#&J-(. MW1#"SME EQ"_W^H]CA7A9;=>M U60[M(*:H:?Q$^#?9O/Z.30HN]&LX$LW7Q:M (R]B[/3JA*K3X+/9,G\YE\<<#2@ M:[]HKC1_M-&@5:;6P#2)'I@V?+IM^:5I=<>69MU.RP+7W'N#FO]NGF=,,DW% MMFC;^X>OL;F4#QTD>E;$'F8Y8Z;8V?K;-LY MV5IK!&\00_(=WD?$)F@T67!AN&QFY: M<$@VXV\LYXLR:U?=0"*:59OQ5]A>-VU?7VPL+G.V9/FXF>K9Q TC.[!1FPL< M]I%K=X41S,=C800P+ ZF //Q7EB<_VD_?70_'L.T]8-('_7IHS[>*X2,W0>+ M$_;)[!7>:98E29IB&1V/@PK&6-[2%+YA-DP;>&!Q(-*?Y1JO-MXAS_+.P;WS*%Z? M4_'FMY/1;U!+ P04 " T37=6EXJ[', 3 @ "P %]R96QS+RYR M96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY M/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL M/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J. MW&,EC'%BM/XU@LD/['X 4$L#!!0 ( #1-=U:D[9"Y#@0 #P? / M>&PO=V]R:V)O;VLN>&ULQ9E-;]LX$$#_"J'+=@]=6Q]QVZ ND,1)ZF(W-6*C MUX*A:(L(17I)*DG[ZW=$P5LJB0:]B#Y9HFCJ:43-&U$?'[6YO]/ZGCS54MEY M4CFW/YU,+*MX3>U?>L\5'-EJ4U,'NV8WL7O#:6DKSETM)]ET.IO45*CDT\?# M6"LS"7>TX\P)K:"Q;?@F^*/]=;S=)0_"BCLAA?LQ3_RVY FIA1*U^,G+>3)- MB*WTXV=MQ$^M')5K9K24\R3M#GSCQ@GVHGG=0F[HG?4MCM[=4@"9)[,I#+@5 MQCK?PX]/@?&!0^=NKW'Z2DC'S8(Z?FUTLQ=JUPX#5S$)+L/'X?#;!?'4_$X8 M]78K&%]HUM1J))?*09#(4G5#0=_V2N'4 MR[*[:@>X00S-J8 #9EEZ\/$@U^UYVSZ6Z"W@,5WS@"Q#R+)QRK*B!/U3 M'!'R>Q9 SA#(64S("VHK6*&X MM82J,H!\CT"^CP!Y#I ^>H#5;< \% ]4AJGF P+Y(0+D!4#^0\T]!]U(>,0Y M:XQP@H=W.YUBF7H:@7(!E$OU #U!J7TVU"(C:\2S77JVUB!D0Y_Z<)A(TI%- MXN&N .Z<*[X5CJP@B_?H,*6D(SO%TUT#W377.T/WE6#^.?D*7C%D&6)B4DE' MMHK'_ R89XR9AD-%\P2CV?Y=QH22CFP4#[@$P'6SWTN?MJDD"V&9U+8Q(2:F ME'1DIWC,+X!YVQZ%.$(- 87AQL"4A%(VQ,3V5$BODEC2&8(0OV,#/,,%D,PPQZD(28F&RR&+)Y M)D+R9M/B]FKP#'U[B2&=YT9\E1*33W9,^?0G)B:?[%CRZ0(:8F(*RF(H:# ; MY2$FIJ LAH(&,8L0$U-0=LSWF^\G(2:FH.RH"IJ%F)B"LJ,J*)R;.::@_)@* MZB6D'%-0'D-!@YB]:&(2RF-(:! S?-)S=%4MAH5>"'T!P$):L@DQ,0OE,2ST M'+-]WZAK:GZ$Y5&.62B/8:$7E<=;LC*ZA0DQ,0OE,2ST"N8M9UJQ'B9FH3R& MA5[!7/ M-R9/_ARC$Q"R4Q[#08+T9YLT"LU 1PT*#F&'> M+# +%3$L-(@95D@%9J$BAH4&,<,*J< L5,2PT*LO&3['AYCHUYT8%AI:Y^I5 M2 5FH2*&A8;6N?J8F(4*;Z')X6MM";E-\?(&3F&AG5')5H:T/]TJ&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V;MNPD 0A>%707X EIE9 M;A%0I:&-> $+EHLPV/)N%'C[("C@6"G2H#V5M;8\_AM_LM:SKU"5Z5"?X_[0 MQ-[E5)WCO-BGU'PX%]?[<"ICOV["^79E6[>G,MV6[ZG;H]Q'T(J>JNRW84T+]RE>IZ. M[GZ0_FURT5MNYD6[W$CA<@BOJK01Z*^JM!'HK MZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z&^IM!'H;ZFT$>AOJ;01Z6V>SA$!O M0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!OCWI[ KT]ZNT)]/:HMR?0 MVZ/>GD!OW]GL)M#;H]Z>0&^/>OMWZAW3M0KQV?-8X_/?276ZW1N>C[\O'R<[ M[_@=9P=_[!:_4$L#!!0 ( #1-=U8F^H>GM0$ -P; 3 6T-O;G1E M;G1?5'EP97-=+GAM;,V9S6[",!"$7P7EBHBQG=(? 9>VUY9#7\!--B0BB2W; M4'C[.N%':D6C(BIU+K$2[\Z,O=)WR?1M9\@-MG75N%E4>&\>&'-I0;5RL3;4 MA)U7T<$A#IU=C2M*XX:A(&)G'=J=GPT.?:\; MLK;,:+!0UK^H.E2Q;<6H?K_=!VU&PO=&AE;64O M=&AE;64Q+GAM;%!+ 0(4 Q0 ( #1-=U;8VFTH7 < *DP 8 M " @0T( !X;"]W;W)K&PO=V]R:W-H M965T&UL4$L! A0#% @ -$UW5D$5*PN*!@ _QH !@ M ("!/10 'AL+W=O&PO=V]R:W-H965T&UL M4$L! A0#% @ -$UW5GVW8LV+ @ ? < !@ ("!$R( M 'AL+W=O,@ & M@($S+ >&PO=V]R:W-H965T&UL4$L! A0#% @ -$UW M5@-I]&UL4$L! A0#% M @ -$UW5N6?,($$ P 9P8 !D ("!>DD 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ -$UW5E99,BUI @ ; 4 !D M ("!3V( 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ -$UW5B_.(62% @ B@4 !D ("!6GL M 'AL+W=O&PO=V]R:W-H965T^! !X;"]W;W)K&UL4$L! A0#% @ M-$UW5OV-)2GN! L0L !D ("!J80 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ -$UW5MT"=H]Z"0 M,%, !D ("!3)$ 'AL+W=O&PO=V]R:W-H965T !X;"]W;W)K&UL4$L! A0#% @ -$UW5E7,K^;B @ 60D !D M ("!^*( 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ -$UW5BBM9*RS @ _08 !D ("!::L 'AL M+W=O#0 &0 @(%3K@ >&PO=V]R:W-H965T&UL4$L! A0#% @ -$UW M5ME0ROA2 @ \@4 !D ("!'[0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ -$UW5N-.&X00! B \ M !D ("!;;T 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ -$UW5J???8'< P \@X !D M ("!,L@ 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ -$UW5F+O($,L P W@D !D ("!$=0 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ -$UW5N8E MEPL? P 2!$ T ( !D-T 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ -$UW5OTLU:6N M 0 P1L !H ( !_N4 'AL+U]R96QS+W=OU 0 W!L !, M ( !Y.< %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& #8 -@"Q#@ RND # end XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 92 229 1 true 50 0 false 6 false false R1.htm 000 - Document - Document And Entity Information Sheet http://u-g.com/20221231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Statements of Income Sheet http://u-g.com/20221231/role/statement-statements-of-income Statements of Income Statements 2 false false R3.htm 002 - Statement - Balance Sheets Sheet http://u-g.com/20221231/role/statement-balance-sheets Balance Sheets Statements 3 false false R4.htm 003 - Statement - Balance Sheets (Parentheticals) Sheet http://u-g.com/20221231/role/statement-balance-sheets-parentheticals Balance Sheets (Parentheticals) Statements 4 false false R5.htm 004 - Statement - Statements of Stockholders' Equity Sheet http://u-g.com/20221231/role/statement-statements-of-stockholders-equity Statements of Stockholders' Equity Statements 5 false false R6.htm 005 - Statement - Statements of Stockholders' Equity (Parentheticals) Sheet http://u-g.com/20221231/role/statement-statements-of-stockholders-equity-parentheticals Statements of Stockholders' Equity (Parentheticals) Statements 6 false false R7.htm 006 - Statement - Statements of Cash Flows Sheet http://u-g.com/20221231/role/statement-statements-of-cash-flows Statements of Cash Flows Statements 7 false false R8.htm 007 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies Sheet http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies- Note A - Nature of Business and Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note B - Cash and Cash Equivalents Sheet http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents- Note B - Cash and Cash Equivalents Notes 9 false false R10.htm 009 - Disclosure - Note C - Marketable Securities Sheet http://u-g.com/20221231/role/statement-note-c-marketable-securities Note C - Marketable Securities Notes 10 false false R11.htm 010 - Disclosure - Note D - Inventories Sheet http://u-g.com/20221231/role/statement-note-d-inventories Note D - Inventories Notes 11 false false R12.htm 011 - Disclosure - Note E - Income Taxes Sheet http://u-g.com/20221231/role/statement-note-e-income-taxes Note E - Income Taxes Notes 12 false false R13.htm 012 - Disclosure - Note F - Benefit Plans Sheet http://u-g.com/20221231/role/statement-note-f-benefit-plans Note F - Benefit Plans Notes 13 false false R14.htm 013 - Disclosure - Note G - Geographic and Other Information Sheet http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information Note G - Geographic and Other Information Notes 14 false false R15.htm 014 - Disclosure - Note H - Accrued Expenses Sheet http://u-g.com/20221231/role/statement-note-h-accrued-expenses Note H - Accrued Expenses Notes 15 false false R16.htm 015 - Disclosure - Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities Sheet http://u-g.com/20221231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities Notes 16 false false R17.htm 016 - Disclosure - Note J - Related Party Transactions Sheet http://u-g.com/20221231/role/statement-note-j-related-party-transactions Note J - Related Party Transactions Notes 17 false false R18.htm 017 - Disclosure - Significant Accounting Policies (Policies) Sheet http://u-g.com/20221231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies- 18 false false R19.htm 018 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies (Tables) Sheet http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables Note A - Nature of Business and Summary of Significant Accounting Policies (Tables) Tables http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies- 19 false false R20.htm 019 - Disclosure - Note B - Cash and Cash Equivalents (Tables) Sheet http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-tables Note B - Cash and Cash Equivalents (Tables) Tables http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents- 20 false false R21.htm 020 - Disclosure - Note C - Marketable Securities (Tables) Sheet http://u-g.com/20221231/role/statement-note-c-marketable-securities-tables Note C - Marketable Securities (Tables) Tables http://u-g.com/20221231/role/statement-note-c-marketable-securities 21 false false R22.htm 021 - Disclosure - Note D - Inventories (Tables) Sheet http://u-g.com/20221231/role/statement-note-d-inventories-tables Note D - Inventories (Tables) Tables http://u-g.com/20221231/role/statement-note-d-inventories 22 false false R23.htm 022 - Disclosure - Note E - Income Taxes (Tables) Sheet http://u-g.com/20221231/role/statement-note-e-income-taxes-tables Note E - Income Taxes (Tables) Tables http://u-g.com/20221231/role/statement-note-e-income-taxes 23 false false R24.htm 023 - Disclosure - Note G - Geographic and Other Information (Tables) Sheet http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-tables Note G - Geographic and Other Information (Tables) Tables http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information 24 false false R25.htm 024 - Disclosure - Note H - Accrued Expenses (Tables) Sheet http://u-g.com/20221231/role/statement-note-h-accrued-expenses-tables Note H - Accrued Expenses (Tables) Tables http://u-g.com/20221231/role/statement-note-h-accrued-expenses 25 false false R26.htm 025 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies (Details Textual) Sheet http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual Note A - Nature of Business and Summary of Significant Accounting Policies (Details Textual) Details http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables 26 false false R27.htm 026 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies - Disaggregated Revenue (Details) Sheet http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details Note A - Nature of Business and Summary of Significant Accounting Policies - Disaggregated Revenue (Details) Details 27 false false R28.htm 027 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies - Revenue by Geographic Region (Details) Sheet http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details Note A - Nature of Business and Summary of Significant Accounting Policies - Revenue by Geographic Region (Details) Details 28 false false R29.htm 028 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies - Property, Plant, and Equipment Useful Lives (Details) Sheet http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-property-plant-and-equipment-useful-lives-details Note A - Nature of Business and Summary of Significant Accounting Policies - Property, Plant, and Equipment Useful Lives (Details) Details 29 false false R30.htm 029 - Disclosure - Note B - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) Sheet http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details Note B - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) Details 30 false false R31.htm 030 - Disclosure - Note C - Marketable Securities (Details Textual) Sheet http://u-g.com/20221231/role/statement-note-c-marketable-securities-details-textual Note C - Marketable Securities (Details Textual) Details http://u-g.com/20221231/role/statement-note-c-marketable-securities-tables 31 false false R32.htm 031 - Disclosure - Note C - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) Sheet http://u-g.com/20221231/role/statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details Note C - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) Details 32 false false R33.htm 032 - Disclosure - Note C - Marketable Securities - Summary of Investments (Details) Sheet http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details Note C - Marketable Securities - Summary of Investments (Details) Details 33 false false R34.htm 033 - Disclosure - Note D - Inventories (Details Textual) Sheet http://u-g.com/20221231/role/statement-note-d-inventories-details-textual Note D - Inventories (Details Textual) Details http://u-g.com/20221231/role/statement-note-d-inventories-tables 34 false false R35.htm 034 - Disclosure - Note D - Inventories - Summary of Inventories (Details) Sheet http://u-g.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details Note D - Inventories - Summary of Inventories (Details) Details 35 false false R36.htm 035 - Disclosure - Note E - Income Taxes - Provision for Income Taxes (Details) Sheet http://u-g.com/20221231/role/statement-note-e-income-taxes-provision-for-income-taxes-details Note E - Income Taxes - Provision for Income Taxes (Details) Details 36 false false R37.htm 036 - Disclosure - Note E - Income Taxes - Reconciliation of the Effective Income Tax Rate (Details) Sheet http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details Note E - Income Taxes - Reconciliation of the Effective Income Tax Rate (Details) Details 37 false false R38.htm 037 - Disclosure - Note E - Income Taxes - Deferred Tax Assets and Liabilities (Details) Sheet http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details Note E - Income Taxes - Deferred Tax Assets and Liabilities (Details) Details 38 false false R39.htm 038 - Disclosure - Note F - Benefit Plans (Details Textual) Sheet http://u-g.com/20221231/role/statement-note-f-benefit-plans-details-textual Note F - Benefit Plans (Details Textual) Details http://u-g.com/20221231/role/statement-note-f-benefit-plans 39 false false R40.htm 039 - Disclosure - Note G - Geographic and Other Information (Details Textual) Sheet http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual Note G - Geographic and Other Information (Details Textual) Details http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-tables 40 false false R41.htm 040 - Disclosure - Note G - Geographic and Other Information - Net Sales (Details) Sheet http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-net-sales-details Note G - Geographic and Other Information - Net Sales (Details) Details 41 false false R42.htm 041 - Disclosure - Note G - Geographic and Other Information - Geographic Information (Details) Sheet http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-geographic-information-details Note G - Geographic and Other Information - Geographic Information (Details) Details 42 false false R43.htm 042 - Disclosure - Note G - Geographic and Other Information - Sales to Major Customers (Details) Sheet http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details Note G - Geographic and Other Information - Sales to Major Customers (Details) Details 43 false false R44.htm 043 - Disclosure - Note H - Accrued Expenses - Summary of Accrued Expenses (Details) Sheet http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details Note H - Accrued Expenses - Summary of Accrued Expenses (Details) Details 44 false false R45.htm 044 - Disclosure - Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities (Details Textual) Sheet http://u-g.com/20221231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities-details-textual Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities (Details Textual) Details http://u-g.com/20221231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities 45 false false R46.htm 045 - Disclosure - Note J - Related Party Transactions (Details Textual) Sheet http://u-g.com/20221231/role/statement-note-j-related-party-transactions-details-textual Note J - Related Party Transactions (Details Textual) Details http://u-g.com/20221231/role/statement-note-j-related-party-transactions 46 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept PropertyPlantAndEquipmentEstimatedUsefulLives in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ug20221231_10k.htm 3618 [dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ug20221231_10k.htm 4133 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 29 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:EntityRegistrantName, ug:DefinedContributionDiscretionaryContributionPlanVestingPeriod, ug:DefinedContributionPlanEmployerDiscretionaryContributionAmountPerYearAuthorized, ug:NumberOfCustomers, ug:NumberOfVendors, us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent, us-gaap:CommonStockDividendsPerShareCashPaid, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:ImpairmentOfLongLivedAssetsHeldForUse, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:UnrecognizedTaxBenefits, us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued - ug20221231_10k.htm 8, 10, 13, 14, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 ug20221231_10k.htm ex_488286.htm ex_488287.htm ex_488288.htm ug-20221231.xsd ug-20221231_cal.xml ug-20221231_def.xml ug-20221231_lab.xml ug-20221231_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 63 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ug20221231_10k.htm": { "axisCustom": 0, "axisStandard": 16, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 391, "http://xbrl.sec.gov/dei/2022": 36 }, "contextCount": 92, "dts": { "calculationLink": { "local": [ "ug-20221231_cal.xml" ] }, "definitionLink": { "local": [ "ug-20221231_def.xml" ] }, "inline": { "local": [ "ug20221231_10k.htm" ] }, "labelLink": { "local": [ "ug-20221231_lab.xml" ] }, "presentationLink": { "local": [ "ug-20221231_pre.xml" ] }, "schema": { "local": [ "ug-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 365, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 24, "http://u-g.com/20221231": 5, "http://xbrl.sec.gov/dei/2022": 6, "total": 35 }, "keyCustom": 23, "keyStandard": 206, "memberCustom": 27, "memberStandard": 23, "nsprefix": "ug", "nsuri": "http://u-g.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://u-g.com/20221231/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note C - Marketable Securities", "menuCat": "Notes", "order": "10", "role": "http://u-g.com/20221231/role/statement-note-c-marketable-securities", "shortName": "Note C - Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note D - Inventories", "menuCat": "Notes", "order": "11", "role": "http://u-g.com/20221231/role/statement-note-d-inventories", "shortName": "Note D - Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note E - Income Taxes", "menuCat": "Notes", "order": "12", "role": "http://u-g.com/20221231/role/statement-note-e-income-taxes", "shortName": "Note E - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note F - Benefit Plans", "menuCat": "Notes", "order": "13", "role": "http://u-g.com/20221231/role/statement-note-f-benefit-plans", "shortName": "Note F - Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note G - Geographic and Other Information", "menuCat": "Notes", "order": "14", "role": "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information", "shortName": "Note G - Geographic and Other Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note H - Accrued Expenses", "menuCat": "Notes", "order": "15", "role": "http://u-g.com/20221231/role/statement-note-h-accrued-expenses", "shortName": "Note H - Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities", "menuCat": "Notes", "order": "16", "role": "http://u-g.com/20221231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities", "shortName": "Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note J - Related Party Transactions", "menuCat": "Notes", "order": "17", "role": "http://u-g.com/20221231/role/statement-note-j-related-party-transactions", "shortName": "Note J - Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "18", "role": "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "19", "role": "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables", "shortName": "Note A - Nature of Business and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Statements of Income", "menuCat": "Statements", "order": "2", "role": "http://u-g.com/20221231/role/statement-statements-of-income", "shortName": "Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:OperatingCostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note B - Cash and Cash Equivalents (Tables)", "menuCat": "Tables", "order": "20", "role": "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-tables", "shortName": "Note B - Cash and Cash Equivalents (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note C - Marketable Securities (Tables)", "menuCat": "Tables", "order": "21", "role": "http://u-g.com/20221231/role/statement-note-c-marketable-securities-tables", "shortName": "Note C - Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note D - Inventories (Tables)", "menuCat": "Tables", "order": "22", "role": "http://u-g.com/20221231/role/statement-note-d-inventories-tables", "shortName": "Note D - Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note E - Income Taxes (Tables)", "menuCat": "Tables", "order": "23", "role": "http://u-g.com/20221231/role/statement-note-e-income-taxes-tables", "shortName": "Note E - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note G - Geographic and Other Information (Tables)", "menuCat": "Tables", "order": "24", "role": "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-tables", "shortName": "Note G - Geographic and Other Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note H - Accrued Expenses (Tables)", "menuCat": "Tables", "order": "25", "role": "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-tables", "shortName": "Note H - Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LoansAndLeasesReceivableAllowanceForLoanLossesPolicy", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies (Details Textual)", "menuCat": "Details", "order": "26", "role": "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "shortName": "Note A - Nature of Business and Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LoansAndLeasesReceivableAllowanceForLoanLossesPolicy", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies - Disaggregated Revenue (Details)", "menuCat": "Details", "order": "27", "role": "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "shortName": "Note A - Nature of Business and Summary of Significant Accounting Policies - Disaggregated Revenue (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies - Revenue by Geographic Region (Details)", "menuCat": "Details", "order": "28", "role": "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "shortName": "Note A - Nature of Business and Summary of Significant Accounting Policies - Revenue by Geographic Region (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R29": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "ug:ProertyPlantAndEquipmentUsefulLivesTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies - Property, Plant, and Equipment Useful Lives (Details)", "menuCat": "Details", "order": "29", "role": "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-property-plant-and-equipment-useful-lives-details", "shortName": "Note A - Nature of Business and Summary of Significant Accounting Policies - Property, Plant, and Equipment Useful Lives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "ug:ProertyPlantAndEquipmentUsefulLivesTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Balance Sheets", "menuCat": "Statements", "order": "3", "role": "http://u-g.com/20221231/role/statement-balance-sheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note B - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)", "menuCat": "Details", "order": "30", "role": "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details", "shortName": "Note B - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2022-12-31_CashAndCashEquivalentsAxis-DemandDepositsMember", "decimals": "INF", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note C - Marketable Securities (Details Textual)", "menuCat": "Details", "order": "31", "role": "http://u-g.com/20221231/role/statement-note-c-marketable-securities-details-textual", "shortName": "Note C - Marketable Securities (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:GainLossOnInvestmentsTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtAndEquitySecuritiesGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note C - Marketable Securities - Net Gains and Losses on Marketable Securities (Details)", "menuCat": "Details", "order": "32", "role": "http://u-g.com/20221231/role/statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details", "shortName": "Note C - Marketable Securities - Net Gains and Losses on Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:GainLossOnInvestmentsTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtAndEquitySecuritiesGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note C - Marketable Securities - Summary of Investments (Details)", "menuCat": "Details", "order": "33", "role": "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details", "shortName": "Note C - Marketable Securities - Summary of Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note D - Inventories (Details Textual)", "menuCat": "Details", "order": "34", "role": "http://u-g.com/20221231/role/statement-note-d-inventories-details-textual", "shortName": "Note D - Inventories (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note D - Inventories - Summary of Inventories (Details)", "menuCat": "Details", "order": "35", "role": "http://u-g.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details", "shortName": "Note D - Inventories - Summary of Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note E - Income Taxes - Provision for Income Taxes (Details)", "menuCat": "Details", "order": "36", "role": "http://u-g.com/20221231/role/statement-note-e-income-taxes-provision-for-income-taxes-details", "shortName": "Note E - Income Taxes - Provision for Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note E - Income Taxes - Reconciliation of the Effective Income Tax Rate (Details)", "menuCat": "Details", "order": "37", "role": "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details", "shortName": "Note E - Income Taxes - Reconciliation of the Effective Income Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note E - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "menuCat": "Details", "order": "38", "role": "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details", "shortName": "Note E - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note F - Benefit Plans (Details Textual)", "menuCat": "Details", "order": "39", "role": "http://u-g.com/20221231/role/statement-note-f-benefit-plans-details-textual", "shortName": "Note F - Benefit Plans (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Balance Sheets (Parentheticals)", "menuCat": "Statements", "order": "4", "role": "http://u-g.com/20221231/role/statement-balance-sheets-parentheticals", "shortName": "Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R40": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note G - Geographic and Other Information (Details Textual)", "menuCat": "Details", "order": "40", "role": "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual", "shortName": "Note G - Geographic and Other Information (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "ug:RevenueFromContractWithCustomerIncludingAssessedTaxGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note G - Geographic and Other Information - Net Sales (Details)", "menuCat": "Details", "order": "41", "role": "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-net-sales-details", "shortName": "Note G - Geographic and Other Information - Net Sales (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "lang": null, "name": "ug:SalesReturnsAndAllowances", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note G - Geographic and Other Information - Geographic Information (Details)", "menuCat": "Details", "order": "42", "role": "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-geographic-information-details", "shortName": "Note G - Geographic and Other Information - Geographic Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "ug:RevenueFromContractWithCustomerIncludingAssessedTaxGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note G - Geographic and Other Information - Sales to Major Customers (Details)", "menuCat": "Details", "order": "43", "role": "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details", "shortName": "Note G - Geographic and Other Information - Sales to Major Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_MajorCustomersAxis-CustomerAMember", "decimals": "INF", "lang": null, "name": "ug:RevenueFromContractWithCustomerIncludingAssessedTaxGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AccruedBonusesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note H - Accrued Expenses - Summary of Accrued Expenses (Details)", "menuCat": "Details", "order": "44", "role": "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details", "shortName": "Note H - Accrued Expenses - Summary of Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AccruedBonusesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "ug:ConvertibleCommonStockSharesIssuableUponConversion", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities (Details Textual)", "menuCat": "Details", "order": "45", "role": "http://u-g.com/20221231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities-details-textual", "shortName": "Note I - Supplemental Disclosures of Cash Flow Information and Non-cash Investing and Financing Activities (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "ug:ConvertibleCommonStockSharesIssuableUponConversion", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_RelatedPartyTransactionAxis-AccountingAndTaxServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-DirectorMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note J - Related Party Transactions (Details Textual)", "menuCat": "Details", "order": "46", "role": "http://u-g.com/20221231/role/statement-note-j-related-party-transactions-details-textual", "shortName": "Note J - Related Party Transactions (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_RelatedPartyTransactionAxis-AccountingAndTaxServicesMember_RelatedPartyTransactionsByRelatedPartyAxis-DirectorMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Statements of Stockholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity", "shortName": "Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R6": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Statements of Stockholders' Equity (Parentheticals)", "menuCat": "Statements", "order": "6", "role": "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity-parentheticals", "shortName": "Statements of Stockholders' Equity (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://u-g.com/20221231/role/statement-statements-of-cash-flows", "shortName": "Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note A - Nature of Business and Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "shortName": "Note A - Nature of Business and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note B - Cash and Cash Equivalents", "menuCat": "Notes", "order": "9", "role": "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-", "shortName": "Note B - Cash and Cash Equivalents", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ug20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 50, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-geographic-information-details" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r441", "r442", "r443" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r441", "r442", "r443" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r441", "r442", "r443" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r441", "r442", "r443" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets", "http://u-g.com/20221231/role/statement-balance-sheets-parentheticals", "http://u-g.com/20221231/role/statement-document-and-entity-information", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-property-plant-and-equipment-useful-lives-details", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables", "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-", "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details", "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-tables", "http://u-g.com/20221231/role/statement-note-c-marketable-securities", "http://u-g.com/20221231/role/statement-note-c-marketable-securities-details-textual", "http://u-g.com/20221231/role/statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details", "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details", "http://u-g.com/20221231/role/statement-note-c-marketable-securities-tables", "http://u-g.com/20221231/role/statement-note-d-inventories", "http://u-g.com/20221231/role/statement-note-d-inventories-details-textual", "http://u-g.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details", "http://u-g.com/20221231/role/statement-note-d-inventories-tables", "http://u-g.com/20221231/role/statement-note-e-income-taxes", "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details", "http://u-g.com/20221231/role/statement-note-e-income-taxes-provision-for-income-taxes-details", "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details", "http://u-g.com/20221231/role/statement-note-e-income-taxes-tables", "http://u-g.com/20221231/role/statement-note-f-benefit-plans", "http://u-g.com/20221231/role/statement-note-f-benefit-plans-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-geographic-information-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-net-sales-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-tables", "http://u-g.com/20221231/role/statement-note-h-accrued-expenses", "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details", "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-tables", "http://u-g.com/20221231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities", "http://u-g.com/20221231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities-details-textual", "http://u-g.com/20221231/role/statement-note-j-related-party-transactions", "http://u-g.com/20221231/role/statement-note-j-related-party-transactions-details-textual", "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies", "http://u-g.com/20221231/role/statement-statements-of-cash-flows", "http://u-g.com/20221231/role/statement-statements-of-income" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r441", "r442", "r443" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets", "http://u-g.com/20221231/role/statement-balance-sheets-parentheticals", "http://u-g.com/20221231/role/statement-document-and-entity-information", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-property-plant-and-equipment-useful-lives-details", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables", "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-", "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details", "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-tables", "http://u-g.com/20221231/role/statement-note-c-marketable-securities", "http://u-g.com/20221231/role/statement-note-c-marketable-securities-details-textual", "http://u-g.com/20221231/role/statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details", "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details", "http://u-g.com/20221231/role/statement-note-c-marketable-securities-tables", "http://u-g.com/20221231/role/statement-note-d-inventories", "http://u-g.com/20221231/role/statement-note-d-inventories-details-textual", "http://u-g.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details", "http://u-g.com/20221231/role/statement-note-d-inventories-tables", "http://u-g.com/20221231/role/statement-note-e-income-taxes", "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details", "http://u-g.com/20221231/role/statement-note-e-income-taxes-provision-for-income-taxes-details", "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details", "http://u-g.com/20221231/role/statement-note-e-income-taxes-tables", "http://u-g.com/20221231/role/statement-note-f-benefit-plans", "http://u-g.com/20221231/role/statement-note-f-benefit-plans-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-geographic-information-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-net-sales-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-tables", "http://u-g.com/20221231/role/statement-note-h-accrued-expenses", "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details", "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-tables", "http://u-g.com/20221231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities", "http://u-g.com/20221231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities-details-textual", "http://u-g.com/20221231/role/statement-note-j-related-party-transactions", "http://u-g.com/20221231/role/statement-note-j-related-party-transactions-details-textual", "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies", "http://u-g.com/20221231/role/statement-statements-of-cash-flows", "http://u-g.com/20221231/role/statement-statements-of-income" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://u-g.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "srt_DirectorMember": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-j-related-party-transactions", "http://u-g.com/20221231/role/statement-note-j-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r204", "r430", "r474", "r558" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details" ], "xbrltype": "stringItemType" }, "srt_MinimumMember": { "auth_ref": [ "r229", "r230", "r231", "r232", "r269", "r367", "r388", "r408", "r409", "r427", "r433", "r437", "r473", "r549", "r550", "r551", "r552", "r553", "r554" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-property-plant-and-equipment-useful-lives-details" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r204", "r430", "r474", "r558" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r200", "r370", "r428", "r435", "r469", "r470", "r474", "r557" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-net-sales-details" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r200", "r370", "r428", "r435", "r469", "r470", "r474", "r557" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-net-sales-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r229", "r230", "r231", "r232", "r253", "r269", "r276", "r277", "r278", "r343", "r367", "r388", "r408", "r409", "r427", "r433", "r437", "r468", "r473", "r550", "r551", "r552", "r553", "r554" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-property-plant-and-equipment-useful-lives-details" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r229", "r230", "r231", "r232", "r253", "r269", "r276", "r277", "r278", "r343", "r367", "r388", "r408", "r409", "r427", "r433", "r437", "r468", "r473", "r550", "r551", "r552", "r553", "r554" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-property-plant-and-equipment-useful-lives-details" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r165", "r274", "r447", "r458" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-f-benefit-plans", "http://u-g.com/20221231/role/statement-note-f-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r201", "r202", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r429", "r436", "r474" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-geographic-information-details" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r201", "r202", "r395", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r429", "r436", "r474" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-geographic-information-details" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r165", "r274", "r447", "r448", "r458" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-f-benefit-plans", "http://u-g.com/20221231/role/statement-note-f-benefit-plans-details-textual" ], "xbrltype": "stringItemType" }, "ug_ASIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to information regarding the entity ASI, which is located in Canada.", "label": "ASI [Member]" } } }, "localname": "ASIMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "ug_AccountingAndTaxServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents accounting and tax services.", "label": "Accounting and Tax Services [Member]" } } }, "localname": "AccountingAndTaxServicesMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-j-related-party-transactions", "http://u-g.com/20221231/role/statement-note-j-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "ug_AccruedAnnualReportExpensesCurrent": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value of accrued annual report expenses classified as current liabilities.", "label": "ug_AccruedAnnualReportExpensesCurrent", "terseLabel": "Annual report expenses" } } }, "localname": "AccruedAnnualReportExpensesCurrent", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "ug_AccruedDistributionFeesCurrent": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "order": 8.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued distribution fees", "label": "ug_AccruedDistributionFeesCurrent", "terseLabel": "Distribution fees" } } }, "localname": "AccruedDistributionFeesCurrent", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "ug_AccruedExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to accrued expenses.", "label": "Accrued Expenses [Member]" } } }, "localname": "AccruedExpensesMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "ug_AccruedReserveForOutdatedMaterial": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value on reserves for outdated material.", "label": "ug_AccruedReserveForOutdatedMaterial", "terseLabel": "Reserve for outdated material returns" } } }, "localname": "AccruedReserveForOutdatedMaterial", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "ug_AllOtherCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Other Customers [Member]" } } }, "localname": "AllOtherCustomersMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details" ], "xbrltype": "domainItemType" }, "ug_AllowanceForMaterialReturns": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of allowance for material returns.", "label": "ug_AllowanceForMaterialReturns", "terseLabel": "Allowance for Material Returns" } } }, "localname": "AllowanceForMaterialReturns", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "ug_ConsultingServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents consulting services.", "label": "Consulting Services [Member]" } } }, "localname": "ConsultingServicesMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-j-related-party-transactions", "http://u-g.com/20221231/role/statement-note-j-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "ug_ConvertibleCommonStockSharesIssuableUponConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issuable upon the conversion of convertible common stock.", "label": "ug_ConvertibleCommonStockSharesIssuableUponConversion", "terseLabel": "Convertible Common Stock, Shares Issuable upon Conversion (in shares)" } } }, "localname": "ConvertibleCommonStockSharesIssuableUponConversion", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities-details-textual" ], "xbrltype": "sharesItemType" }, "ug_CosmeticIngredientsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to cosmetic ingredients.", "label": "Cosmetic Ingredients [Member]" } } }, "localname": "CosmeticIngredientsMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-net-sales-details" ], "xbrltype": "domainItemType" }, "ug_CostOfGoodsAndServicesSoldShippingAndHandlingCostPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.", "label": "Cost of Goods and Services Sold, Shipping and Handling Cost, Policy [Policy Text Block]" } } }, "localname": "CostOfGoodsAndServicesSoldShippingAndHandlingCostPolicyPolicyTextBlock", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "ug_CustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents customer A.", "label": "Customer A [Member]" } } }, "localname": "CustomerAMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details" ], "xbrltype": "domainItemType" }, "ug_CustomerBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a second customer.", "label": "Customer B [Member]" } } }, "localname": "CustomerBMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details" ], "xbrltype": "domainItemType" }, "ug_CustomerCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a third customer.", "label": "Customer C [Member]" } } }, "localname": "CustomerCMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details" ], "xbrltype": "domainItemType" }, "ug_CustomerDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a fourth customer.", "label": "Customer D [Member]" } } }, "localname": "CustomerDMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details" ], "xbrltype": "domainItemType" }, "ug_DCPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents DC plan.", "label": "DC Plan [Member]" } } }, "localname": "DCPlanMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-f-benefit-plans", "http://u-g.com/20221231/role/statement-note-f-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of investment in debt securities classified as held to maturity and equity securities.", "label": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost", "totalLabel": "Marketable securities, cost" } } }, "localname": "DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "xbrltype": "monetaryItemType" }, "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt securities classified as held to maturity and equity securities.", "label": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue", "totalLabel": "Marketable securities" } } }, "localname": "DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "xbrltype": "monetaryItemType" }, "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized gain (loss) in debt securities classified as held to maturity and equity securities.", "label": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss", "totalLabel": "Marketable securities, unrealized gain" } } }, "localname": "DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "xbrltype": "monetaryItemType" }, "ug_DeferredTaxAssetsAccountsPayable": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accounts payable.", "label": "ug_DeferredTaxAssetsAccountsPayable", "terseLabel": "Accounts payable" } } }, "localname": "DeferredTaxAssetsAccountsPayable", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "ug_DeferredTaxAssetsCapitalizedResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.", "label": "R&D expenses" } } }, "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "ug_DeferredTaxLiabilitiesAccountsReceivable": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from accounts receivable.", "label": "ug_DeferredTaxLiabilitiesAccountsReceivable", "negatedLabel": "Accounts receivable" } } }, "localname": "DeferredTaxLiabilitiesAccountsReceivable", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "ug_DefinedContributionDiscretionaryContributionPlanVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the vesting period of discretionary contributions made under the defined contribution plan.", "label": "ug_DefinedContributionDiscretionaryContributionPlanVestingPeriod", "terseLabel": "Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year)" } } }, "localname": "DefinedContributionDiscretionaryContributionPlanVestingPeriod", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-f-benefit-plans-details-textual" ], "xbrltype": "durationItemType" }, "ug_DefinedContributionPlanEmployerDiscretionaryContributionAmountPerYearAuthorized": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Defined Contribution Plan, Employer Discretionary Contribution Amount Per Year, Authorized.", "label": "ug_DefinedContributionPlanEmployerDiscretionaryContributionAmountPerYearAuthorized", "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount Per Year Authorized" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmountPerYearAuthorized", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-f-benefit-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "ug_DiscretionaryContributionsVestingAtTwoYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents discretionary contributions vesting after two years of employment.", "label": "Discretionary Contributions Vesting at Two Years [Member]" } } }, "localname": "DiscretionaryContributionsVestingAtTwoYearsMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-f-benefit-plans", "http://u-g.com/20221231/role/statement-note-f-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "ug_DiscretionaryContributionsVestingEachAdditionalYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents discretionary contributions vesting each additional year of employment.", "label": "Discretionary Contributions Vesting Each Additional Year [Member]" } } }, "localname": "DiscretionaryContributionsVestingEachAdditionalYearMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-f-benefit-plans", "http://u-g.com/20221231/role/statement-note-f-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "ug_DistributorsAndMarketingPartnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents distributors and marketing partners of the company.", "label": "Distributors and Marketing Partners [Member]" } } }, "localname": "DistributorsAndMarketingPartnersMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "ug_EquityAndOtherMutualFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity And Other Mutual Funds Member", "label": "Equity And Other Mutual Funds [Member]" } } }, "localname": "EquityAndOtherMutualFundsMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "xbrltype": "domainItemType" }, "ug_EquitySecuritiesFvniAccumulatedUnrealizedGainLoss": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details": { "order": 0.0, "parentTag": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of unrealized gain (loss) on equity securities.", "label": "Equity securities, unrealized gain" } } }, "localname": "EquitySecuritiesFvniAccumulatedUnrealizedGainLoss", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "xbrltype": "monetaryItemType" }, "ug_FactoryEquipmentAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Factory Equipment And Fixtures [Member]" } } }, "localname": "FactoryEquipmentAndFixturesMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-property-plant-and-equipment-useful-lives-details" ], "xbrltype": "domainItemType" }, "ug_IndustrialAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Industrial And Other [Member]" } } }, "localname": "IndustrialAndOtherMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-net-sales-details" ], "xbrltype": "domainItemType" }, "ug_LUBRAJELAndRENACIDINIRRIGATIONMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to the products LUBREJEL and RENACIDIN IRRIGATION.", "label": "LUBRAJEL and RENACIDIN IRRIGATION [Member]" } } }, "localname": "LUBRAJELAndRENACIDINIRRIGATIONMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "ug_LubrajelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lubrajel [Member]" } } }, "localname": "LubrajelMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "ug_MedicalLubricantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents medical lubricants.", "label": "Medical Lubricants [Member]" } } }, "localname": "MedicalLubricantsMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-net-sales-details" ], "xbrltype": "domainItemType" }, "ug_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_NumberOfCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of customers affecting an entity's concentration risk.", "label": "ug_NumberOfCustomers", "terseLabel": "Number of Customers" } } }, "localname": "NumberOfCustomers", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual" ], "xbrltype": "integerItemType" }, "ug_NumberOfVendors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of vendors affecting an entity's concentration risk.", "label": "ug_NumberOfVendors", "terseLabel": "Number of Vendors" } } }, "localname": "NumberOfVendors", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "ug_PaymentsForAccruedDividendsOnUnconvertedShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow for payments for accrued dividends on unconverted shares.", "label": "ug_PaymentsForAccruedDividendsOnUnconvertedShares", "terseLabel": "Payments for Accrued Dividends on Unconverted Shares" } } }, "localname": "PaymentsForAccruedDividendsOnUnconvertedShares", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities-details-textual" ], "xbrltype": "monetaryItemType" }, "ug_PersonalCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The products for personal care.", "label": "Personal Care [Member]" } } }, "localname": "PersonalCareMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "ug_PharmaceuticalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pharmaceuticals [Member]" } } }, "localname": "PharmaceuticalsMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-net-sales-details" ], "xbrltype": "domainItemType" }, "ug_PreviousPresidentAndCeoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents previous President and CEO.", "label": "Previous President and CEO [Member]" } } }, "localname": "PreviousPresidentAndCeoMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-j-related-party-transactions", "http://u-g.com/20221231/role/statement-note-j-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "ug_ProertyPlantAndEquipmentUsefulLivesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Proerty Plant and Equipment, Useful Lives [Table Text Block]" } } }, "localname": "ProertyPlantAndEquipmentUsefulLivesTableTextBlock", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "ug_PurchaseOfUsedVehicleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents purchase of used vehicle.", "label": "Purchase of Used Vehicle [Member]" } } }, "localname": "PurchaseOfUsedVehicleMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-j-related-party-transactions", "http://u-g.com/20221231/role/statement-note-j-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "ug_RenacidinMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the product line, Renacidin.", "label": "Renacidin [Member]" } } }, "localname": "RenacidinMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "ug_RevenueFromContractWithCustomerIncludingAssessedTaxGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gross Amount before sales allowance and return, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Gross Sales" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTaxGross", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-net-sales-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details" ], "xbrltype": "monetaryItemType" }, "ug_SalesReturnsAndAllowances": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions) and price reductions (allowance, price protection agreements) given by the entity. Returns and allowances are a deduction from gross revenue in arriving at net revenue.", "label": "ug_SalesReturnsAndAllowances", "negatedTerseLabel": "Less: Discounts and allowances" } } }, "localname": "SalesReturnsAndAllowances", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-net-sales-details" ], "xbrltype": "monetaryItemType" }, "ug_SixRawMaterialVendorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to six raw materials vendors.", "label": "Six Raw Material Vendors [Member]" } } }, "localname": "SixRawMaterialVendorsMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "ug_TradeinReceivedFromSaleOfAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of trade-in received from sale of assets.", "label": "Trade-in received from sale of asset" } } }, "localname": "TradeinReceivedFromSaleOfAsset", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "ug_USWithSubsequentShipmentToForeignLocationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents products sold in the United States and subsequently shipped to foreign locations.", "label": "US with Subsequent Shipment to Foreign Locations [Member]" } } }, "localname": "USWithSubsequentShipmentToForeignLocationsMember", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual" ], "xbrltype": "domainItemType" }, "ug_VendorConcentrationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vendor concentration policy text block.", "label": "Vendor Concentration [Policy Text Block]" } } }, "localname": "VendorConcentrationPolicyTextBlock", "nsuri": "http://u-g.com/20221231", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "ug_statement-statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note A - Nature of Business and Summary of Significant Accounting Policies - Disaggregated Revenue (Details)" } } }, "localname": "statement-statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-property-plant-and-equipment-useful-lives-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note A - Nature of Business and Summary of Significant Accounting Policies - Property, Plant, and Equipment Useful Lives (Details)" } } }, "localname": "statement-statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-property-plant-and-equipment-useful-lives-details", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note A - Nature of Business and Summary of Significant Accounting Policies - Revenue by Geographic Region (Details)" } } }, "localname": "statement-statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note A - Nature of Business and Summary of Significant Accounting Policies" } } }, "localname": "statement-statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note B - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)" } } }, "localname": "statement-statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-b-cash-and-cash-equivalents-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note B - Cash and Cash Equivalents" } } }, "localname": "statement-statement-note-b-cash-and-cash-equivalents-tables", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note C - Marketable Securities - Net Gains and Losses on Marketable Securities (Details)" } } }, "localname": "statement-statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-c-marketable-securities-summary-of-investments-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note C - Marketable Securities - Summary of Investments (Details)" } } }, "localname": "statement-statement-note-c-marketable-securities-summary-of-investments-details", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-c-marketable-securities-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note C - Marketable Securities" } } }, "localname": "statement-statement-note-c-marketable-securities-tables", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-d-inventories-summary-of-inventories-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note D - Inventories - Summary of Inventories (Details)" } } }, "localname": "statement-statement-note-d-inventories-summary-of-inventories-details", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-d-inventories-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note D - Inventories" } } }, "localname": "statement-statement-note-d-inventories-tables", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note E - Income Taxes - Deferred Tax Assets and Liabilities (Details)" } } }, "localname": "statement-statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-e-income-taxes-provision-for-income-taxes-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note E - Income Taxes - Provision for Income Taxes (Details)" } } }, "localname": "statement-statement-note-e-income-taxes-provision-for-income-taxes-details", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note E - Income Taxes - Reconciliation of the Effective Income Tax Rate (Details)" } } }, "localname": "statement-statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-e-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note E - Income Taxes" } } }, "localname": "statement-statement-note-e-income-taxes-tables", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-g-geographic-and-other-information-geographic-information-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note G - Geographic and Other Information - Geographic Information (Details)" } } }, "localname": "statement-statement-note-g-geographic-and-other-information-geographic-information-details", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-g-geographic-and-other-information-net-sales-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note G - Geographic and Other Information - Net Sales (Details)" } } }, "localname": "statement-statement-note-g-geographic-and-other-information-net-sales-details", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-g-geographic-and-other-information-sales-to-major-customers-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note G - Geographic and Other Information - Sales to Major Customers (Details)" } } }, "localname": "statement-statement-note-g-geographic-and-other-information-sales-to-major-customers-details", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-g-geographic-and-other-information-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note G - Geographic and Other Information" } } }, "localname": "statement-statement-note-g-geographic-and-other-information-tables", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note H - Accrued Expenses - Summary of Accrued Expenses (Details)" } } }, "localname": "statement-statement-note-h-accrued-expenses-summary-of-accrued-expenses-details", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-note-h-accrued-expenses-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note H - Accrued Expenses" } } }, "localname": "statement-statement-note-h-accrued-expenses-tables", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "ug_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://u-g.com/20221231", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r14", "r434" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r206", "r207" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net of allowance for doubtful accounts of $20,063 in 2022 and $20,252 in 2021" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedBonusesCurrent", "terseLabel": "Bonuses" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r2", "r102", "r116" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets", "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedMarketingCostsCurrent": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedMarketingCostsCurrent", "terseLabel": "Sales rebates" } } }, "localname": "AccruedMarketingCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedProfessionalFeesCurrent", "terseLabel": "Audit fee" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r15", "r415" ], "calculation": { "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedSalariesCurrent", "terseLabel": "Payroll and related expenses" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r75", "r133" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r283" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "us-gaap_AdvertisingExpense", "terseLabel": "Advertising Expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r136", "r208", "r213", "r215", "r217" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r136", "r208", "r213" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts receivable, allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r101", "r114", "r134", "r149", "r187", "r191", "r196", "r211", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r314", "r316", "r323", "r434", "r471", "r472", "r547" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r128", "r139", "r149", "r211", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r314", "r316", "r323", "r434", "r471", "r472", "r547" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r90", "r91" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingImprovementsMember": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building Improvements [Member]" } } }, "localname": "BuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-property-plant-and-equipment-useful-lives-details" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-property-plant-and-equipment-useful-lives-details" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r74" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r38", "r131", "r411" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets", "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.", "label": "Cash and Cash Equivalents Disclosure [Text Block]" } } }, "localname": "CashAndCashEquivalentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r33", "r38", "r41" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents, end of year", "periodStartLabel": "Cash and cash equivalents, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r33", "r96" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "us-gaap_CashUninsuredAmount", "terseLabel": "Cash, Uninsured Amount" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r18", "r106", "r120" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Dividends declared per share (in dollars per share)", "terseLabel": "Common Stock, Dividends, Per Share, Cash Paid (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r456", "r457", "r544" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r6", "r80" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r6", "r434" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $.10 par value; 10,000,000 shares authorized; 4,594,319 shares issued and outstanding at December 31, 2022 and 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r49", "r50", "r94", "r95", "r204", "r396" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r49", "r50", "r94", "r95", "r204", "r394", "r396" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r49", "r50", "r94", "r95", "r204", "r396", "r559" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r112", "r177" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r49", "r50", "r94", "r95", "r204" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r49", "r50", "r94", "r95", "r204", "r396" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r245", "r246", "r249" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue", "terseLabel": "Contract with Customer, Liability, Current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r26", "r370" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-income": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of sales", "terseLabel": "Cost of Goods and Services Sold, Total" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsProductLineMember": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Cost of product sold and service rendered from specified product or service, when it serves as benchmark in concentration of risk calculation.", "label": "Cost of Goods and Service, Product and Service Benchmark [Member]" } } }, "localname": "CostOfGoodsProductLineMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r24" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-income": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "us-gaap_CostsAndExpenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r455", "r540", "r542" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-provision-for-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "us-gaap_CurrentFederalTaxExpenseBenefit", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r88", "r299", "r307", "r455" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-provision-for-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "us-gaap_CurrentIncomeTaxExpenseBenefit", "totalLabel": "Total current provision for income taxes" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r455", "r540", "r542" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-provision-for-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "us-gaap_CurrentStateAndLocalTaxExpenseBenefit", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r46", "r204" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndEquitySecuritiesGainLoss": { "auth_ref": [ "r22", "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in debt and equity securities.", "label": "Net losses recognized during the year on marketable securities" } } }, "localname": "DebtAndEquitySecuritiesGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt and equity securities.", "label": "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss", "terseLabel": "Debt and Equity Securities, Realized Gain (Loss), Total", "verboseLabel": "Less: Net losses (gains) realized during the year on marketable securities sold during the period" } } }, "localname": "DebtAndEquitySecuritiesRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-c-marketable-securities-details-textual", "http://u-g.com/20221231/role/statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in debt and equity securities.", "label": "Net unrealized loss recognized during the reporting year on marketable securities still held at the reporting date" } } }, "localname": "DebtAndEquitySecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r455", "r541", "r542" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-provision-for-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r287", "r288" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred income taxes, net" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r36", "r88", "r300", "r306", "r307", "r455" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-provision-for-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 }, "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredIncomeTaxExpenseBenefit", "terseLabel": "Deferred income taxes", "totalLabel": "Total deferred benefit from income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-provision-for-income-taxes-details", "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r4", "r5", "r103", "r113", "r296" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "us-gaap_DeferredIncomeTaxLiabilities", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r287", "r288" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "us-gaap_DeferredIncomeTaxLiabilitiesNet", "terseLabel": "Deferred income taxes (net)" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r86", "r539" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "us-gaap_DeferredTaxAssetsInventory", "terseLabel": "Inventories" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r538" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "totalLabel": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r538" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r86", "r539" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "terseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r86", "r539" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross": { "auth_ref": [ "r539" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross", "terseLabel": "Unrealized loss on marketable securities" } } }, "localname": "DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r83", "r538" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "us-gaap_DeferredTaxLiabilities", "negatedTotalLabel": "Net deferred tax liability" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.", "label": "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses", "negatedLabel": "Prepaid expenses" } } }, "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r86", "r539" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "negatedLabel": "Depreciation on property, plant and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities": { "auth_ref": [ "r86", "r539" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities.", "label": "us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities", "negatedLabel": "Unrealized gain on marketable securities" } } }, "localname": "DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount", "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-f-benefit-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-f-benefit-plans-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.", "label": "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "terseLabel": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage" } } }, "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-f-benefit-plans-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DemandDepositsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits.", "label": "Demand Deposits [Member]" } } }, "localname": "DemandDepositsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details" ], "xbrltype": "domainItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r36", "r185" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-", "http://u-g.com/20221231/role/statement-note-c-marketable-securities", "http://u-g.com/20221231/role/statement-note-d-inventories", "http://u-g.com/20221231/role/statement-note-e-income-taxes", "http://u-g.com/20221231/role/statement-note-f-benefit-plans", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20221231/role/statement-note-h-accrued-expenses", "http://u-g.com/20221231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities", "http://u-g.com/20221231/role/statement-note-j-related-party-transactions" ], "xbrltype": "stringItemType" }, "us-gaap_DividendDeclaredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distribution of earnings in the form of cash, property or capital stock declared by the board of directors to be distributed to shareholders.", "label": "Dividend Declared [Member]" } } }, "localname": "DividendDeclaredMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity", "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity-parentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_DividendPaidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distribution of earnings to shareholders either in cash, property, or capital stock.", "label": "Dividend Paid [Member]" } } }, "localname": "DividendPaidMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity", "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity-parentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r81", "r111" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "us-gaap_Dividends", "negatedLabel": "Dividends", "terseLabel": "Dividends, Total" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.", "label": "Dividends [Axis]" } } }, "localname": "DividendsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity", "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity-parentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock.", "label": "Dividends [Domain]" } } }, "localname": "DividendsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity", "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity-parentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r2", "r3", "r104", "r115" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "us-gaap_DividendsPayableCurrentAndNoncurrent", "terseLabel": "Dividends Payable" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r146", "r157", "r158", "r159", "r160", "r161", "r166", "r167", "r169", "r170", "r171", "r172", "r320", "r321", "r383", "r386", "r423" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings per common share (basic and diluted) (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-income" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r44", "r45" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r290" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "totalLabel": "Provision for income taxes, percent" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r150", "r290", "r308" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "terseLabel": "Income taxes at statutory federal income tax rate of 21%, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsDividends": { "auth_ref": [ "r537", "r543" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for dividend.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsDividends", "negatedTerseLabel": "Non-taxable dividends, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductionsDividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": { "auth_ref": [ "r537", "r543" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details": { "order": 0.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment", "negatedTerseLabel": "Research & development credits, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r537", "r543" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Other, net, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r80", "r126", "r143", "r144", "r145", "r152", "r153", "r154", "r156", "r162", "r164", "r174", "r212", "r244", "r279", "r280", "r281", "r302", "r303", "r319", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r135", "r322", "r413" ], "calculation": { "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details": { "order": 0.0, "parentTag": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiCost": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details": { "order": 0.0, "parentTag": "ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.", "label": "Equity securities, cost" } } }, "localname": "EquitySecuritiesFvNiCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r92", "r93" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r209", "r210", "r214", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r242", "r243", "r318", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r425", "r463", "r464", "r465", "r560", "r561", "r562", "r563", "r564", "r565", "r566" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "xbrltype": "stringItemType" }, "us-gaap_FixedIncomeSecuritiesMember": { "auth_ref": [ "r432", "r498" ], "lang": { "en-us": { "role": { "documentation": "Investment that provides a return in the form of fixed periodic payments and eventual return of principal at maturity.", "label": "Fixed Income Securities [Member]" } } }, "localname": "FixedIncomeSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FixturesAndEquipmentGross": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines.", "label": "Factory equipment and fixtures" } } }, "localname": "FixturesAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r453" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "us-gaap_GainLossOnDispositionOfAssets1", "negatedLabel": "Loss (gain) on sale of asset" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnInvestmentsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.", "label": "Gain (Loss) on Securities [Table Text Block]" } } }, "localname": "GainLossOnInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-c-marketable-securities-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r48", "r396" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r36", "r73", "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse", "terseLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r71", "r78" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r20", "r99", "r107", "r122", "r187", "r190", "r195", "r198", "r384", "r424" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-income": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r150", "r291", "r294", "r298", "r304", "r309", "r311", "r312", "r313" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r151", "r163", "r164", "r186", "r289", "r305", "r310", "r387" ], "calculation": { "http://u-g.com/20221231/role/statement-note-e-income-taxes-provision-for-income-taxes-details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://u-g.com/20221231/role/statement-statements-of-income": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes", "terseLabel": "Provision for income taxes", "totalLabel": "Total provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-provision-for-income-taxes-details", "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details", "http://u-g.com/20221231/role/statement-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r142", "r285", "r286", "r294", "r295", "r297", "r301" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationDeductionsDividends": { "auth_ref": [ "r537" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for dividend.", "label": "us-gaap_IncomeTaxReconciliationDeductionsDividends", "negatedLabel": "Non-taxable dividends" } } }, "localname": "IncomeTaxReconciliationDeductionsDividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "terseLabel": "Income taxes at statutory federal income tax rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": { "auth_ref": [ "r537" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.", "label": "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment", "negatedTerseLabel": "Research & development credits" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r537" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Other, net" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r537" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "State taxes, net of federal benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r35" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r35" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r35" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r35" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r368", "r452" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r35" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Decrease (increase) in operating assets:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "(Decrease) increase in operating liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r35" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidTaxes": { "auth_ref": [ "r35" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.", "label": "us-gaap_IncreaseDecreaseInPrepaidTaxes", "negatedLabel": "Prepaid income taxes" } } }, "localname": "IncreaseDecreaseInPrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-d-inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r67", "r416" ], "calculation": { "http://u-g.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Finished products" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r138", "r412", "r434" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://u-g.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories (net)", "totalLabel": "Total Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets", "http://u-g.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r130", "r137", "r173", "r225", "r227", "r228", "r369", "r419" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r67", "r418" ], "calculation": { "http://u-g.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details": { "order": 0.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r66", "r450" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "us-gaap_InventoryValuationReserves", "terseLabel": "Inventory Valuation Reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-d-inventories-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r67", "r417" ], "calculation": { "http://u-g.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r226" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "us-gaap_InventoryWriteDown", "terseLabel": "Reserve for inventory obsolescence" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r27", "r29" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-income": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r65", "r100", "r110", "r123", "r410" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-c-marketable-securities" ], "xbrltype": "textBlockItemType" }, "us-gaap_Land": { "auth_ref": [ "r449" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r10", "r105", "r118", "r434", "r454", "r466", "r545" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r17", "r129", "r149", "r211", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r315", "r316", "r317", "r323", "r434", "r471", "r547", "r548" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansAndLeasesReceivableAllowanceForLoanLossesPolicy": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for estimating the allowance for losses on loans and lease receivables. The disclosure may include (a) how the entity determines each element of the allowance, (b) which loans are evaluated individually and which loans are evaluated as a group, (c) how the entity determines both the allocated and unallocated portions of the allowance, (d) how the entity determines the loss factors applied to graded loans in order to develop a general allowance, and (e) what self-correcting mechanism the entity uses to reduce differences between estimated and actual losses.", "label": "Loans and Leases Receivable, Allowance for Loan Losses Policy [Policy Text Block]" } } }, "localname": "LoansAndLeasesReceivableAllowanceForLoanLossesPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "us-gaap_MarketableSecuritiesCurrent", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesGainLoss": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-income": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).", "label": "Net loss on marketable securities" } } }, "localname": "MarketableSecuritiesGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesRealizedGainLoss": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).", "label": "us-gaap_MarketableSecuritiesRealizedGainLoss", "negatedLabel": "Net loss on marketable securities" } } }, "localname": "MarketableSecuritiesRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Marketable Securities [Table Text Block]" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-c-marketable-securities-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r148" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r148" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r33", "r34", "r37" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r21", "r37", "r108", "r121", "r127", "r140", "r141", "r145", "r149", "r155", "r157", "r158", "r159", "r160", "r163", "r164", "r168", "r187", "r190", "r195", "r198", "r211", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r321", "r323", "r424", "r471" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://u-g.com/20221231/role/statement-statements-of-income": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows", "http://u-g.com/20221231/role/statement-statements-of-income", "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-geographic-information-details" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash items:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r28" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-income": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other (loss) income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other (loss) income:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-income" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingCostsAndExpenses": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-income": { "order": 0.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.", "label": "Operating expenses" } } }, "localname": "OperatingCostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and expenses:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-income" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r187", "r190", "r195", "r198", "r424" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-income": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r0", "r43", "r54", "r89" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "us-gaap_OtherAccruedLiabilitiesCurrent", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "Other Liabilities Disclosure [Text Block]" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-h-accrued-expenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r32" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "us-gaap_PaymentsOfDividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "us-gaap_PaymentsOfDividendsCommonStock", "terseLabel": "Payments of Ordinary Dividends, Common Stock" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r64" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "us-gaap_PaymentsToAcquireMarketableSecurities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r31" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Acquisitions of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r253", "r254", "r255", "r256", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r275", "r432" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-f-benefit-plans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "auth_ref": [ "r2", "r250", "r251", "r252", "r432" ], "calculation": { "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.", "label": "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "terseLabel": "Company 401(k) contribution" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r451" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r414", "r426", "r467" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid income taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from sales of marketable securities", "terseLabel": "Proceeds from Sale and Maturity of Marketable Securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-c-marketable-securities-details-textual", "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "auth_ref": [ "r30" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Proceeds from sale of asset" } } }, "localname": "ProceedsFromSaleOfProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, plant, and equipment:" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-property-plant-and-equipment-useful-lives-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives", "terseLabel": "Building improvements" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-property-plant-and-equipment-useful-lives-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r74", "r132" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "us-gaap_PropertyPlantAndEquipmentGross", "totalLabel": "Total property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r76", "r119", "r385", "r434" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "us-gaap_PropertyPlantAndEquipmentNet", "totalLabel": "Total property, plant, and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r76", "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-property-plant-and-equipment-useful-lives-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, plant, and equipment, useful lives (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-property-plant-and-equipment-useful-lives-details" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r147", "r216" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "us-gaap_ProvisionForDoubtfulAccounts", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r57", "r59" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.", "label": "Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]" } } }, "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r257", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-j-related-party-transactions", "http://u-g.com/20221231/role/statement-note-j-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r98", "r333" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "terseLabel": "Related Party Transaction, Amounts of Transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-j-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r125", "r333", "r334", "r546" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-j-related-party-transactions", "http://u-g.com/20221231/role/statement-note-j-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-j-related-party-transactions", "http://u-g.com/20221231/role/statement-note-j-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "terseLabel": "Related Party Transaction, Expenses from Transactions with Related Party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-j-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r257", "r333", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r546" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-j-related-party-transactions", "http://u-g.com/20221231/role/statement-note-j-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r331", "r332", "r334", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-j-related-party-transactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r82", "r124", "r555" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-income": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r69", "r70", "r124" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r7", "r81", "r117", "r392", "r393", "r434" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r126", "r152", "r153", "r154", "r156", "r162", "r164", "r212", "r279", "r280", "r281", "r302", "r303", "r319", "r389", "r391" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanNameAxis": { "auth_ref": [ "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r433", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536" ], "lang": { "en-us": { "role": { "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Axis]" } } }, "localname": "RetirementPlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-f-benefit-plans", "http://u-g.com/20221231/role/statement-note-f-benefit-plans-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanNameDomain": { "auth_ref": [ "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r433", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536" ], "lang": { "en-us": { "role": { "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Domain]" } } }, "localname": "RetirementPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-f-benefit-plans", "http://u-g.com/20221231/role/statement-note-f-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r183", "r184", "r189", "r193", "r194", "r200", "r201", "r204", "r247", "r248", "r370" ], "calculation": { "http://u-g.com/20221231/role/statement-statements-of-income": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Net Sales", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-geographic-information-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-net-sales-details", "http://u-g.com/20221231/role/statement-statements-of-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r204", "r460" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueProductLineMember": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Revenue, Product and Service Benchmark [Member]" } } }, "localname": "SalesRevenueProductLineMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-e-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r1", "r11", "r12", "r13" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-d-inventories-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r25", "r61" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r55", "r56", "r58", "r68" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r180", "r181", "r182", "r187", "r188", "r192", "r196", "r197", "r198", "r199", "r200", "r203", "r204", "r205" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShippingAndHandlingMember": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Packing and transport of product.", "label": "Shipping and Handling [Member]" } } }, "localname": "ShippingAndHandlingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r19", "r80", "r126", "r143", "r144", "r145", "r152", "r153", "r154", "r156", "r162", "r164", "r174", "r212", "r244", "r279", "r280", "r281", "r302", "r303", "r319", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets", "http://u-g.com/20221231/role/statement-balance-sheets-parentheticals", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-property-plant-and-equipment-useful-lives-details", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables", "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-", "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details", "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-tables", "http://u-g.com/20221231/role/statement-note-c-marketable-securities", "http://u-g.com/20221231/role/statement-note-c-marketable-securities-details-textual", "http://u-g.com/20221231/role/statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details", "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details", "http://u-g.com/20221231/role/statement-note-c-marketable-securities-tables", "http://u-g.com/20221231/role/statement-note-d-inventories", "http://u-g.com/20221231/role/statement-note-d-inventories-details-textual", "http://u-g.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details", "http://u-g.com/20221231/role/statement-note-d-inventories-tables", "http://u-g.com/20221231/role/statement-note-e-income-taxes", "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details", "http://u-g.com/20221231/role/statement-note-e-income-taxes-provision-for-income-taxes-details", "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details", "http://u-g.com/20221231/role/statement-note-e-income-taxes-tables", "http://u-g.com/20221231/role/statement-note-f-benefit-plans", "http://u-g.com/20221231/role/statement-note-f-benefit-plans-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-geographic-information-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-net-sales-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-tables", "http://u-g.com/20221231/role/statement-note-h-accrued-expenses", "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details", "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-tables", "http://u-g.com/20221231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities", "http://u-g.com/20221231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities-details-textual", "http://u-g.com/20221231/role/statement-note-j-related-party-transactions", "http://u-g.com/20221231/role/statement-note-j-related-party-transactions-details-textual", "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies", "http://u-g.com/20221231/role/statement-statements-of-cash-flows", "http://u-g.com/20221231/role/statement-statements-of-income", "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity", "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity-parentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r152", "r153", "r154", "r174", "r370" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets", "http://u-g.com/20221231/role/statement-balance-sheets-parentheticals", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-disaggregated-revenue-details", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-property-plant-and-equipment-useful-lives-details", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-revenue-by-geographic-region-details", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables", "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-", "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details", "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-tables", "http://u-g.com/20221231/role/statement-note-c-marketable-securities", "http://u-g.com/20221231/role/statement-note-c-marketable-securities-details-textual", "http://u-g.com/20221231/role/statement-note-c-marketable-securities-net-gains-and-losses-on-marketable-securities-details", "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details", "http://u-g.com/20221231/role/statement-note-c-marketable-securities-tables", "http://u-g.com/20221231/role/statement-note-d-inventories", "http://u-g.com/20221231/role/statement-note-d-inventories-details-textual", "http://u-g.com/20221231/role/statement-note-d-inventories-summary-of-inventories-details", "http://u-g.com/20221231/role/statement-note-d-inventories-tables", "http://u-g.com/20221231/role/statement-note-e-income-taxes", "http://u-g.com/20221231/role/statement-note-e-income-taxes-deferred-tax-assets-and-liabilities-details", "http://u-g.com/20221231/role/statement-note-e-income-taxes-provision-for-income-taxes-details", "http://u-g.com/20221231/role/statement-note-e-income-taxes-reconciliation-of-the-effective-income-tax-rate-details", "http://u-g.com/20221231/role/statement-note-e-income-taxes-tables", "http://u-g.com/20221231/role/statement-note-f-benefit-plans", "http://u-g.com/20221231/role/statement-note-f-benefit-plans-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-details-textual", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-geographic-information-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-net-sales-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-sales-to-major-customers-details", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-tables", "http://u-g.com/20221231/role/statement-note-h-accrued-expenses", "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-summary-of-accrued-expenses-details", "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-tables", "http://u-g.com/20221231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities", "http://u-g.com/20221231/role/statement-note-i-supplemental-disclosures-of-cash-flow-information-and-noncash-investing-and-financing-activities-details-textual", "http://u-g.com/20221231/role/statement-note-j-related-party-transactions", "http://u-g.com/20221231/role/statement-note-j-related-party-transactions-details-textual", "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies", "http://u-g.com/20221231/role/statement-statements-of-cash-flows", "http://u-g.com/20221231/role/statement-statements-of-income", "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity", "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity-parentheticals" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r6", "r8", "r9", "r63", "r434", "r454", "r466", "r545" ], "calculation": { "http://u-g.com/20221231/role/statement-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets", "http://u-g.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityPolicyTextBlock": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.", "label": "Stockholders' Equity, Policy [Policy Text Block]" } } }, "localname": "StockholdersEquityPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplierConcentrationRiskMember": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "label": "Supplier Concentration Risk [Member]" } } }, "localname": "SupplierConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-", "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-tables", "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-tables", "http://u-g.com/20221231/role/statement-note-c-marketable-securities-tables", "http://u-g.com/20221231/role/statement-note-d-inventories-tables", "http://u-g.com/20221231/role/statement-note-e-income-taxes-tables", "http://u-g.com/20221231/role/statement-note-g-geographic-and-other-information-tables", "http://u-g.com/20221231/role/statement-note-h-accrued-expenses-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r209", "r210", "r242", "r243", "r318", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r463", "r464", "r465", "r560", "r561", "r562", "r563", "r564", "r565", "r566" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-c-marketable-securities-summary-of-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r422", "r431", "r432", "r556" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-b-cash-and-cash-equivalents-schedule-of-cash-and-cash-equivalents-details" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r284", "r293" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "us-gaap_UnrecognizedTaxBenefits", "terseLabel": "Unrecognized Tax Benefits, Ending Balance" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r292" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-note-a-nature-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r51", "r52", "r53", "r175", "r176", "r178", "r179" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r166", "r171" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average shares (basic and diluted) (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://u-g.com/20221231/role/statement-statements-of-income" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(9)(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r42": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "https://asc.fasb.org/topic&trid=2134446", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r43": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r438": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r439": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r441": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r442": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r443": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r444": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r445": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r446": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21459-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 64 0001171843-23-001846-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-23-001846-xbrl.zip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�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